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Summary 
Human E-selectin (hE-selectin) is a cell adhesion molecule expressed on the membrane of 
endothelial cells. It is a C-type lectin whose key role is to mediate the initial rolling and 
adhering of leukocytes in the leukocyte recruitment in inflammation and metastasis of some 
cancer cells. It is fundamentally involved in many physiological and pathological processes, 
and hence is an attractive target for developing anti-inflammation drugs. The lectin and EGF 
domains of hE-selectin (hE-LecEGF) were identified as the minimum functional unit. Crystal 
structures of hE-LecEGF complexed with its natural ligand, tetrasaccharide sialyl Lewisx 
(sLex), as well as NMR studies of hE-selectin/IgG bound with this ligand, have been reported 
and utilized as the structural basis for the development of potent antagonists for hE-selectin. 
More potent antagonists with better binding affinity than sLex, such as CGP69669, were 
reported, but their binding modes in hE-LecEGF remain unknown. To obtain the improved 
structural information of hE-LecEGF complexed with an antagonist and develop more potent 
antagonists of hE-selectin are challenging tasks. To meet the demands of the protein for the 
structure determination and the binding assay, a sufficient amount of pure and active 
hE-LecEGF is needed. 
 
In this thesis, insect cell expression systems were initially used to produce the hE-LecEGF 
protein. hE-LecEGF was cloned, transiently expressed and characterized in Sf9 and High 
fiveTM cells. The expression plasmid pFastBacYJSE was constructed for expression of the 
hE-LecEGF protein fused with a N-terminal Flag tag. The recombinant baculovirus was 
generated and used in the expression of protein in the suspension culture. Pure hE-LecEGF 
was obtained by anti-Flag M2 affinity chromatography under the optimized condition. The 
purified protein was active and glycosylated, as identified by mAb 7A9 and glycan detection, 
respectively. Unfortunately, the homogeneous hE-LecEGF protein was not obtained after the 
deglycosylation with PNGase F and N-glycosidase A.  
 
hE-LecEGF was then cloned, stably expressed and characterized in CHO K1 cells. Stable 
subclones CHO-YJES and CHO-YJEGS expressing the hE-LecEGF protein with or without a 
human IgG1 tag were achieved. The CHO-YJES construct was used for production. The 
monoclonal anti-E-selectin functional blocking antibody 7A9 (mAb 7A9) was produced, 
purified and coupled to sepharose for functional purification of the hE-LecEGF protein. Highly 
pure hE-LecEGF protein was obtained in a one-step purification with an mAb 7A9 coupled 
column. Page, western-blotting, ELISA, MS and NMR were performed to characterize the 
hE-LecEGF protein. Pure, monomeric and active hE-LecEGF with the molecular weight of 
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20.444 kDa was obtained. In contrast to the insect cell expression system, pure, active and 
uniform deglycosylated hE-LecEGF protein was obtained after treatment with PNGase F and 
purification by a Sepharose Q matrix. A prescreening of the crystallization condition of 
hE-LecEGF was also performed using a sitting-drop method. 
 
Furthermore, a novel cell-free assay “capture-binding assay” was developed with the tag-free 
hE-LecEGF protein to evaluate the binding activity of the hE-LecEGF protein and the binding 
affinity of hE-selectin antagonists. The rIC50 of six hE-selectin antagonists was determined. 
The obtained results were in close agreement with the published results. Compared to the 
previously unstable polymer assay with hE-selectin/IgG, the capture-binding assay with 
hE-LecEGF is accurate, sensitive and reproducible. It can correctly evaluate the binding 
affinities of hE-selectin antagonists. In addition, the antibody BBA1 was used to solve the 
problem of immobilization of the hE-LecEGF protein on ELISA plates in the assay.  
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1. Introduction 
1.1 Selectins 
Lectins are carbohydrate-binding proteins. They typically play a role in biological recognition 
phenomena involving cells and proteins. Lectins are not enzymes. They bind to soluble 
carbohydrates or carbohydrate moieties of glycoproteins or glycolipids. Most animal lectins 
can be classified as either intracellular lectins or extracellular lectins (Table 1.0). 
 
Table 1.0. Intracellular lectins and extracellular lectins. 
Intracellular lectins Extracellular lectin 
● L-type lectins (β-sandwich)[1,2] ● C-type lectins (unique α/β)[3,4] 
     -Selectins[5,6] 
     -DC-Sign[7] 
     -Asialoglycoprotein receptor[8] 
     -Dectins[9,10] 
     -Mannose-binding protein[11,12] 
     -etc. 
● P-type lectins (unique β-rich)[13] ● I-type lectins[14] (Siglecs[15], Ig superfamily[16]) 
● Calnexin[17] ● R-type lectins (β-trefoil)[18] 
 ● Galectins (β-sandwich)[19] 
 
 
Cellular adhesion is the binding of a cell to another cell, a surface or a matrix. Cell adhesion 
molecules (CAMs) specifically regulate cellular adhesion by interacting with molecules on the 
opposing cell or surface. Such cell adhesion molecules are also termed "receptors" and the 
molecules they recognize are termed "ligands" (or "counterreceptors").  
 
Selectins are a family of CAMs[20,21], consisting of E-selectin, P-selectin and L-selectin. They 
are single-chain transmembrane glycoproteins. Since they recognize specific carbohydrate 
moities in a calcium-dependent manner[6], they are called C-type lectins. Selectins play an 
important role in the initial step of inflammation by mediating the rolling and adhering of 
leukocytes[22-24]. Hence, selectins are an attractive target for developing therapeutics for acute 
and chronic inflammatory diseases. 
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1.1.1 Structure of selectins 
The three members of the selectin family (E-, P- and L-selectin) share common structural 
motifs, including a N-terminal C-type lectin domain, an epidermal growth factor (EGF)-like 
domain, a variable number of consensus repeats domains (CR domains), a membrane 
spanning segment and a short cytoplasmic region[25] (Figure 1.1). 
 
Human E-, P- and L-selectin showed an overall homology of approximately 40% at the nucleic 
acid and 60% at the protein level, with the highest degree of conservation in the lectin and 
EGF-like domains. The sequence conservation between species of a selectin displays 
60-80% homology. This high degree of conservation supports their general role in the 
interaction with carbohydrate determinants. 
 
 
Figure 1.1. The common structure of the selectin family[26]. 
 
1.1.2 Functions of the domains in the selectin structure 
The lectin domain 
The N-terminal lectin domain (carbohydrate recognition domain, CRD), 120-130 amino acids 
in length, shows typical features of C-type animal lectins[25,27]. It plays a major role in ligand 
recognition and determines the carbohydrate binding specificity. 
 
The major role of the ligand recognition by the lectin domain was identified by epitope 
mapping of blocking antibodies[25], blocking peptides[28,29] and site-specific mutagenesis of the 
lectin domain[25,30]. Five critical amino acids, namely Tyr48, Asn82, Tyr94, Lys111 and Lys113, 
all part of the lectin domain, were identified. These amino acids are crucial for ligand 
recognition. Information from the crystal structures of human E-selectin and human P-selectin 
co-crystallized with sialyl Lewis x (sLex) confirmed these findings[30,31]. The chimera proteins 
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generated by domain replacement of PE-1 (the E-selectin lectin domain replaced with the 
lectin domain from P-selectin)[32,33] and LP (the lectin and EGF-like domains of L-selectin 
substituted into P-selectin)[32,33] also showed that the lectin domain determines the 
carbohydrate binding specificity of the selectins. 
  
The EGF-like domain 
The EGF-like domain (35-40 amino acids) adjacent to the lectin domain contains six 
conserved cysteine residues, which form three intramolecular disulfide bonds. Compared to 
the lectin domain, the functional role of the EGF-like domain is less understood. It may 
stabilize the conformation of the lectin domain or directly interact with the ligand. It has been 
reported that the minimum functional unit of E-selectin consists of both the lectin and the 
EGF-like domain[34-36]. The chimeric selectin, containing the lectin domain of L-selectin and 
EGF-like domain of P-selectin, exhibited the adhesive properties of both L- and P- selectin[35], 
indicating that the EGF-like domain of P-selectin may participate directly in the physiological 
glycoprotein ligand recognition via protein-protein interaction. 
 
The CR domains 
The number of the CR domains varies among the selectin family members. Human E-, P- and 
L- selectin contain the six, nine and two elements, respectively. Each CR domain is about 
sixty amino acids in length and contains three disulfide bonds. The number of CR domains 
differs between species as well. Compared with human E-selectin, rat and rabbit E-selectins 
only have five elements. Some reports indicate that the CR domains of selectins are not 
required for the ligand recognition, but they may enhance the ligand binding affinity[36,37]. 
 
The cytoplasmic domain 
The cytoplasmic domain of the three selectins contains 20-35 amino acids. There is no 
sequence homology between the different members, but it is well conserved between the 
different species[38], suggesting that this region has distinct functions. It probably plays a 
functional role in the signal transduction, but is not yet fully understood[39]. Combined with the 
transmembrane region, the cytoplasmic domain is responsible for the targeting of different 
compartments, e.g. leading P-selectin to the secretory granules, E-selectin to the plasma 
membrane or L-selectin to the tips of microfold on leukocytes.  
 
1.1.3 The role of selectins in inflammation and human diseases 
Inflammation is a complex biological response of vascular tissues to harmful stimuli, such as 
pathogens, damaged cells or irritants. It is a protective attempt by the organism to remove the 
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injurious stimuli and initiate the healing process. Inflammation is divided into acute and 
chronic inflammation. Acute inflammation is the initial response of the body to detrimental 
stimuli and is achieved by the increased movement of plasma and leukocytes from the blood 
into the injured tissues. Chronic inflammation causes a progressive shift in the type of cells 
which are present at the site of inflammation and is characterized by simultaneous destruction 
and healing of the inflamed tissue. 
 
1.1.3.1 Organ specificity of leukocyte recruitment  
Recruitment of leukocytes from the bloodstream into inflamed tissues is the key feature of 
inflammation. The leukocytes interact with endothelial cells in order to exit the blood vessel. 
This interaction was noted more than a century ago[40]. Only in the last two decades, however, 
has the mechanism been identified at a molecular level. The recruitment of leukocytes shows 
organ-specificity, and is either selectin-dependent or selectin-independent[40]. In general, most 
tissues show selectin-dependent leukocyte recruitment, including skin and mucosal 
membranes, kidney, skeletal muscle and heart, but not liver, lung after ischemia-reperfusion 
or brain[41,42]. 
 
1.1.3.2 The inflammatory cascade and its cellular mechanisms 
The recruitment of leukocytes is dependent on many adhesion molecules (selectins, selectin 
ligands, integrins and members of the immunoglobulin superfamily), chemotactic mediators, 
and regulatory and activating signals in and between the cells.  
 
The recruitment is also referred as the inflammatory cascade (Figure 1.2). It contains five 
major steps: (1) inflammatory stimulus, (2) tethering and rolling, (3) integrin activation, (4) firm 
adhesion and (5) transendothelial migration. Selectins participate in the second step, i.e. 
tethering and rolling. 
 
(1) Inflammatory stimulus 
The stimuli, such as proinflammatory mediators (cytokines, histamine and free radicals)[43,44], 
initiate the inflammatory cascade. These stimuli lead to the expression of E- and P-selectin on 
vascular endothelial cells.  
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        E-selectin    P-selectin   L-selectin 
 
Figure 1.2. Schematic representation of the inflammatory cascade. 
 
(2) Tethering and rolling  
After cell activation by stimuli, P-selectin stored in α-granules of platelets and Waibel-Palade 
bodies is quickly moved to the cell surface within minutes[45,46]. E-selectin, however, is rapidly 
synthesized de-novo and then translocated to the luminal surface of the venular endothelium. 
The well-known tethering and rolling of leukocytes onto the endothelial surface (Figure 1.3) is 
mediated by endogenous ligands of E- and P-selectin (such as PSGL-1, ESL-1)[47,48]. 
L-selectin is constitutively expressed on leukocytes and is shed from the cell surface on cell 
activation, which is assumed to occur immediately after rolling begins. L-selectin plays an 
important role in the so-called “secondary tethering” process[49], i.e. the tethering of leukocytes 
on leukocytes, which are already associated to the endothelium by the interaction with 
PSGL-1[50,51]. The “secondary tethering” expands the pool of leukocytes attracted to sites of 
inflammation. After cell activation by a variety of chemo-attractants and activating factors, 
L-selectin is cleaved at an extracellular cleavage site by metalloproteases within minutes[52,53]. 
This process is supposed to facilitate the detachment of leukocytes from endothelial cells prior 
to the migration through the endothelium[54-59]. 
 
In the tethering and rolling phase, the velocity of leukocytes is reduced from the microvascular 
free stream blood flow of 1-10 mm/s (fast rolling) down to ~5 µm/s (slow rolling). E-selectin 
was reported to be mainly responsible for the slow rolling of leukocytes (5 µm/s). Hence, 
E-selectin-dependent ”slow-rolling” drastically increases the transit time through the inflamed 
tissue and enables the activation of leukocytes by chemo-attractants[60]. 
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Figure 1.3. Leukocyte adhering to the endothelium[61]. 
 
(3) & (4) Integrin activation and firm adhesion  
Although rolling is a prerequisite for eventually firm adherence to blood vessels, 
selectin-dependent adhesion of leukocytes does not contribute to firm adhesion and 
transmigration unless another set of adhesion molecules is engaged, such as the integrins 
(Figure 1.4). 
 
Figure 1.4. Major ligands of selectin and integrin involved in leukocyte recruitment[26]. 
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The activation and deactivation of these integrins at the proper time and place is one of the 
key events of the adhesion cascade. It has been reported that β2-integrins (CD18) on the 
cellular surface of leukocytes are activated and upregulated by exposure to chemoattractants 
molecules, such as PAF (platelet-activating factor) and IL-8 (interleukin-8)[49,62]. The activated 
β2-integrins then recognize their ligands (ICAM-1, VCAM-1) on the endothelial surface and 
enable the firm adhesion. 
 
CD11/CD18 integrins, specifically CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-1), are 
typical members of the integrin family[63]. They are heterodimers composed of unique α 
subunits non-covalently bound to a common β subunit (β2)[64]. The conformational changes of 
these integrins are activated by chemoattractants. After stimulation with thrombin, histamine 
or cytokines, the chemoattractants PAF and IL-8 are synthesized by endothelial cells and 
expressed on the cell surface[65]. The activated integrins then bind to the immunoglobulin 
superfamily member, such as ICAM-1[66]. ICAM-1 and ICAM-2[65], ligands for the integrins, are 
constitutively present on endothelia cells in vitro[67] and in vivo[68]. The constitutive expression 
can be increased by inflammatory mediators, such as TNF and endotoxin. The interaction of 
integrin with their ligands enables the firm adhesion of leukocytes onto the endothelium and 
leads to a flattening which further increases the contact area of leukocytes to 
endothelium[52,62,69,70]. 
 
(5) Transendothelial migration 
Transmigration of leukocytes across the endothelial monolayer can be achieved by two 
processes (Figure 1.5). One occurs by the interaction of integrins located on leukocytes with 
the platelet-endothelial cell adhesion molecule-1 (PECAM-1) located at the junctions between 
endothelial cells)[71]. PECAM-1 is a member of the immunoglobulin superfamily. It is 
expressed at a relatively low level on the surface of leukocytes and platelets but at a higher 
level (>106 molecules per cell) on the endothelium[72]. Anti-PECAM-1 antibody significantly 
blocks leukocyte transmigration but does not affect the adhesion of neutrophils. The second 
process in transendothelial migration is the ability of endothelial monolayer to regulate the 
opening of its junctions, allowing neutrophil transmigration[73].  
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Figure 1.5. Leukocyte transmigrating through the endothelium[61]. 
1.1.3.3 Biophysics of selectin-based adhesion 
The high on-rates (attachment) and high off-rates (detachment) are unique properties of 
selectins enabling the support of leukocytes rolling under flow[74]. The capture or tethering of 
leukocytes is closely related to the on-rate, but the actual rolling velocity and the lifetime of 
selectin-ligand interaction are determined by the off-rate. The relationship between them is 
that the faster the off-rate, the higher the rolling velocity and the shorter the lifetime of the 
interaction.  
 
1.1.3.4 The pathophysiological role of selectins 
A variety of acute or chronic inflammatory diseases are reported to be caused by the 
selectin-dependent recruitment of leukocytes into inflamed tissues.  
 
In 1992, “Leukocyte adhesion deficiency type II” (LAD II) was first described in two patients[75]. 
It is a rare autosomal recessive genetic disorder. These individuals have a point mutation in 
the gene of a highly conserved GDP-fucose transporter on chromosome 11[76,77], resulting in 
the insufficient incorporation of fucose into selectin ligands. Consequently, leukocytes cannot 
bind E-, P-, or L- selectin and patients suffered from infections of the mucosal membranes 
and skin[78,79]. In some patients, the effect can be overcome by oral administration of 
fucose[80,81]. The LAD II deficiency clearly demonstrates the importance of interactions 
between selectins and their ligands in the inflammatory response. 
 
In addition, the tissue and organ damage that result from ischemia, reperfusion[82,83] and 
asthma[84] can be significantly reduced when the excessive recruitment of neutrophil or 
eosinophils is averted by a blockade of P- and E-selectin[85]. Some monoclonal antibodies[86-91], 
carbohydrates[88,92,93], soluble forms of PSGL-1[94] and small molecular antagonists[95,96] 
showed protective effects in reperfusion injury models. 
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Recently, soluble E-selectin and ICAM-1 in serum and synovial fluid were recognized as 
important indicators of the severity of rheumatoid arthritis, allowing early differentiation 
between mild and severe courses of the disease and providing essential information for 
therapeutic decisions[97-100]. However, the exact molecular mechanisms of rheumatoid arthritis 
have not yet been fully elucidated. 
 
Many studies also report that metastasis of some malignant cells follows the pathway of 
leukocytes[101-118]. The expression of selectins on the endothelium could initiate or even be a 
prerequisite for the development of metastases. Colon cancers[119-129] and several breast 
cancer cell lines[130, 131] express selectin ligands, which are correlated with their metastatic 
behaviour. 
 
E-selectin, compared to P- and L-selectin, plays a particularly important role in this process of 
metastasis. It mediates the initial rolling of tumor cells on the endothelium, followed by the 
subsequent firm adhesion involving other, as yet unknown adhesion molecules.  An elevated 
serum level of E-selectin in patients with various types of cancer may reflect the 
tumor-progression[108,132-137]. P-selectin in the metastasis of tumor cells probably has an 
identical action mode. Additionally, the stimulation of P-selectin expression on platelets could 
facilitate the interaction between platelets and tumor cells in the haematogenous 
metastasis[138-140]. The role of L-selectin in cancer metastasis remains uncertain. It may be 
involved in the metastasis of malignant lymphoma to distant nodes[141]. 
 
In summary, many inflammatory diseases, such as immune complex-dependent acute lung 
injury[142], sepsis[143,144], skin inflammation[145-148], organ transplantation[149], atherosclerosis, 
asthma[84], COPD, organ rejection, hemorrhagic shock, thrombosis, rheumatoid arthritis[150], 
atopic dermatitis, psoriasis[151], diabetes caused microangiopathy, myocardial and cerebral 
ischemia, and some cancer cell metastasis, are closely related to the selectin-dependent 
recruitment of leucocytes/tumor cells. Small molecule antagonists or antibodies for blocking 
the selectin function are promising to be the anti-inflammatory agents. Because inhibition of 
E-selectin to date appears to have no anti-adhesive and immunosuppressive activity in other 
organs, inhibition of E-selectin, rather than general selectin inhibition, is an appealing specific 
therapeutic approach. 
 
1.1.4 E-selectin 
E-selectin, also called CD62E or endothelial-leukocyte adhesion molecule- 1 (ELAM-1), was 
identified as a cytokine-inducible adhesion receptor on endothelial cells. The key role of 
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E-selectin in the inflammatory cascade is to mediate the initial rolling and adhering of 
neutrophils, eosinophils, basophils, a subpopulation of T-lymphocytes and monocytes. 
Human E-selectin is closely related to many acute and chronic inflammatory diseases (see 
above). Soluble E-selectin is found in human plasma and synovial fluids[152] . Its elevated level 
in some inflammatory disorders[153] make it the potential marker of disease progress[154]. 
 
1.1.4.1 Transient expression of E-selectin by cytokines induction 
The transient expression of E-selectin on endothelial cells is induced by cytokines, such as 
interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α) or liposaccharide (LPS)[155]. Induction by 
cytokines is conserved across species[156,157]. In contrast, transforming growth factor-ß[158], 
IL-4[159], corticosteroids[160] and elevation of cAMP[161-163] inhibit the expression of E-selectin. 
This indicates that the expression of E-selectin is modulated by differernt mechanisms.  
 
E-selectin mRNA and protein are presented within 4-6 hours of induction and decline to the 
basal levels over the next 12-24 hours, even in the continous presence of the agonist. The 
rapid decline could be due to the destabilizing sequence of AUUUA in the 3’-untranslated 
region[21]. Newly-synthesized E-selectin enters the endoplasmic reticulum and Golgi complex 
to attach the complex N-linked oligosaccharides before reaching the cell suface. For 
degradation, E-selectin is delivered much more rapidly to lysosomes than most membrane 
proteins[164-166]. 
 
1.1.4.2 Structure features of human E-selectin 
Human E-selectin has the common selectin structure and contains six consensus repeat 
domains (see Table 1.1). The N-terminal C-type lectin domain of E-selectin (118 amino acids 
in length, CRD)[21,35,167,168] contains four cysteine residues which form two disulfide bridges 
(Cys19-Cys117 and Cys90-Cys109). The EGF-like domain (36 amino acids in length) 
contains six cysteine residues that form three disulfide bridges (Cys122-Cys133, Cys127- 
Cys142 and Cys144 –153) (Figure 1.6). The C-type lectin domain and EGF-like domain were 
identified as the minimum functional unit of E-selectin[34-36]. The crystal structures of the lectin 
and EGF-like domains of human E-selectin (hE-LecEGF) with or without its natural ligand of 
sialyl Lewis x (sLex) have been reported[30,31] (Table 1.1). 
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Table 1.1. Brief summary of selectins. 
  E-selectin P-selectin L-selectin 
Structure Lectin domain 1 1 1 
 EGF-like domain 1 1 1 
 CR domains 6 9 2 
 Transmembrane  1 1 1 
 Cytoplamic region 1 1 1 
Location  Endothelial cell Endothelial cell Leukocyte 
   & palatelets  
Recognition  Neutrophils, monocytes, Myeloid Cytokine-activated 
  Memory T cells  endothelial cells 
Crystallization Apo-LecEGF Yes NO NO 
 Glycosylated- Yes NO NO 
 LecEGF    
 Deglycosylated- Yes Yes Yes 
 LecEGF    
? Deglycosylated- Yes Yes NO 
? LecEGF+sLe x ? ? ?
 
 
 
 
 
 
 
 
 
 
 
      
Figure 1.6. The primary protein sequence of E-LecEGF in the crystal structure[30,31]. 
 
• Calcium binding sites of E-selectin 
Four amino acids of the lectin domain (Glu80, Asn82, Asn105 and Asn106) were identified to 
be involved in the calcium binding from the crystal structure of hE-LecEGF complexed with 
sLex[30,31] and the site-specific mutagenesis of the lectin domain[25]. 
 
Human E-selectin may contain more than one calcium-binding site. The equilibrium dialysis 
method showed that E-selectin contains a high affinity Ca2+-site with a KD of ∼ 3.5 µM. At a 
: α helix; : β sheet 
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high concentration of Ca2+, additional calcium-binding sites were found[169], coinciding with the 
crystal data that three calcium ions are presented in the complex of hE-LecEGF with sLex[30]. 
 
The apo-E-selectin was revealed to be sensitive to the partial proteolysis by Glu-C 
endoproteinase, whereas the holo-E-selectin is not. It suggests that the binding of Ca2+ to 
E-selectin induces a conformational change (in the loop with residues 94-103) and hence 
facilitates ligand binding.  
 
It was also reported that Sr2+ could replace Ca2+ and restore the function of all selectin 
members[170]. Sr2+ binds tighter to apo-E-selectin than Ca2+. However, Sr2+-regenerated 
E-selectin exhibited only 50% ligand binding activity. Ba2+ was found to bind to apo-E-selectin 
five times more strongly than Ca2+, but Ba2+-regenerated E-selectin did not show significant 
binding activity to HL-60 cells, the carcinoembryonic antigen (CEA) or sLex-carrying 
proteins[169,171].  
 
In summary, Ca2+-binding of E-selectin could induce a minor, but critical conformational 
change. Perturbations in the conformation of the Ca2+-binding region by either limited 
proteolysis or substitutions with other metal ions can abolish the function of E-selectin. 
 
• Structure feature of hE-LecEGF complexed with sLex  
The molecular interactions between E-selectin and its natural ligand sialyl Lewisx (sLex) were 
elucidated by the crystal structure of hE-LecEGF co-crystallized with sLex[30,31]. The interaction 
was discovered to be an intricate network with mainly electrostatic interaction in nature. 
 
The sLex-binding site reveals high conservation between E-LecEGF and P-LecEGF[30,31]. The 
common feature of this site is the coordination of a calcium ion by the side chains of Glu80, 
Asn82, Asn105, Asp 106, and the backbone carbonyl of Asp106, and two water molecules to 
form a pentagonal bipyramid coordination sphere. It is also the structural basis for the 
metal–dependency of the selectin function. The difference in this binding site of E-LecEGF 
and P-LecEGF is that the area of Arg97-Glu98-Lys99-Asp100 in E- LecEGF is substituted by 
Ser97-Pro98-Ser99-Ala100 in P-LecEGF. In E-LecEGF, this region presents a 
positively-charged surface and Arg97 is stabilized by a hydrogen bond with Asp100. In 
contrast, this position in P-LecEGF contains uncharged and non-interacting resides. 
Furthermore, Lys99 in E-LecEGF points away to form the binding sites, whereas Ser99 in 
P-LecEGF is directed inward.  
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sLex binds to E-LecEGF and P-LecEGF using essentially the same site and with similar 
conformation of the tetrasaccharide. Compared to the size of the free ligand, the total buried 
surface area of sLex is small (549 Å2 in E-LecEGF, 501 Å2 in P-LecEGF). The interactions of 
sLex and E-LecEGF are shown in Figure 1.7 and Figure 1.8. The 3- and 4- hydroxyl groups of 
Fuc coordinate with calcium and form hydrogen bonds with the residues Asn82, Glu80 and 
Asn105, which are involved in calcium coordination. The Gal residue of sLex forms hydrogen 
bonds to Tyr94 and Glu92 and the carboxylate group of NeuNAc forms hydrogen bonds to 
Tyr48. 
 
 
      
 
 
 
 
Figure 1.8. The binding mode of sLex as determined from the crystal structure[30]. 
a.                                         b. 
Figure 1.7. Interactions between sLex and E-LecEGF in the crystal structure with focus on Fuc (a), Gal and
NeuNAc (b) [30, 31]. 
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P-selectin binds sLex with a KD of 7.8 mM. E-selectin shows an approximately ten times higher 
affinity to sLex than P-selectin[172]. The structural basis for the higher affinity of E-selectin with 
sLex could be mainly due to the formed salt bridge of NeuNAc in the E-LecEGF/sLex complex 
with the side chain of Arg97 and to the side chain of Tyr48, whereas these salt bridges can 
not be formed in P-LecEGF.  
 
The folding of the lectin domain in E-selectin is very similar to the lectin domain of the rat 
mannose binding protein (MBP). The EGF-like domain in E-selectin has the same general fold 
and arrangement of disulphide bonds as other EGF-like domains. However, only residues 
135-139 of the EGF-like domain in E-selectin make contact with the lectin domain by several 
hydrogen bonds and a limited number of van der Waals contacts.  
 
1.1.4.3 Natural Ligands of E-selectin 
The counter-receptors of E-selectin have been identified on neutrophils[173], monocytes[174,175], 
eosinophils[176], memory T-lymphocytes[146,177,178], natural killer cells[179] and colon carcinoma 
cells.  
 
The interaction of E-selectin with its ligands is described as a lectin-carbohydrate interaction. 
These interactions are characteristically less firm than most described protein-protein 
interactions, such as antibody-antigen, hormone-receptor interactions.  
 
Many studies indicate that there are clear differences in carbohydrate recognition by the 
different selectins. E-selectin recognizes the sialylated and fucosylated lactosaminoglycans. A 
common trisaccharide domain is the minimal binding epitope for E-selectin[180]. The natural 
ligands of E-selectin include: 
 
(1) Sialyl Lewisx (sLex): 
Tetrasaccharide sLex (Neu5Ac-α2-3Gal-β1-4(Fuc-α1-3)-GlcNAc) represents a family of 
α(2,3)sialylation and α(1,3)fucosylation polylactosamines. It is typically found in abundance 
on circulating neutrophils, monocytes[181-186] and on a small percentage of blood 
lymphocytes[180,186,187]. It is also highly expressed on a variety of adenocarcinomas[38,188-197]. It 
is the epitope recognized by E-[198-202], P-[203,204] and L-selectins[205,206], albeit with different 
affinities. Its structure is shown in Figure 1.9a. 
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(2) Sialyl Lewisa (sLea):  
sLea (Neu5Ac-α2-3Gal-β1-3 (Fuc α1-4)-GlcNAc), is a positional isomer of sLex[180,206-208]. It 
binds to E-selectin[106,180] with a higher affinity than sLex. sLea is not typically expressed by 
blood leukocytes, but by certain cancer cells, such as the human colorectal carcinoma cell line 
COLO201. It is a marker of gastrointestinal and pancreatic cancers[209]. The structure of sLea 
is shown in Figure 1.9b. 
 
 
a.                                                    b. 
Figure 1.9. The carbohydrate epitope of sLex (a) and sLea (b). 
 
(3) Sialyl di-Lex: 
Sialyl di-Lex is a carbohydrate containing sLex plus Lex. It was isolated from HL-60 cells and 
showed much higher affinity than sLex, suggesting that sialyl di-Lex is responsible for the 
specificity of E-selectin-dependent adhesion[210]. Its structure is shown in Figure 1.10. 
 
 
Figure 1.10. The carbohydrate epitopes of sialyl di-Lex. 
 
(4) PSGL-1  
PSGL-1 (P-selectin glycoprotein ligand-1) is a disulfide-linked homodimer of two identical 120 
kDa proteins[211,212]. It contains tyrosine sites for sulfation and 15 consecutive Ser/Thr rich 
decameric repeats for addition of clustered O-linked carbohydrate side chains. α(2,3) 
sialylation, α(1,3) fucosylation[213,214] are necessary for E-selectin dependent binding[212,214,215]. 
The sulfation of Tyr on the NH2-terminus is essential for the recognition by P-selectin[216], but 
not by E-selectin[217-219]. It is found on human neutrophils, human activated T-cells and HL60 
cells. PSGL-1 is a mucin-like protein and shows apparently lower binding affinity to E-selectin 
than to P-selectin[213]. 
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(5) ESL1 (E-selectin ligand 1) 
ESL-1[220-222] is a 150 kDa glycoproteins with sequence similarity to a Golgi-localized 
polypeptide[223]. It is expressed on HL60 cells, murine neutrophils and myeloid cells lines. 
Effective function of ESL-1 requires α(1,3) fucosylation[222].  
 
Some other ligands were also identified for the E-selectin, such as the 250 kDa glycoprotein 
purified from bovine γ/δ T lymphocytes[210], CLA (Cutaneous Lymphocyte antigen) on memory 
T-cells[224], LAMP-1, LAMP-2, CD44[225,226] and the recently reported Death receptor-3[227] on 
colon cancer cells.  
 
1.1.5 P-selectin 
P-selectin, also known as GMP140 (granule membrane protein)[228], PADGEM (platelet 
activation-dependent granule to external membrane protein) or CD62P, is a 140 kDa 
glycoprotein stored in α granules of platelets[228,229], megakaryocytes and Waibel-Palade 
bodies of endothelial cells. P-selectin mediates the leukocyte rolling in leukocyte recruitment 
in acute and chronic inflammation[230-232] as described above. Platelet-derived P-selectin could 
also contribute to hemostatic processes[233] by stimulation of monocytes to express tissue 
factor[234] or facilitating fibrin deposition during clot formation[235]. Moreover, it could also 
mediate platelet function in tumor angiogenesis[236,237]. 
 
1.1.6 L-selectin 
L-selectin, known as gp90MEL, LAM-1[238], CD62L, or TQ1[239], is constitutively expressed on 
virtually all leukocytes except memory T-cells[240]. It is expressed on the majority of blood 
borne T- and B-cells, a subset of natural killer cells[240-243], as well as immature hematopoietic 
cells, including the majority of myeloid colony–forming cells[244,245]. The expression of 
L-selectin can be downmodulated at the transcriptional level during lymphocyte differentiation 
from a naive to memory cell phenotype[246] and also rapidly downregulated by a 
membrane-proximal proteolysis. It recognizes the cytokine-activated endothelial cells in 
inflammation cascades and is involved in the extravasation of neutrophils, monocytes, 
possibly eosinophils into inflammatory sites[240,247] and the homing of naive lymphocytes to 
peripheral lymph nodes[241,248].  
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1.1.7 Development of selectins inhibitors for therapeutic application 
Selectins play an important role in the initial step of cell adhesion in inflammation and in 
numerous human diseases (see section 1.1.3). Hence, inhibition of selectins is an appealing 
strategy to develop novel drugs for acute and chronic inflammatory diseases. Four classes of 
selectin inhibitor have been developed so far and tested in preclinical models and some in 
clinical trials. 
 
(1) Sialyl Lewisx-type antagonists 
sLex inhibits all three selectins at high concentrations and was therefore used to study 
structure-function relationships and as a sloshing point for the development of drug 
candidates. Hitherto, sLex-type antagonists failed as drug candidates due to their poor 
pharmacokinetics, low affinity and complex synthesis[249].  
 
(2) Antibodies against selectins 
Antibodies against selectins have been developed and humanized for therapeutic use. 
DREG-55 (anti-L-selectin antibody)[250] is conducting a phase-II, multicenter, double-blind, 
placebo-controlled trial for psoriasis and multiple trauma with injuries involving two or more 
organ systems.  
 
(3) Truncated form of a PSGL-1 immunoglobulin fusion protein 
Truncated PSGL-1 showed good affinity and pharmacokinetics as selectin inhibitor[251]. Its 
production in mammalian cells co-transfected with fucosyl transferase and core-2 GlcNAc 
transferase is complex and expensive. It entered clinical trials which were, however, 
discontinued. 
 
(4) Small molecule inhibitors of selectins (glycomimetics) 
Mimics of sLex were developed by substitution of sugar moieties with other moieties without 
affecting the pharmacophores’ presentation. Based on this strategy, several antagonists of 
E-selectin have been developed[249,252]. TBC-1269, a low molecular weight dimeric 
glycomimetic, started phase II study in 2002 for childhood psoriasis and for asthma[253,254]. The 
anti-inflammatory effects of this mimetic are still contradictory[255]. In addition, GMI-1070 (a 
glycomimetic) commenced phase I clinical trial for vaso-occlusive crisis of sickle cell disease 
in 2008. 
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1.2 Recombinant Protein Expression System 
Protein expression is an important tool for research and development in the life sciences. 
Prokaryotic (bacterial) and eukaryotic (usually yeast, insect cells or mammalian cell) systems 
are two main systems used in the expression of recombinant proteins. The features of these 
expression systems[256] are shown in Table 1.2. The choice of which system to use must take 
into account the protein target (including solubility, function and the amount needed) and time 
involved. 
 
1.2.1 Prokaryotic recombinant protein expression system 
Very rapid cell growth, easy expression by induction and simple purification step are the 
advantages of prokaryotic recombinant protein expression systems. Many commercial kits 
are available. However, most proteins expressed in prokaryotic systems are insoluble in 
inclusion bodies and are very difficult to be recovered as functional proteins. 
Post-translational modifications cannot be accomplished[257,258], which may affect the activity, 
stability or response to antibodies of the protein. 
 
Escherichia coli (E. coli) is one of the most widely used hosts for production of heterologous 
proteins. Its genetics are better characterized than any other microorganism. Recent progress 
in the fundamental understanding of transcription, translation and protein folding in E. coli, 
together with serendipitous discoveries and the availability of improved genetic tools are 
making this bacterium more valuable than ever for expression of complex eukaryotic proteins. 
 
1.2.2 Eukaryotic recombinant protein expression system 
Eukaryotic recombinant protein expression systems can secrete the protein of interest into the 
media and post-translational modifications can be carried out, including methylation, sulfation, 
phosphorylation, lipid addition and glycosylation. These modifications are crucial for the 
function of expressed proteins. However, eukaryotic cells grow more slowly than prokaryotic 
cells and the cost is higher than for the prokaryotic system.  
 
1.2.2.1 Insect cell expression system 
The insect cell expression system is a higher eukaryotic system than yeast[259]. It is able to 
carry out more complex post-translational modifications (Table 1.2), including proper 
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proteolysis, N- and O-glycosylation, acylation, amidation, carboxymethylation, 
phosphorylation and prenylation. Insect cell expression systems also have good machinery 
for folding and expression of soluble proteins of mammalian origin[259].  
 
In insect cell expression system, the most commonly used vector system is baculovirus. The 
transfer of recombinant DNA can be done by direct transfection or co-transfection. For direct 
transfection, the target gene is incorporated into the viral genome prior to transfection; for 
co-transfection, the target gene is simultaneously transfected with linearized viral DNA into 
insect cells. The genomes of the Autographa californica nuclear polyhedrosis virus (AcNPV) 
and the Bombyx mori nuclear polyhedrosis virus (BmPV) are widely used for the transfer. The 
strong virus polyhedrin promoter increases the expression level of heterologous proteins up to 
30% of total cell proteins. The signal sequence, such as the honey-bee prepromelittin 
secretory sequence[260] or gp 67 signal sequence[261], enable the proteins to be secreted from 
insect cells or targeted to different subcellular locations. The host is usually a lepidopteran 
insect cell line, such as Spodoptera frugiperda (Sf9 and Sf21) and Trychlopusia ni (High 
fiveTM). High fiveTM cells are suitable for secretion of the recombinant protein[262]. 
 
Insect cell expression systems provide significant advantages, such as high expression levels, 
ease of scale-up and production of proteins with post-translational modifications. Insect cells 
do not require CO2 for growth and can be readily adapted to a high-density suspension culture 
for large-scale expression[262]. The expressed protein is antigenically, immunogenically and 
functionally similar to the native mammalian protein. However, particular patterns of 
post-translational processing and expression must be empirically determined for each 
construct. The complex glycosylation cannot be accomplished in insect cells. To date, several 
new systems for more robust and convenient application of baculovirus-based protein 
expression in insect cells have been invented[263,264], including transient expression systems 
using a non-viral vector system and novel insect cell lines with “humanized glycosylation 
function” for better glycosylation of expressed recombinant proteins. 
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1.2.2.2 Mammalian cell expression system 
The mammalian cell expression system has become the dominant system used to produce 
eukaryotic recombinant proteins and antibodies, since this system has the unique ability to 
control recombinant protein qualities, including protein folding, disulfide bond formation and 
post-translational modifications (most are glycosylation)[259]. These are critical features for 
conformation and activity of the recombinant protein. Compared to other expression systems, 
yield, time and costs are greater in mammalian systems, although significant progress has 
been made, especially in preparative scale protein production[265,266]. Transient expression (an 
episomally replicating plasmid lost gradually) and stable expression (stably integrated copies 
of the transgene into the host genome) can be carried out for the recombinant protein 
expression. CHO, BHK and myeloma cells are commonly used for stable protein expression, 
COS cells for transient expression[267], NS0, HEK-293, NIH3T3 and other cell lines are also 
used in industry and research.  
 
1.2.3 Post-translational modifications: glycosylation 
1.2.3.1 Glycosylation in eukaryotic cells 
Glycosylation is the most common form of post-translational modification in eukaryotic cells. 
Secreted proteins, membrane proteins and proteins targeted to vesicles or certain intracellular 
organelles are likely to be glycosylated[259]. It is estimated that more than half of all human 
proteins are glycoproteins. These glycoproteins are involved in a wide range of biological 
functions, such as receptor binding, cell signalling, immune recognition, inflammation and 
pathogenicity. The carbohydrate components of glycoproteins affect the functionality of the 
molecule by determining the protein folding, oligomer assembly and secretion processes. 
Glycosylation also affects solubility and prevents aggregation of proteins. The 
oligosaccharides or sugar chains of glycoproteins are covalently linked to proteins. The 
predominant sugars found on human glycoproteins include galactose (Gal), mannose (Man), 
fucose (Fuc), N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc) and 
N-acetylneuraminic acid (the human form of sialic acid). Attaching the sugars through the 
process of glycosylation is the most extensively post-translational modification mode in 
eukaryotic cells[259].  
 
Mammalian glycoproteins have three major types of oligosaccharides (glycans): N-linked, 
O-linked and glycosylphosphatidylinositol (GPI) lipid anchors. The most common and best 
studied is N-linked glycosylation. In this glycosylation pattern, oligosaccharides are uniquely 
added to asparagine in Asn-X-Ser/Thr recognition sequences of proteins[259]. It occurs 
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co-translationally in the lumen of the endoplasmic reticulum and continues in the Golgi 
apparatus. O-linked glycosylation involves either simple oligosaccharide chains or 
glycosaminoglycan chains to the hydroxyl group of serine or threonine[268]. It occurs 
post-translationally in the Golgi apparatus.  
 
The attachment of sugars is catalyzed by specific glycosyltransferases. The specific sugars 
attached to an individual protein depend on the cell type and the physiological status of the 
cell. However, eukaryotic expression systems do not maintain complete glycosylation under 
high-volume production conditions[259]. 
  
(1) Glycosylation in yeast 
The yeast expression system offers a simple production process with high yield, powerful 
secretory pathways and limited post-translational modifications. The glycosylation patterns 
are obviously different from mammalian cells. Yeast cells add the non-human type of 
high-mannose structures to proteins in N-glycosylation pattern (Figure 1.11). Although these 
structures may not be immunogenic, the expressed glycoprotein has a short half-life. And 
there is also evidence that different O-glycosylation patterns occur in yeast cells[269]. 
 
(2) Glycosylation in insect cells 
Insect cells put on shorter mannose structures to the expressed proteins than yeast does. The 
nature of N-linked glycosylation in insect cells (Sf21, Sf9, High Five™) is dependent on the 
feature of expressed proteins and the host cell line[259]. N-linked glycans are generally of the 
high-mannose type, which are not identical to mammalian cells[259] (Figure 1.10). 
 
N-linked glycosylation modified by Drosophila is less complex, not trimmed and sialylated. 
Proteins expressed from Drosophila have high mannose contents. High Five™ cells, but not 
Sf9 cells, modify many glycoproteins with a core alpha (1,3)-fucose[270], which is also found in 
the glycoproteins of several parasitic worms. Mimic™ Sf9 insect cells, modified Sf9 cells, can 
stably express a variety of mammalian glycosyltransferases. These enzymes allow for 
production of the biantennary, terminally sialyated N-glycans from insect cells. Therefore, 
Mimic™ Sf9 insect cells are used to produce more mammal-like proteins[259]. 
 
(3) Glycosylation in mammalian cells 
N-linked glycoproteins expressed by mammalian cells contain the standard branched 
structures composed of mannose, galactose, N-acetylglucosamine and neuramic acids 
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(Figure 1.11). O-linked glycoproteins contain various numbers of sugars, including galactose, 
N-acetylglucosamine, N-acetylgalactosamine and neuramic acids. 
 
CHO cells, the system most commonly used today, glycosylate protein close to human cells. 
However, it does not maintain complete glycosylation under the production conditions[259]. 
 
(4) Glycosylation in plant cells 
N-glycan structures of human proteins expressed in plants are often simple, without the 
galactose and terminal sialic acids (Figure 1.11). The presence of alpha 1-3 linked core 
fucose and xylose residues are potentially immunogenic[271, 272]. 
 
Figure 1.11. Glycosylation in different expression system[259]. 
 
1.2.3.2 Enzymes in analysis of N-linked glycosylation 
Several protocols for carbohydrate analysis of glycoproteins have been established[273]. 
Specific deglycosidases have proven useful in the elucidation of the structures and 
biosynthetic pathways of biologically important glycoproteins. For N-linked glycans, 
endoglycosidase D, endoglycosidase H, endoglycosidase F, Peptide-N-glycosidase-F 
(PNGase F) and N-glycosidase A are widely utilized. Endoglycosidases D, H and F can 
cleave various high-mannose glycans. Endoglycosidase D recognizes the 
unsubstituted-mannosyl residue linked to the innermost β-mannosyl residue by 1-3 
linkage[274,275]. Endoglycosidase H cleaves between the N-acetylglucosamine residues of the 
chitobiose core of N-linked glycans, leaving one N-acetylglucosamine residue attached to the 
asparagine[276,277]. Endoglycosidases F1, F2, and F3 are responsible for endohydrolysis of the 
di-N-acetylchitobiosyl unit in high-mannose-content glycopeptides and glycoproteins (Figure 
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1.12a). They are intended for deglycosylation of the N-linked oligosaccharides from 
glycoproteins under native conditions.  Some glycoproteins are resistant to the traditional 
deglycosylation methods using PNGase F due to their conformation[278,279]. Endoglycosidases 
F1, F2, and F3 are less sensitive to protein conformation than PNGase F. Hence they are 
more suitable for deglycosylation of native proteins. The linkage specificities of 
endoglycosidases F1, F2, and F3 suggest a general strategy for deglycosylation of proteins 
that may remove all classes of N-linked oligosaccharides without denaturing the protein. 
However, they leave one N-acetylglucosamine residue attached to the asparagine of 
glycoprotein. 
 
Peptide-N-glycosidase F (PNGase F) is one of the most widely used enzymes for 
deglycosylation of glycoproteins[280]. The enzyme releases asparagine-linked (N-linked) 
oligosaccharides from glycoproteins and glycopeptides (Figure 1.12b). The minimum 
substrate of it is a tripeptide with the glycan-linked asparagine as the central residue. The 
glycan recognized by PNGase F can be a high-mannose, hybrid or complex type[281]. The 
reaction mechanism of PNGase F differs from that of endoglycosidases D, H and F. However, 
N-glycans modified with a fucose linked alpha (1-3) to Asn-GlcNAc are resistant to PNGase F.  
 
N-glycosidase A can cleave all types of asparagine bound N-glycans, including high 
mannose-, hybrid-, biantennary-, triantennary- and tetraantennary-complex types[282]. It can 
also cleave a single N-acetylglucosamine residue from the peptide, albeit at a slower reaction 
rate[283]. In contrast to PNGase F, N-glycosidase A can degrade N-linked glycans carrying a 
fucose-linked alpha(1-3) to Asn-GlcNAc[284] , which is present in proteins expressed by plant 
and insect cells. However, in most cases, N-glycosidase A is not able to efficiently remove all 
susceptible oligosaccharides from glycoproteins[285]. 
 
In this thesis, PNGase F and N-Glycosidase A have been used for removing the glycans of 
hE-LecEGF expressed in insect cells and CHO K1 cells. 
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 a.                                                    
 
b. 
 
Figure 1.12. The cleavage sites for endoglycosidase F1 (a) and PNGase F (b).  
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1.3 Antibody 
1.3.1 Structure of the antibody 
Antibodies(immunoglobulins) all share a basic structure. It is a capital letter "Y" shaped 
molecule formed by two heavy chains (H, ~50 kDa/each) and two light chains (L, ~25 
kDa/each), linked by disulphide bonds. Each chain contains the variable region (V) and the 
constant region (C) (Figure 1.13). The variable region (V), composed of 110-130 amino acids, 
confers the antibody specificity for binding the antigen. It is located in the tips of the "Y" and 
the amino acids in this region vary greatly between different antibodies. The constant region 
(C) determines the mechanism used to destroy antigen.  
 
The fragment antigen binding region (Fab fragment), composed of one constant and one 
variable domain of each of the heavy and the light chains, can be produced with a protease. 
The fragment crystallizable region (Fc region), composed of two identical protein fragments, is 
the tail region of an antibody that interacts with cell surface receptors (Fc receptors) and some 
proteins of the complement system. It allows antibodies to activate the immune system.  
 
Based on the constant region structure and immune function, antibodies are divided into five 
major classes, IgM, IgG, IgA, IgD, and IgE[286-288]. The most common immunoglobulin class is 
IgG. Its basic monomer structure is shown in Figure 1.13. Each chain is divided into regions or 
domains consisting of around 110 amino acid residues. The light chain has two domains and 
the heavy chain has four. The Fv domain on the N-terminal of both the heavy and light chains 
is known to be variable in amino acid sequences and called variable domains (VL and VH). By 
contrast, the other domains of antibodies are relatively constant, and are called constant 
domains (CL, CH1, CH2, CH3). The variable region is further subdivided into hypervariable (HV) 
and framework (FR) regions. The HV regions, which directly contact a portion of the antigen's 
surface, are referred to as complementarity determining region (CDR). Within light and heavy 
chains, there exist three hypervariable regions (HV 1, 2 and 3) and four FR regions. The FR 
regions have more stable amino acid sequences than HV regions and separate the HV 
regions. The FR regions form a beta-sheet structure and serve as a scaffold to hold the HV 
regions in position. 
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Figure 1.13. Basic antibody structure. Fab: antigen binding region, Fc: crystallizable region, S-S bonds (—) and 
sugar (hexagon). 
 
1.3.2 Antibody production 
1.3.2.1 Monoclonal antibody 
Monoclonal antibody (mAb) is an antibody made to target a specific epitope. It is identical and 
produced from a single parent cell.  
 
The classic method for generation of monoclonal antibodies is hybridoma technology. The 
technology typically involves fusing myeloma cells with the spleen cells from a mouse 
immunized with the desired antigen. The production of monoclonal antibodies consists of 
three stages: (1) immunization to stimulate antigen-specific B-cells in vivo, (2) selection of 
immortalized antigen-specific B-cell clones in vitro, (3) propagation of selected B-cell clone in 
vitro, followed by isolation of antibodies from supernatant.  
 
In contrast to production of polyclonal antibodies, monoclonal antibody production includes a 
clone selection step in vitro, therefore, identical monoclonal antibodies are secreted from one 
single clone. The produced monoclonal antibody is homogenous, specific to a single epitope 
and exhibits the defined affinity. The monoclonal antibody-secreting clones produce virtually 
unlimited quantities of a specific antibody, whereas polyclonal antibodies are limited (200 ml to 
several liters). Since myeloma cells are professional immunoglobulin-secreting cells and they 
are able to make post-translational modifications, the produced proteins are properly 
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glycosylated, which is important for the function of antibodies. However, the generation of 
monoclonal antibodies is more expensive and time consuming.  
 
1.3.2.2 Polyclonal antibody 
Polyclonal antibodies (or antisera) are a mixture of immunoglobulin molecules derived from 
different B-cell lines. Polyclonal antibodies react against a specific antigen, each of them 
however recognising a different epitope. Therefore, polyclonal antibodies are a mixture of 
various antibody types and epitope affinities. 
 
Polyclonal antibodies are obtained from the serum of an immunized animal. They are 
commonly produced by the following procedures: (1) immunizing animals (goats or rabbits) 
with an antigen, (2) bleeding the animal periodically (3) extracting the antibodies directly from 
the serum.
 
The process is relatively inexpensive and large quantities of an antibody can be 
isolated from a single extraction. 
 
1.3.2.3 Other techniques 
Recombinant and phage display technologies have emerged as useful techniques for the 
generation of antibodies of human origin.  
In recombinant technologies, the antibody is produced by placing human genes expressing a 
particular antibody into a common cell line, such as E. coli, in order to reduce immunogenicity, 
increase affinity or alter the specificity of antibody. 
With phage display technologies, large quantities and human original antibodies can be 
produced but with low affinity.  
1.3.3 Applications of antibody  
Antibody is a common and essential tool for research applications, including western blotting, 
immunohistochemistry, immunocytochemistry, enzyme-linked immunosorbent assay (ELISA), 
immunoprecipitation and flow cytometric analysis. In most immunochemical techniques, 
polyclonal and monoclonal antibodies are both applicable. Polyclonal antibodies allow the 
staining of fixed cells, since they bind to the distinct denaturation-sensitive epitopes on one 
antigen and result in stronger staining. However, due to non-specific or specific binding to 
irrelevant proteins, “background problems” are common for polyclonal antibodies. Monoclonal 
antibodies bind only to a single epitope with background seldom low, but they may fail in 
some techniques due to low avidity, epitope alteration or modification and cross-reactions. 
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In addition, antibodies are now being designed and used for therapeutic applications, 
including suppression of the immune system after organ transplantation[289,290], treatment of 
cancers such as leukemia[291], and inhibition of angiogenesis[292,293]. Monoclonal antibodies 
achieve their therapeutic effect[294] through the direct or indirect mechanism. For example, 
they can have direct effects in producing apoptosis or programmed cell death, or blocking 
growth factor receptors. 
 
1.3.4 Anti-E-selectin antibody 
1.3.4.1 Monoclonal antibody 7A9 
Anti-E-selectin monoclonal antibody 7A9 (mAb 7A9) produced by hybridoma cell line 
HB-10135 (ATCC) is an IgG1 subclass antibody. It recognizes the lectin and EGF-like domain 
of human E-selectin[295]. mAb 7A9 is a functional blocking antibody of E-selectin[296]. The 
tertiary structure of the Fab fragment of mAb 7A9 has been reported at 2.8Å resolution[297]. 
The antigen combining site of mAb 7A9 presents a groove resembling the structure of 
antibodies. The floor and walls of the groove are formed by residues from six complementary 
determining regions (CDRs) and the framework residues of Fab fragment. The groove is large 
enough to accommodate the binding site of the lectin domain of E-selectin formed by the loop 
between β-strands β4 and β5 (Figure 1.6). 
 
In the thesis, mAb 7A9 was produced, purified and coupled to cyanogen activated sepharose 
4B matrix for functional purification of the hE-LecEGF protein. It was also employed to identify 
the binding activity of hE-LecEGF protein expressed in insect cells and CHO K1 cells. 
 
1.3.4.2 Other anti-E-selectin antibodies 
Many monoclonal or polyclonal anti-E-selectin antibodies are available to identify E-selectin, 
such as BBA1, BBA2, BBA18, ENA1, ENA2 and N18. In the thesis, monoclonal 
anti-E-selectin N18 antibody (Santa-Cruz biotechnology) was used for identification of the 
denatured hE-LecEGF protein and monoclonal anti-E-selectin/anti-P-selectin antibody BBA1 
(R&D system) was utilized for capturing the hE-LecEGF protein in a novel capture-binding 
assay.  
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1.4 Protein Crystallography  
X-ray crystallography is a very powerful tool for determining the three-dimensional structure of 
macromolecules and macromolecular complexes. It is currently a major contributor to the 
study of three-dimensional structures of proteins, critical in determining mechanisms of 
proteins actions. Additionally it can aid the development of novel medications, vaccines and 
diagnostics. However, the production of soluble, pure protein and good diffraction-quality 
crystals are clearly the major obstacles in the structural determination of proteins.  
 
1.4.1 Protein sample 
The protein sample for crystallization must be homogeneous and pure (≥95% pure by 
SDS-PAGE). It should have a sufficient amount and exist in an appropriate concentration (1.5 
- 200 mg/ml)[298]. SDS-PAGE, gel filtration and dynamic light scattering are suitable methods 
for assessing the purity and monodispersity of a protein.  
 
1.4.2 Crystallization Method 
A primary screening is necessary for finding the crystallization conditions at which protein 
samples are obtained. The screening is carried out under a rather large number of 
wide-ranging conditions. These conditions are unrelated to one another and mainly consist of 
varying ratios of salt, buffer or precipitating agent. The goal of this procedure is to narrow the 
crystallization conditions. Numerous kits are available, which apply preassembled ingredients 
in systems and guarantee to produce successful crystallization.  
 
Several different crystallization techniques are used for crystallization of macromolecules[299]. 
Two of the most commonly used methods, hanging drop and sitting drop methods, fall under 
the category of vapour diffusion (Figure 1.14). Both methods involve a droplet containing 
purified protein, buffer and precipitant. The droplet is equilibrated with a larger reservoir 
containing similar buffers and precipitants in higher concentrations. Initially, the droplet of 
protein solution contains an insufficient concentration of precipitant for crystallization, but as 
water vaporizes from the drop and transfers to the reservoir, the precipitant concentration 
increases to a level optimal for crystallization. Since the system is in equilibrium, these 
optimum conditions are maintained until the crystallization is achieved[300,301]. The two 
methods have to be performed in a closed system, that is, the system must be sealed off from 
the outside using an airtight container or high-vacuum grease between the glass surfaces. 
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However, even with identical precipitant, protein solution concentrations and volumes for the 
two set-ups, the experimental results are not always the same.  
 
1.4.2.1 Sitting-drop technique  
The advantages of the sitting-drop technique are that the automated nano-dispensing system 
can be used for preparation of the crystallization conditions, and that the minimum samples 
are consumed. The high-throughput screening is performed by this method. However, protein 
crystal sediment on the glass or plastic surface in this method can be damaged during the 
retrieval, and adhered crystals are much more likely to crack during the growth.  
 
1.4.2.2 Hanging-drop technique  
Contrary to the sitting-drop method, the protein drop of the hanging-drop method is in the 
vertical orientation within the system (see Figure 1.14a). The hanging-drop method largely 
eliminates the problems in the sitting-drop method, since crystal sediment is directed away 
from the supporting surface toward the liquid–air interface. Freely suspended crystals often 
have unperturbed facets, show less cracking and are easily retrieved for diffraction studies. 
Hence, hanging-drops are preferred for the final crystallization trials to obtain the largest, 
highest quality crystals for data collection. However, obtaining well-formed hanging drops with 
well-defined surface-to-volume ratios are very difficult. In addition, there is no automated 
instrument available for high-throughput screening and more protein is consumed in the 
method, compared with the sitting-drop method. 
 
 
 a. 
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Figure 1.14. Schematic representation of hanging drop method (a) and sitting drop method (b)[301]. Reservoir 
solution (blue) usually contains buffer and precipitant. Protein solution (red) contains the same compounds, but in 
lower concentrations. The protein solution may also contain trace metals or ions necessary for precipitation of 
particular proteins. 
 
 
In this thesis, the first crystallization pre-screening of the hE-LecEGF protein expressed in 
CHO K1 cells was performed using the sitting-drop method with an automated 
nano-dispensing system.  
b. 
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1.5 The Aim 
Human selectins (E-, P- and L-selectin) are fundamentally involved in many physiological and 
pathological processes. They represent an attractive drug target to develop novel drugs 
against inflammatory diseases. Pan-selectin antagonism is a desired treatment strategy. 
Inhibition of E-selectin, rather than general selectins, is an appealing specific therapeutic 
approach, since inhibition of E-selectin appears to have no anti-adhesive and 
immunosuppressive activity in other, non-targeted organs. 
 
Human E-selectin (hE-selectin), a C-type lectin, is transiently expressed on endothelial cells. 
The key role of hE-selectin is to mediate the initial rolling and adhering of leukocytes in cell 
adhesion. The crystal structure of hE-LecEGF complexed with its natural ligand sLex, as well 
as NMR studies of ligand binding, were reported and served for the rational design of 
hE-selectin antagonists. In the past decade, numerous sLex analogues or small molecule 
mimics were designed and synthesized as hE-selectin antagonists. However, the binding 
mode of hE-LecEGF complexed with the potent antagonist remains unknown. To develop 
more potent antagonists, the structure of hE-LecEGF co-crystallized with its antagonist is 
required. Therefore, a sufficient amount of the pure, active and characterized protein is 
needed for the demands of protein for structure determination.  
 
In addition, synthesized antagonists need to be correctly evaluated in a cell-free assay. To 
date, the binding affinity of hE-selectin antagonists has only been evaluated with 
hE-selectin/IgG or LecEGFFlag. The C-terminal hIgG1 tag or Flag tag in hE-selectin/IgG or 
LecEGFFlag protein may interfere with the binding activity of the protein. The binding activity 
of hE-LecEGF has only been screened by a cell-based assay. Thus, a reliable, cell-free assay 
using the monomeric, soluble and tag-free hE-LecEGF is required to evaluate the binding 
affinity of hE-selectin antagonists and the binding activity of hE-LecEGF. 
 
In the first part of the thesis, we aim to clone, express and characterize the functional unit of 
human E-selectin (hE-LecEGF) for future structural studies. Insect cell expression systems 
and mammalian expression systems will be used to achieve this goal. 
 
Furthermore, we aim to functionally purify the hE-LecEGF protein using antibody-based 
affinity chromatography. MAb 7A9, a monoclonal functional blocking anti-E-selectin antibody, 
will be produced, purified and coupled to the matrix for functional purification. 
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In the second part of the thesis, we aim to develop a cell-free binding assay using the purified 
hE-LecEGF protein to evaluate the binding affinity of hE-selectin antagonists. It will give more 
accurate and reliable results compared to the previous unstable polymer assay. Several 
antagonists of hE-selectin will be tested in the developed assay. 
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2. Materials and Methods 
2.1 Sequence analysis 
2.1.1 DNA sequence 
The nucleic acid sequence of human E-selectin was extracted with the entry number of 
M30640 from GenBank and the amino acid sequence was extracted with the entry number of 
P16581 from UniProtKB/Swiss-Prot. These sequences were used for primer designs, 
sequence analysis and prediction of post-translational modification of the lectin and the 
EGF-like domains of human E-selectin (hE-LecEGF). 
 
2.1.2 Prediction of post-translational modification  
The post-translational modification of N-glycosylation sites and O-glycosylation sites in 
hE-LecEGF were predicted with the programs of NetNglyc server1.0[302], NetOGlyc3.1 
Server[303] and OGPET of Expert Protein Analysis System (ExPASy), respectively. 
 
2.1.2.1 Prediction of N-glycosylation sites 
The NetNglyc1.0 server predicts N-Glycosylation sites in human proteins using artificial neural 
networks that examine the sequence context of Asn-Xaa-Ser/Thr sequons, including 
Asn-Pro-Ser/Thr. The N-glycosylation sites of hE-LecEGF were predicted by submitting the 
amino acid sequence of hE-LecEGF in FASTA format. 
 
2.1.2.2 Prediction of O-glycosylation sites 
The NetOGlyc3.1 Server and OGPET program were used for prediction of the O-glycosylation 
sites of hE-LecEGF by submitting the amino acid sequence of hE-LecEGF in FASTA format. 
The NetOGly3.1 produces neural network predictions of mucin type GalNAc O-glycosylation 
sites in mammalian proteins. The OGPET algorithm is another algorithm to predict the 
potential O-glycosylation sites in eukaryotic (non-protozoan) proteins.   
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2.1.3 Prediction of isoelectric point (pI) and molecular weight (Mw)  
The isoelectric point (pI) and Molecular weight (Mw) of the hE-LecEGF protein expressed in 
insect cells and CHO K1 cells were predicted respectively with the program ProtParam[304] of 
ExPASy by submitting the amino acid sequence of hE-LecEGF. 
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2.2 Cloning, Expression, Purification and Characterization of Human 
E-LecEGF in Insect Cells 
2.2.1 Buffers and Media 
• Buffers 
TBE buffer 0.5x   (45 mM Tris-Borate, 1 mM EDTA) 
TE buffer         (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) 
TBS buffer        (20 mM Tris-HCL, 500 mM NaCl, pH 7.5) 
TTBS buffer      (20 mM Tris-HCL, 500 mM NaCl, 0.05% Tween 20, pH 7.5) 
 
• Media 
LB medium 
Bacto tryptone 10.0 g, Bacto yeast 5.0 g and NaCl 10.0 g were dissolved in 950 ml water. 
After the pH was set to 7.5 with NaOH, volume was adjusted to 1000 ml with water and 
medium was autoclaved for 20 min at 121˚C. LB medium was stored at 4˚C until use. 
 
LB agar plate 
LB agar plates were prepared by adding Bacto agar 15 g per liter LB medium. The medium 
was autoclaved for 20 min at 121˚C and cooled down to 50˚C. The appropriate antibiotics 
were then added and 25 ml were poured into each Petri-dish. Solid LB agar plates were 
enveloped with parafilm and stored at 4˚C until use. 
 
SOC medium 
Bacto tryptone 2.0 g, Bacto yeast 0.5 g, 1 ml 1M NaCl, 0.5 ml 1M KCl and 1 ml 2M MgCl2 
were dissolved in 95 ml water. After pH was set to 7.0 with NaOH, volume was adjusted to 99 
ml with water. Medium was autoclaved for 20 min at 121˚C, cooled down to room temperature 
(RT) prior to addition of 1 ml sterile filtered 2 M glucose. 
 
Grace’s Medium (Invitrogen) 
 
Sf-900 II SFM  (Invitrogen) 
 
Express-Five SFM (Invitrogen) 
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Complete Sf-900 II medium:  
Sf-900 II SFM supplemented with 10% FBS (Gibco) 
 
Cryopreservation media: 
Sf-900 II SFM supplemented with 10% FBS (Gibco) and 7.5% DMSO (Invitrogen) 
 
RPMI1640-0 medium:  
RPMI 1640 medium (Gibco) supplemented with 1 mM Sodium pyruvate (Sigma), 2 mM 
GlutaMAX (Sigma) and 50U/ml Penicillin/Streptomycin (Sigma). 
 
RPMI1640-2 medium: 
RPMI1640-0 medium supplemented with 2% FBS (Gibco, ultra low IgG) 
 
RPMI1640-6 medium: 
RPMI1640-0 medium supplemented with 6% FBS (Gibco) 
 
RPMI1640-15 medium: 
RPMI1640-0 medium supplemented with 15% FBS (Gibco) 
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2.2.2 Cloning  
2.2.2.1 General DNA methods 
(1) OD600 measurement 
The cell density of E.coli cultures was measured by a SmartSpec3000 cuvette 
spectrophotometer (Bio-Rad) at optical density 600 nm (OD600)[305]. Cell numbers were 
calculated with Equation 1 using a conversion factor at OD600 of 5.0X108 cells/ml. 
 
C= f x OD600 
Equation 1: Calculation of E.coli cell density(c) in cultures by measuring OD600 using the conversion factor (f) of 
E.coli (5x108 cells/ml). 
 
E.coli culture aliquots were diluted to an appropriate concentration in medium. 300 µl diluted 
cultures or blank (medium) were transferred into plastic semi-micro cuvettes (path length 1cm) 
and the turbidity was measured at OD600. 
 
(2) Bacterial glycerol stocks for the long time storage  
A single clone from the LB agar plate was inoculated into LB medium containing appropriate 
antibiotics at 37˚C until reach mid-logarithmic phase (OD600 of 0.6-0.8). 850 µl cell culture was 
mixed with 150 µl sterile glycerol in cryotubes and followed by shock-freezing in liquid 
nitrogen (LN2) and stored at - 80˚C.  
 
(3) Preparation of CaCl2 competent cells  
The CaCl2 competent cells were prepared according to the method from Sambrook J.[305]. A 
single clone of E.coli DH 5α was inoculated into 3 ml LB medium and cultured overnight at 
37˚C, 300 rpm. 50 ml LB medium was inoculated with 1 ml overnight culture and incubated at 
37˚C, 300 rpm until an OD600 of 0.5-0.7. Cells were collected by centrifugation at 3000 rpm for 
20 min at 4˚C. The cell pellets were then resuspended in 10 ml of 100 mM CaCl2 and 
incubated on ice for 30 min. After centrifugation at 2000 rpm for 10 min at 4˚C, the cells were 
resuspended in 1 ml of 100 mM CaCl2 with 20% glycerol and aliquotted at 50 µl in cryotubes. 
The competent E.coli glycerol aliquots were then shock-freezing in liquid nitrogen and stored 
at - 80˚C.          
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(4) Agarose-gel electrophoresis 
Agarose-gel electrophoresis[305] was performed with appropriate concentration of the gel. The 
optimal separating resolution for DNA in the range of 0.5-7 kbp is on 1% gel, of 0.4-6 kbp on 
1.2% gel, of 0.2-3 kbp on 1.5% gel and of 0.1- 2 kbp on 2% gel. 
 
• DNA sample preparation 
DNA sample and DNA ladder were diluted to 9 µl with TE buffer (pH 8.0) and mixed with 1 µl 
10x Sample loading buffer. 
 
• Agarose-gel preparation 
0.8 g to 1.6 g agarose was dissolved in 80 ml 0.5x TBE buffer by heating in a microwave to 
prepare 1-2% agarose-gel. Agarose solution was cooled down to about 50 ˚C prior to adding 
0.8 µl ethidium bromide solution (10 mg/ml) and pouring into a horizontal electrophoresis 
chamber (100x100 mm, 16 pockets). 
 
• Electrophoresis 
Solid 1-2% agarose-gel containing ethidium bromide (EB, 0.1 µg/ml) was overlaid with 
0.5xTBE buffer just prior to use. The gel electrophoresis was run at 80-100 mV (0.8-1 mV/mm) 
after loading samples into gel pockets. Ethidium bromide stained DNA fragments were 
visualized under UV light (302 nm) and documented using GelDoc2000 and software Quantity 
One 4.1 (Bio-Rad). 
 
(5) Quantification of DNA 
DNA was quantified by the methods described below. 
 
• Quantification of the bacterial plasmid DNA by A260/ A280 measurement  
The plasmid dsDNA concentration was determined by measuring absorbance at 260 nm 
(A260)[305] in a SmartSpec3000 cuvette spectrophotometer (Bio-Rad). The concentration was 
calculated with Equation 2 using the conversion factor at A260 for dsDNA (50 µg/ml). The purity 
of DNA was controlled by comparing the absorbance at 260 nm (A260) to 280 nm A280.  
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C= f x A260 
Equation 2: Calculation of the plasmid dsDNA concentration (c) by measuring the absorbance at 260nm (A260) 
using a conversion factor (f) of dsDNA (50 µg/ml). 
 
 
The plasmid dsDNA samples were diluted in TE buffer (pH 8.0) to an appropriate 
concentration. 300 µl samples or blank (TE buffer, pH 8.0) were transferred into a quartz 
semi-micro cuvette (path length 1cm) and absorbance was measured at 260 nm and 280 nm. 
Using SmartSpec software, the concentration of plasmid dsDNA and ratios of A260/ A280 were 
calculated. 
 
• Quantification of the dsDNA by agarose-gel electrophoresis 
Quantification of the bacterial plasmid DNA was also performed on an agarose-gel stained 
with ethidium bromide (EB)[305]. λ dsDNA standards (0.25, 0.5, 1.0, 2.0, 3.0, 4.5, 6.0, 8.0 and 
10.0 µg/ml) and sample in an appropriate concentration in TE buffer (pH 8.0) were run on an 
agarose-gel containing EB. Using GelDoc2000 and Quantity One 4.1 software, the gel was 
photographed (UV mode) and the standard calibration curve was drawn to estimate the 
concentration of the plasmid dsDNA in samples. 
 
2.2.2.2 Construction of the secretion plasmid pFastBacYJS 
The secretion plasmid pFastBacYJS was first constructed for secretion of hE-LecEGF into the 
medium in insect cells. The gp67 signal sequence was cloned into the vector pFastBacTM1 to 
get the plasmid pFastBacYJS.  
 
(1) Amplification of the gp67 signal sequence by Polymerase Chain Reaction (PCR) 
The forward primer SN1 containing a BamH I restriction site and backward primer SN2 
containing an Xba I site (Figure 2.1) were designed for amplification of the gp67 signal 
sequence[261] from the plasmid pAcGP67-A Baculovirus transfer plasmid (Figure 2.2). 
 
Primer SN1:   5’- CGCGGATCCATGCTACTAGTAAATCAGTCA -3’ 
                      BamH I 
 
Primer SN2:   5’- CTAGTCTAGACGCAAAGGCAGAATGCGC –3’ 
                        Xba I  
 
Figure 2.1. The forward primer SN1 and the backward primer SN2 designed for amplification of the gp67 signal 
sequence. 
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• Calculation of the melting temperature and annealing temperature 
The melting temperatures (Tm) of the selected primers were calculated according to the 
Equation 3[306]. The annealing temperature for SN1 (Tm: 58 ˚C) and SN2 (Tm: 56˚C) primers 
was determined as 58 ˚C to avoid the non-specific amplification. 
 
Tm (˚C) = 2 ˚C (a + t) + 4˚C (c + g)        
Equation 3: Tm determination of a primer containing a: adenine, t: thymidine, c: cytosine and g: guanosine 
nucleotides.     
 
 
• PCR amplification using Pfu DNA polymerase 
The PCR method was adapted from the method generated by S. S. Saiki[307]. The lyophilized 
SN1 and SN2 primers (Figure 2.1) were dissolved in sterile water at 100 pmol/µl. For the PCR 
reaction, primers were then diluted to 10 pmol/µl in sterile water. Mastermix was prepared with 
the appropriate amounts of template, primers and Pfu DNA polymerase (Promega) in a PCR 
tube (0.2 ml, GeNunc) on ice according to Table 2.1. The template for the negative control 
was millipore water.  
 
Table 2.1. Composition of mastermix for 50 µl PCR reaction to get the final concentrations of 200 µM dNTP, 400 
nM forward primer/ backward primer, 2.5 U Pfu DNA polymerase in 1x PCR buffer. 
 
 Mastermix 
Template DNA (25-250 ng) 5 µl 
Forward Primer (10 pM) 2 µl 
Backward Primer (10 pM) 2 µl 
dNTP Mix (dATP, dGTP, dCTP, dTTP, 10 mM) 1 µl 
10x Pfu PCR buffer 5 µl  
Pfu DNA polymerase (5 U/µl) 1 µl 
Millipore water 34 µl 
Total 50 µl 
 
Figure 2.2. Map of the plasmid pAcGP67-A (9761bp). 
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The amplification was performed using the oil-free iCycler thermal cycler (Bio-Rad) with the 
program shown in Table 2.2. The amplified PCR products were then analyzed by agarose-gel 
electrophoresis (see section 2.2.2.1) and purified with GenPCR purification Kit (Sigma) 
according to the manufacturer’ s instructions. 
 
 
Table 2.2. Program of PCR amplification of the gp67 signal sequence. 
 Temperature Time Cycle 
Initial denaturation 94˚C 5 min 1 
Denaturation 94˚C 30 sec 30 
Annealing 58˚C 1 min 30 
Extension 72˚C 1 min 30 
Final extension 70˚C 10 min 1 
Storage 4˚C ∞  
 
(2) Restriction enzyme digestion 
The purified PCR fragments of the gp67 signal sequence and the plasmid vector pFastBac1 
(Figure 2.3) were digested respectively with restriction endonucleases BamH I (New England 
Biolabs, NEB) and Xba I (NEB) in the NEB buffer 2, since those two enzymes have 100% 
activity in the buffer. The reaction mixture was prepared according to Table 2.3 and performed 
by incubation at 37˚C for 3 h. BamH I produces 5’-gatcc- protruding termini and Xba I produce 
3’-agatc- protruding termini, allowing the specific sticky ligation. 
 
 
 
Table 2.3. Composition of BamH I and Xba I digestions of the gp67 signal sequence fragments and the plasmid 
pFastBacTm1. 
 gp67 signal fragments pFastBacTM1 
DNA fragments 30 µl 15 µl 
10xNEB buffer2 5 µl 5 µl 
BamH I  (10 U/µl) 1 µl 1 µl 
Xba I (10 U/µl) 1 µl 1 µl 
BSA (1 mg/ml) 0.5 µl 0.5 µl 
Sterilized water 12.5 µl 27.5 µl 
Total 50 µl 50 µl 
Figure 2.3. Map of the plasmid pFastBacTM 1 (4775bp). 
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The Digested gp67 signal fragments and the plasmid pFastBac1 were then analyzed by 
agarose-gel electrophoresis (see section 2.2.2.1) and purified by agarose-gel extraction with 
the GenEluteTM Gel Purification kit (Sigma) according to the manufacturer’s instructions. 
 
(3) Ligation of the gp67 signal sequence into the pFastBacTM1 vector 
The ligation mixture containing the gp67 signal fragments and the vector pFastBacTM1 in a 
ratio of 3:1[308] was prepared according to Table 2.4. The ligation of the digested gp67 signal 
fragments into the digested pFastBacTM1 was conducted with T4 DNA ligase at 16 ˚C 
overnight[308].   
 
Table 2.4. Composition for the ligation of the gp67 signal fragment into the pFastBacTM1. 
 Volume 
10xT4 DNA ligase buffer 2 µl 
plasmid pFastBacTM1  2 µl (0.15 µg)
gp67 signal fragments 10 µl (0.45 µg)
T4 DNA ligase (400 U/µl) 1 µl  
Sterilized water 5 µl 
Total 20µl 
 
(4) Transformation and isolation of plasmids from transformants 
• Transformation 
The plasmid pFastBacYJS was transformed into chemical competent E.coli DH5α cells 
according to the Competent Cell Manual[309]. Two aliquots of 50 µl DH5α competent cells were 
thawed on ice. 5-10 ng purified plasmids or ligation products and negative control (sterilized 
water, the same volume to samples) were added and mixed by flicking, respectively. After 
incubation on ice for 30 min, the cells were heat shocked at 42 ˚C for 45s on a heating block 
and immediately chilled on ice for 2-3 min. After addition of 500 µl SOC medium, the cells 
were incubated at 37˚C, 300 rpm for 1h. 200 µl - 400 µl transformed E.coli cells were then 
plated on a LB agar plate containing appropriate antibiotics and incubated (cover-side down) 
at 37˚C overnight. The transformants were then analyzed to validate the transformation. 
 
• Isolation of plasmids 
The single colony of transformants was picked from the transformation LB agar plate and 
inoculated in 3 ml LB medium containing appropriate antibiotics at 37˚C, 300 rpm and 
overnight. The plasmid DNA from E.coli transformant was prepared with GenElute Plasmid 
Miniprep kit (Sigma) according to the supplier’s instruction. The purified plasmid was eluted in 
100 µl Millipore water and stored at - 20°C until use. 
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(5) Analysis of E.coli transformants 
PCR amplification, restriction endonuclease digestion and DNA sequencing were used to 
verify the transformants. 
 
• PCR analysis 
Colony PCR 
Colony PCR of E.coli transformants was performed according to the pET System Manual[310]. 
The single colony of transformed E.coli was picked from the transformation LB agar plate and 
suspended in 25 µl 0.1% Triton X-100 by pipetting and vortexing. After incubation at 55˚C for 
1h with shaking at 300 rpm, cell lysates were cleared by centrifuge at 12000 rpm for 5min. 10 
µl lysate supernatants were taken as the template DNA in PCR for amplifying the target gene 
following the procedure described in section 2.2.2.2. PCR products were analyzed by 
agarose-gel electrophoresis (see section 2.2.2.1). 
 
Standard PCR 
The purified plasmid from the transformant was diluted in water and served as the template 
DNA in PCR for amplifying the target gene following the procedure described in section 
2.2.2.2. 
 
• Restriction digestion analysis 
According to Table 2.5, the purified plasmid pFastBacYJS was double-digested with BamH I 
and Xba I at 37˚C for 3h, together with the negative control (without restriction enzyme) and 
the blank control (without plasmid). The digested plasmid was analyzed by agarose-gel 
electrophoresis (see section 2.2.2.1). 
 
Table 2.5. Set up of double digestions with BamH I and Xba I. Both enzymes are 100% active in NEB buffer 2. 
 BamH I and Xba I Negative control Blank 
10xNEB buffer 2 2 µl   2 µl   2 µl   
Plasmid DNA 2 µl   2 µl   - 
BSA(1mg/ml) 2 µl   2 µl   2 µl   
BamH I (10 U/µl) 1 µl   - 1 µl   
Xba I (10 U/µl) 1 µl   - 1 µl   
Sterilized water 12 µl   14 µl   14 µl   
Total 20 µl   20 µl   20 µl   
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• Plasmid DNA sequence verification  
A single clone of transformant was streaked on a LB agar plate containing antibiotics and 
incubated upside-down at 37˚C overnight. The cultured plate was then sent to Microsynth 
GmbH sequencing group (Balgach) for DNA sequencing. The plasmid pFastBacYJS was 
sequenced with the forward primer FastBacf for the forward sequencing. Sequencing results 
of the gp67 signal fragment were verified by alignment with the gp67 DNA sequence using the 
Blast programs bl2seq of NCBI server. 
 
Primer FastBacf:  5’- TACTGTTTTCGTAACAGTTTTG -3’ 
 
2.2.2.3 Construction of the hE-LecEGF expression plasmid pFastBacYJSE 
(1) Genomic DNA isolation from CHO-E-sel/IgG cells  
For isolation of the genomic DNA, CHO-E-sel/IgG cells expressing human E-selectin fused 
with a C-terminal human IgG1 tag (human IgG1 Fc fragment) were subcultured in T25 flask 
and collected by Trypsin-EDTA method. After removal of the culture medium, the cell layer was 
briefly rinsed with 5 ml of Ca2+/Mg2+ free Dulbecco's phosphate-buffered saline (D-PBS, 
Sigma). The cells were detached by rinse with 2 ml 0.25% (w/v) Trypsin-0.53 mM EDTA 
solution (sigma) and incubation at 37°C for 1-3 min. 5.0 ml of complete growth medium was 
then added into the flask and the cells were suspended by gently pipetting up and down. The 
cells were then collected by centrifugation at 1000 rpm at 4°C for 10 minutes and the genomic 
DNA was isolated from the harvested cells with WIZARD Genomic Purification Kit (Promega) 
according to the manufacturer’s instructions. 
 
(2) PCR-amplification of the hE-LecEGF sequence 
The forward primer E-FLE1 containing an Xba I restriction enzyme site and a N-terminal flag 
tag (DYKDDDDK) and the backward primer E-FLE2 containing an Xho I site were designed 
for amplification of hE-LecEGF from the genomic DNA of CHO-E-sel/IgG cells (Figure 2.4). 
The PCR amplification was performed with the annealing temperature of 56 ˚C as described 
in section 2.2.2.2. The amplified PCR products were analyzed by agarose-gel electrophoresis 
and purified with GenPCR purification Kit (Sigma) according to the manufacturer’s 
instructions. 
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Primer E-FLE1:    
       5′-CTAGTCTAGAGACTACAAGGACGATGACGACAAGTGGTCTTACAACACCTCCA-3′ 
 
 
Primer E-FLE2: 
5′- CCGCTCGAGTTACACAATTTGCTCACACTTGA-3′ 
 
 
 
(3) Restriction enzyme digestion 
Restriction digestions of the hE-LecEGF PCR fragments and the plasmid pFastBacYJS were 
conducted with Xba I and Xho I at 37˚C for 3 h with Table 2.6. 
 
Table 2.6. Composition of double digestions of the hE-LecEGF PCR fragments and the plasmid pFastBacYJS with 
Xba I and Xho I. 
  hE-LecEGF fragments pFastBacYJS
DNA fragments 30 µl    15 µl   
10xNEB-buffer2 5 µl   5 µl   
Xba I (10U/µl) 1 µl   1 µl   
Xho I (10U/µl) 1 µl   1 µl   
BSA (1mg/ml) 0.5 µl   0.5 µl   
Sterilized water 12.5 µl   27.5 µl   
Total 50 µl   50 µl   
 
(4) Ligation of the hE-LecEGF fragments into the pFastBacYJS 
The doubly digested hE-LecEGF fragments were inserted into the same digested vector 
pFastBacYJS by T4 DNA ligase as described in section 2.2.2.2. 
 
(5) Transformation and isolation of the plasmid pFastBacYJSE 
The transformation of the plasmid pFastBacYJSE into E.coli DH 5α competent cells and 
isolation of plasmids pFastBacYJSE from transformants were done as described in section 
2.2.2.2. A number of transformed clones were then analyzed as below. 
 
(6) Analysis of E.coli transformants 
• Colony PCR 
Colony PCR of E.coli transformants was performed with E-FLE1 and E-FLE2 primers and Taq 
DNA polymerase as described in section 2.2.2.2.  
Xho 
Xba I Flag tag 
D   Y   K    D   D   D    D   K                
Figure 2.4. The forward primer E-FLE1 and backward primer E-FLE2 designed for amplification of the
hE-LecEGF sequence. 
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• Restriction digestion analysis 
Double digestions of the plasmids isolated from transformants were performed with Xba I and 
Xho I at 37˚C for 3 h as described in section 2.2.2.2. 
 
• Plasmid DNA sequence verification 
The expression plasmids pFastBacYJSE were sequenced with the forward primer FastBacf 
for the forward sequencing as described in section 2.2.2.2. The sequencing results of the 
gp67 signal sequence and the hE-LecEGF sequence were verified by alignment using the 
Blast programs bl2seq of NCBI server. 
 
2.2.2.4 Generation of the recombinant bacmid 
(1) Transforming DH10BacTM E. coli  
100 µl MAX Efficiency® DH10BacTM competent cells (Invitrogen) was thawed on ice and 
gently mixed with 5 µl plasmid pFastBacYJSE (1 ng). After incubating on ice for 30 min, the 
cells were heat-shocked for 45 seconds at 42°C without shaking. The cells were then 
immediately transferred to ice and chilled for 2 min. 900 µl of S.O.C. Medium was add into the 
cells and cells were cultivated at 37°C, 300 rpm for 4 h. 200 µl, 300 µl and 500 µl of the cells 
were plated on transposition LB agar plates containing 50 µg/ml kanamycin, 7 µg/ml 
gentamicin, 10 µg/ml tetracycline, 100 µg/ml Bluo-gal and 40 µg/ml IPTG, respectively. The 
plates were incubated at 37°C for 48 h. The white colonies were then picked and restreaked 
on fresh transposition LB agar plates for verifying the phenotype. The restreaked plates were 
incubated overnight at 37°C. The single colony with a white phenotype on restreaked plates 
containing Bluo-gal and IPTG was picked for further analysis.  
 
(2) Isolation of the recombinant Bacmid DNA 
The single colony confirmed on restreaked plates was picked and inoculated in a 3 ml LB 
medium containing 50 µg/ml kanamycin, 7 µg/ml gentamicin and 10 µg/ml tetracycline. The 
culture was grown at 37°C, 300rpm until cells reach stationary phase. The cell pellet of 1.5 ml 
of bacterial culture was collected by centrifugation at 12, 000 rpm for 1 min and resuspended 
in 0.3 ml of Solution I (15 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 µg/ml RNase A, 
filter-sterilize) by gentle vortexing. 0.3 ml of Solution II (0.2 N NaOH, 1% SDS; filter-sterilize) 
was added, gently mixed and incubated at room temperature (RT) for 5 minutes. The 
appearance of the suspension changed from turbid to almost translucent. The thick white 
precipitates of protein and E. coli genomic DNA were formed by slowly addition of 0.3 ml of 3 M 
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potassium acetate (pH 5.5), mixing gently during addition and incubation on ice for 5 to 10 min. 
After centrifugation at 12,000 rpm for 10 min, the supernatant was gently transferred without 
any white precipitates to a fresh microcentrifuge tube containing 0.8 ml of isopropanol. After 
mixing the sample by invertion of the tube a few times and incubation on ice for 5 to 10 min, 
the sample was centrifuged at 12,000 rpm for 15 minutes at RT. After removing the 
supernatant, the pellet was washed with 0.5 ml of 70% ethanol by inverting the tube several 
times. After centrifugation at 12,000 rpm for 5 min at RT, the cell pellet was washed with 70% 
ethanol once again. The supernatant was then removed as much as possible and the pellet 
was air dried for 5 to 10 min at RT. The DNA pellet was then dissolved in 40 µl of 1X TE Buffer 
(pH 8.0) with occasionally gentle tapping of the bottom of the tube. The purified Bacmid DNA 
was then stored at +4°C for further analysis and transfection into insect cells.  
 
(3) PCR analysis of the recombinant Bacmid DNA  
The primer pair of E-FLE1 (Forward) and E-FLE2 (Reverse) (Figure 2.4), and the primer pair 
of M13 Forward (-40) and M13 Reverse (Figure 2.5) were used to verify the presence of the 
hE-LecEGF sequence in the recombinant bacmid by PCR with Table 2.7 and Table 2.8 as 
described in section 2.2.2.2. PCR products were then analyzed by agarose-gel 
electrophoresis. 
 
Primer M13 Forward (-40):  5’- GTTTTCCCAGTCACGAC -3’ 
Primer M13 Reverse:       5’- CAGGAAACAGCTATGAC -3’ 
 
 
 
 
 Table 2.7. Composition of mastermix for PCR analysis of the recombinant Bacmid DNA. 
 Mastermix 
Template DNA (100 ng) 1 µl   
Forward Primer (10 µM) 1.25 µl   
Backward Primer (10 µM) 1.25 µl   
dNTP Mix (dATP, dGTP, dCTP, dTTP, 10 mM) 1 µl   
10x Taq PCR buffer 5 µl   
Taq DNA polymerase (5 U/µl) 0.5 µl   
50 mM MgCl2 1.5 µl   
Millipore water 38.5 µl   
Total 50 µl   
 
 
 
 
Figure 2.5. The M13 Forward (-40) and M13 Reverse primers for amplification of the transposition sequence in the
Bacmid. 
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    Table 2.8. Program of PCR amplification with M13 forward and M13 reverse primers. 
  Temperature Time Cycle 
Initial denaturation 93˚C 3 min 1 
Denaturation 94˚C 45 sec  30 
Annealing 55˚C 45 sec 30 
Extension 72˚C 5 min  30 
Final extension 72˚C 7 min 1 
Storage 4˚C ∞   
 
2.2.3 Production of the recombinant baculovirus  
2.2.3.1 General cell culture methods 
(1) Viability determination and cell counting 
The cell number and the viability were determined according to the protocol of Harlow Ed[311]. 
The mixture of cell suspension and the same volume of trypan blue dye (0.4%) were filled into 
a Neubauer counting chamber. White living cells and blue dead cells of four big squares (1 
mm2, volume of 0.1 mm3) were counted with 100X magnification under the microscope (IM, 
binocular KpI-W10x/18, objective Ph1F10/0.25, Zeiss). The cell density was calculated using 
Equation 4 and the viability was estimated using Equation 5. 
 
ccells /ml = nviable · d ·104 
                f    
Equation 4: Determination of the cell density using a Neubauer counting chamber. c (cells/ml): the cell density of a 
cell suspension, d: the dilution factor with trypan blue, nviable: the number of viable cells, f : the number of big 
squares. 
 
 
v% =         · 100% 
        ntotal                                                                                              
 
Equation 5: Determination of the cell viability using a Neubauer counting chamber. v (%): the cell viability of a cell 
suspension stained with trypan blue, nviable: the number of viable cells, ntotal: the total number of cells. 
 
(2) Recovering cells from liquid nitrogen storage 
Cells were thawed according to a protocol from Stokmaier D[312]. Cells, frozen at –185°C in 
liquid nitrogen, were quickly thawed at 37°C in a water bath and immediately diluted with 9 ml 
complete medium in a Falcon tube and pipetted carefully up and down. After centrifugation at 
1000 rpm for 10 min, cells were collected and resuspended in supplemented culture medium 
at a appropriate concentration.  
 
nviable 
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(3) Cell freezing  
Cells were frozen by the procedure optimized from Harlow Ed[311]. Briefly, one day before 
freezing, cells were split 1:2 in fresh medium. Cells in T175 flask were counted, the viability 
checked (see section 2.2.3.1) and transferred to a sterile, chilled centrifuge tube. After 
centrifugation at 1000 rpm for 10 min at 4°C, the cells were resuspended in the remaining 
medium by tapping the tube and were diluted by cold freezing medium (7.5-15%DMSO in 
appropriate medium) to get ∼ 1x106-1x107 viable cells/ml. 0.5-1.0 ml aliquots were distributed 
in labeled cryotubes, which were placed in a styropore support. Cells were immediately frozen 
1-10 days at – 80°C prior to storage in liquid Nitrogen for infinite time. 
 
2.2.3.2 Cell culture of Sf9 and Hi-5 cells 
(1) Recovering cells from liquid nitrogen 
Insect cells of Sf9 and High-FiveTM (Hi-5) were recovered from liquid nitrogen in the complete 
Sf-900 II medium (Sf-900 II SFM containing 10% FBS) in T25 flasks (see above). They were 
then subcultured in Sf-900II SFM medium with no adaptation.  
 
(2) Subculture of adherent cells 
When the cell monolayer reaches 80% to 90% confluency, the medium was aspirated and 
discarded from the monolayer. The appropriate fresh Sf-900II SFM was added to resuspend 
cells by pipetting the medium across the monolayer with a Pasteur pipette (4-6 ml for T25cm2 
flask and 15 ml for T75cm2 flasks). The detachment of cells from the surface of flask was 
observed using an inverted microscope. The viable cells were counted by the trypan blue dye 
exclusion method (see section 2.2.3.1). Cells were then inoculated at 2 x104 to 5 x 104 viable 
cells/cm2 into fresh T flasks and incubated at 27°C ± 0.5°C with loose caps to allow gas 
exchange. The cells were subcultured approximately 2 to 4 days post-inoculation. 
 
(3) Subculture of suspension cells 
Insect cells Sf9 and Hi-5 were adapted to suspension culture from monolayer for the protein 
production according to the below procedure. Insect cells subcultured in Sf-900 II SFM 
medium in T flask were dislodged from the bottom of the flask by shaking the flask vigorously 
two to three times in a wrist-snapping motion. The cell suspension was cultured with 
approximately 5x105 viable cells/ml at 27.0°C with a stirring rate of 100 rpm. The cells were 
then subcultured when the viable cell count reaches 1x106 to 2x106 cells/ml (3 to 7 days 
post-planting). The stirring speed of the cell culture was increased by 5 to 10 rpm with each 
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subsequent passage until the constant stirring speed reached 120 rpm and cell viability was 
above 80%.  When cells have fully adapted to suspension culture, the cells were subcultured 
for routine maintenance. Cells were inoculated at 3x105 viable cells/ml in Sf-900II SFM 
medium and incubated until the cells reach 2x106 to 3x106 viable cells/ml. Suspension cells 
were subcultured twice weekly. And every 3 weeks, the cell suspension was gently centrifuged 
at 100 g for 5 min and the cell pellet was resuspended in fresh medium to reduce the 
accumulation of cell debris and metabolic byproducts. 
 
(4) Cell Freezing 
Insect cells Sf9 and Hi-5 were frozen in cryopreservation medium (Sf-900II SFM medium 
containing 7.5% DMSO and 10% FBS) as described in section 2.2.3.1.  
 
2.2.3.3 Transfection  
9x105 Sf9 cells in 2 ml Sf-900II SFM medium were seeded in a 6-well tissue culture plate per 
well with the viability > 97% and incubated at 27°C for at least one hour to allow cells to attach. 
Bacmid DNA:Cellfectin® Reagent was prepared for each transfection sample in 12x75 mm 
sterile tubes as follows: a) 1-2 µg of purified bacmid DNA was diluted in 100 µl of 
unsupplemented Grace’s Medium (No FBS or antibiotics); b) 6 µl of Cellfectin® Reagent was 
diluted in 100 µl of unsupplemented Grace’s Medium and mixed thoroughly by inverting the 
tube 5-10 times; c) The diluted bacmid DNA was mixed gently with the diluted Cellfectin® 
Reagent (total volume is ~210 µl) and incubated for 15 to 45 minutes at room temperature. 
While DNA:lipid complexes are incubating, the media were removed from the cells and the 
cells were washed once with 2 ml of unsupplemented Grace’s Medium. After removing the 
washing medium, 0.8 ml of unsupplemented Grace’s Medium was added to each tube 
containing the DNA:lipid complexes and mixed gently. The DNA:lipid complexes were then 
added to each well and incubated with cells at 27°C for 5 hours. After removing the DNA:lipid 
complexes, 2 ml of Sf-900 II SFM was added to the cells and the cells were incubated in a 27°C 
humidified incubator for further 72 hours or until signs of viral infection were observed. The 
cells were inspected daily for signs of infection beginning at 72 hours after transfection, using 
an inverted phase microscope at 250-400X magnification. P1 Viral Stock was then isolated as 
described in section 2.2.3.4.  
 
2.2.3.4 Isolation of P1 viral stock  
When the transfected cells showed signs of late and very late stages of infection, the medium 
(~2 ml) containing virus was collected from 6-well tissue culture plates and transferred to 
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sterile 15 ml snap-cap tubes. After centrifugation at 500 g for 5 min to remove cells and large 
debris, the clarified supernatant was transferred to a fresh 15 ml snap-cap tube. This P1 viral 
stock was stored at 4oC with a final concentration of 2% fetal bovine serum (FBS) and 
protected from light.  
 
2.2.3.5 Viral plaque assay 
In order to determine the titer of a viral stock or isolate a single viral clone, viral plaque assay 
was performed using the below procedure. 
 
(1) Preparation of Sf-900 plaquing medium  
An empty, sterile 100 ml bottle and Sf-900 Medium (1.3X) were warmed in a 40oC water bath. 
The 4% agarose gel was heated in a microwave oven to be liquefied. The Sf-900 plaquing 
medium was prepared in a sterile hood by combining 30 ml of Sf-900 Medium (1.3X) and 10 ml 
of the melted 4% agarose gel in the empty 100 ml bottle. After mixing gently, the plaquing 
medium was put to the 40oC water bath until use. 
 
(2) Plaque Assay 
1x106 Sf9 cells in 2 ml Sf-900II SFM medium were seeded in three 6-well tissue culture plates 
per well and incubated at room temperature for one hour to allow the cells to settle to the 
bottom of the plate until the attachment of Sf9 cells inspected by an inverted microscope is at 
50% confluence. The 8-log serial dilution (10-1 to 10-8) of the clarified viral stock was prepared 
in Sf-900 II SFM by sequentially diluting 0.5 ml of the viral stock or previous dilution in 4.5 ml of 
medium in 12 ml disposable tubes. 1 ml of the appropriate virus dilution (10-3, 10-4, 10-5, 10-6, 
10-7, 10-8) was immediately added to cells after removal of the medium from each well in a 
6-well tissue culture plate. Two 6-well tissue culture plates were used for the sample plus 
duplicate for the serial dilution viral stock and one 6-well tissue culture plate was used for the 
negative control (no virus). After incubation of cells with virus for 1 hour at room temperature, 
the medium containing the virus was removed from the wells and the wells were replaced with 
2 ml of plaquing medium by sequentially starting from the highest dilution (10-8) to the lowest 
dilution (10-3). The agarose was overlayed to harden for 10-20 min at room temperature before 
incubating the cells in a 27oC humidied incubator for 7-10 days until plaques are visible and 
ready to count.  
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3) Neutral Red staining and titer calculation 
Neutral Red staining was performed on day 7-10 post tranfection to facilitate the plaques 
counting. Neutral Red solution (1 mg/ml) was prepared with sterile and distilled water 
(cell-culture grade). 0.5 ml of Neutral Red solution was added to each well containing the 
plaquing overlay and incubated for 1 to 2 hours at room temperature. The plaques were 
counted after gently removing excess stain with a pipet. Plaques appear as clear spots in a 
nearly clear gel against a red background. Titer (plaque forming units, pfu/ml) of the viral stock 
was calculated by the equation 6. The optimal range for counting is 3 to 20 plaques/well in the 
6-well plate.  
 
                                                         1                                   
Titer (pfu/ml) = number of plaques x dilution factor x                                                  
   ml of inoculum/well 
 
Equation 6: Estimation of the titer of the recombinant baculovirus. 
 
(4) Plaque purification 
Plaque purification was performed to generate a viral stock from a single viral clone. 1x106 Sf9 
cells in 2 ml Sf-900II SFM medium were seeded in 6-well tissue culture plates and incubated 
at room temperature for one hour to attach. The clear plaque in plaque assay was picked 
using the sterile Pasteur pipette. The agarose plug (containing virus) was transferred to a 1.5 
ml microcentrifuge tube containing 500 µl of Sf-900II SFM and mixed well by vortexing. 100 µl 
of the agarose plug solution was then added to cells in the well of 6-well tissue culture plates 
and incubated in a 27oC humid incubator for 72 hours. The medium containing the virus from 
each well (~2 ml) was collected in a sterile 15 ml snap-cap tube and centrifuged at 500g for 5 
min to remove the cells and large debris. The clarified supernatant (the plaque-purified viral 
stock) was stored in a fresh 15 ml snap-cap tube with a final concentration of 2% FBS for 
further amplification.  
 
2.2.3.6 Preparation of P2 viral stock  
2 x 106 cells/well Sf9 cells in 2ml (viability > 97%) were plated in a 6-well tissue culture plate 
and incubated at room temperature for one hour to allow the attachment. The attachment was 
inspected under an inverted microscope. The appropriate amount of P1 viral stock was added 
to each well with MOI (Multiplicity Of Infection) of 0.05 and incubated at 27oC for 48-72 hours. 
MOI is defined as the number of virus particles per cell. The inoculum volume of a viral stock 
was calculated with a specific MOI using the equation 7. The medium (~2 ml) containing virus 
from each well was then collected and transferred to sterile 15ml snap-cap tubes. After 
centrifugation at 500 g for 5 min, the clarified supernatant (P2 viral stock) was collected and 
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stored with a final concentration of 2% FBS at 4oC or at -80oC for the long-term storage.  
                                   
 
 
Inoculum required (ml)  =          
                                titer of viral stock (pfu/ml) 
 
Equation 7: Estimation of inoculation volume according to the number of cells, MOI and titer of viral stock. 
 
2.2.3.7 Preparation of P3 viral stock  
1 x 107 Sf9 cells/well in 10 ml (viability > 97%) was seeded in a T25cm2 tissue culture flask 
and incubated at room temperature for one hour to allow the attachment. After verification of 
the attachment, a appropriate amount of P2 viral stock was added to cells with MOI of 0.05 
and incubated at 27oC for 48-72 hours. The viral stock was then collected and stored as 
described in section 2.2.3.5. 
 
2.2.3.8 Identification of the viral stock by PCR 
In order to verify the recombinant virus, the hE-LecEGF sequence was amplified by PCR from 
the viral stock with E-FLE1 and E-FLE2 primers. 
 
2.2.4 Expression of hE-LecEGF in insect cells 
2.2.4.1 General Protein methods 
(1) Polyacrylamide-gel Electrophoresis and staining 
• Polyacrylamide-gel electrophoresis 
The discontinuous polyacrylamide-gel electrophoresis (PAGE) was performed according to 
the protein methods[313,314]. Proteins were separated in the native PAGE under native 
condition and in the denaturing SDS-PAGE under reducing or non-reducing conditions. 
Reducing SDS-PAGE 
Proteins were separated according to their molecular weights on a SDS-PAGE gel by the 
method of Laemmli[313]. 
 
a. Polyacrylamide-gel preparation  
The percentage of polyacrylamide in the gel was adjusted according to the molecular weight of 
the analyzed protein. The best separation resolution for proteins with a molecular weight in the 
MOI (pfu/cell) x number of cells 
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range of 16-68 kDa was on a 10% gel, of 14-55 kDa on a 12% gel and of 12-43 kDa on a 15% 
gel. 
 
Inner and outer glass plates, spacers and the comb were rinsed with water and ethanol before 
assembling. The separating gel solution (375 mM Tris-HCl, x% polyacrylamide, 1% SDS, 
0.05% TEMED, 0.03-0.1% APS, pH 8.8) was mixed according to Table 2.9, poured 
immediately and mounted with water. After polymerization, the stacking gel (125 mM Tris-HCl, 
5% polyacrylamide, 1% SDS, 0.1% TEMED, 0.03-0.1% APS, pH 6.8) was prepared, 
immediately poured and the comb was inserted prior to polymerization.  
 
Table 2.9. Composition of the separating gel x% and the stacking gel. 
 Separating gel x% Stacking gel
Acrylamide solution 30% (acrylamide:bisacrylamide 
37.5:1) 0.5· x ml 1.7 ml 
Water 11.8-(0.5·x) ml 7.2 ml 
1.875 M Tris-HCl (pH 8.8) 3.0 ml  
1.25 M Tris-HCl (pH6.8)  1.0 ml 
Sodiumdodecylsulfate (SDS) 10% (w/v) 150 µl 100 µl 
Ammoniumpersulfate (APS) 10-40% (w/v) 50 µl 33 µl 
N,N,N,N‘-Tetramethylethylenediamine (TEMED) 7.5 µl 10 µl 
 15.0 ml  10.0 ml 
 
b. Protein sample preparation  
The low molecular weight marker (Sigma) and protein samples were diluted with 0.25 x 
sample protein volume 5x sample buffer (200 mM Tris-HCl, 37.5% glycerol, 5% SDS, 250 mM 
DTT or 2 M β-mercaptoethanol, 0.015% bromophenol blue, pH 6.8) by vortexing. After a brief 
spin, the samples were boiled for 5 min at 95°C. The denatured samples were then spun down 
briefly and stored on ice until use.  
 
c. Electrophoresis  
The gels were submersed in the running buffer (25 mM Tris, 200 mM glycine, 0.1% SDS, pH 
8.6) after complete polymerization and samples were loaded into the gel-pockets using a 
Hamilton syringe. The electrophoresis was run at a constant current of 30 mA/gel for the 
stacking gel and of 40 mA/gel for the separating gel in a Mini Protein gel cell (Mini Protean II, 
Bio-Rad).  
 
Non-reducing SDS-PAGE  
The non-reducing SDS-PAGE was done under the same procedure as described for reducing 
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SDS-PAGE (see section 2.2.4.1), but using the sample buffer composition without reductants 
of mercaptoethanol or DTT.  
 
Native-PAGE  
The native PAGE was prepared under the same procedure as described for reducing 
SDS-PAGE (see above), but the PAGE gel, gel running buffer and sample buffer contained 
no SDS and no reductants (mercaptoethanol or DTT). And protein samples were not boiled.  
 
• Staining methods 
Silver staining  
Electrophoretically separated proteins on a PAGE gel slab were silver-stained for the 
qualitative protein analysis, which has a sensitive detection of protein down to 2-10 
ng/band[315].  
 
The PAGE gel was incubated in 125 ml fixation buffer (40% ethanol, 10% acetic acid) in a 
plastic container for 30 min, while shaking with 70 rpm in the whole procedure and was then 
soaked in 125 ml sensitizing solution (30% ethanol, 68 mg/ml Sodium Acetate, 2 mg/ml sodium 
thiosulphate, 0.125% glutaraldehyde) for 30 min. After washing three times with 200 ml water 
for 5 min, the gel was stained in 125 ml silver solution (2.5 mg/ml silvernitrate, 0.015% 
formaldehyde) for 20 min and destained twice in ∼ 200 ml water for 1 min. The stain of protein 
bands was then developed in 125 ml developing solution (25 mg/ml sodium carbonate, 
0.0075% formaldehyde) for an appropriate time (2-7 min) and stopped in 125 ml stopping 
solution (14.6 mg/ml Na2EDTA·2H2O) by incubation for 10 min, followed by rinsing once in ∼ 
200ml water. The stained gel was documented using the GelDoc2000 and Quantity One 4.1 
software (Bio-Rad) in the white mode.  
 
Commassie staining 
The commassie staining method was performed for the quantitative analysis with the protein 
detection of 100 ng-1000 ng/band. After electrophoresis, the gel was fixed in the fixing solution 
(50% methanol, 10% glacial acetic acid) for 30 min to overnight with gentle agitation. Then the 
gel was stained in staining solution (0.22% Commassie Brilliant Blue G-250, 0.22% 
Commassie Brilliant Blue R-250, 50% methanol, 10% glacial acetic acid) for 30-40 min with 
gentle agitation. The destaining of the gel was performed in destaining solution (40% ethanol, 
10% glacial acetic acid) in several times washing. The stained gel was then photographed 
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with the GelDoc2000 and Quantity One 4.1 software (Bio-Rad) in the white mode. 
 
(2) Bradford assay 
Bradford assay, originally described by Bradford M.M[316], was performed for quantification of 
the protein with the standard assay or the micro-assay[317]. The assay is sensitive in the range 
of 25-200 µg/ml proteins[318]. 
 
• Bradford standard assay  
The BSA standard (0, 20, 40, 60, 80, 100, 120, 160 and 200 µg/ml) and samples of 
appropriate concentrations in the range of the standard were prepared by dilution with sample 
buffer (blank). The standards and samples were measured in duplicates or triplicates in the 
assay. In semi-microcuvettes (path length 1cm), 20 µl BSA standard dilutions, protein samples 
or blank were mixed with 50 µl of 1M NaOH by pipetting prior to addition of 1ml dye solution 
(0.01% Commassie Brilliant Blue G250, 10% phosphoric acid 85%, 5% ethanol). After mixing 
and incubation for at least 5 min, the absorbance was measured within 1h at 595 nm in a 
SmartSpec3000 cuvette spectrophotometer. Using the SmartSpec or Excel software, the 
linear regression graph of standards was drawn and the concentrations of the samples were 
calculated when the correlation coefficient R2 was above 0.95. 
 
• Bradford micro-assay  
The BSA standard (0, 100, 200, 400, 600, 800 and 1’000 µg/ml or 0, 20, 40, 60, 80 and 100 
µg/ml) and samples were prepared as described for Bradford standard assay (see above). 
They were measured in duplicates or triplicates. 10 µl BSA standard dilutions, protein 
samples or blank were added to wells on 96- Microwell V-bottom plates (Nunc), 200 µl dye 
solution (0.01% Commassie Brilliant Blue G250, 10% phosphoric acid 85%, 5% ethanol) were 
added then and mixed by tapping the plate gently. After incubation for 10-12 min, the 
absorbance was measured within 1 h at 595 nm in a Spectramax190 plate reader. Using 
software Spectramax PRO 4.0, the linear regression graph of the standards was drawn and 
the concentrations of the samples were calculated when the correlation coefficient R2 was 
above 0.95. 
 
(3) Western blotting (Immunoblotting)  
A semi-dry transfer method[319] was used for electrophoretically transferring the separated 
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proteins on a PAGE gel to the nitrocellulose membrane with three different buffers[320].  
 
• PAGE  
The sample proteins were separated by SDS-PAGE or native PAGE as described above. 
 
• Electroblotting  
18 sheets of Whatman 3 M absorbent paper and 1 sheet of nitrocellulose membrane (pore size 
0.2 m) were cut to the size of the PAGE gel (60mm x 85mm) and the membrane was wet in 
water first. To assemble the blot sandwich, 6 papers were soaked for a few minutes in Anode 
buffer I (300 mM Tris, 20% methanol) and piled up on the bottom on anode, followed by 3 
papers and the membrane soaked in Anode buffer II (25 mM Tris, 20% methanol), the PAGE 
gel and 9 papers soaked in Cathode buffer (40 mM 6-aminocaproicacid, 20% methanol) at the 
top. The electroblotting was performed for 60 min at 15 V using a TransBlot semi-dry transfer 
cell (BIO-RAD).  
 
• Staining  
Ponceau S staining of the blotted total proteins  
The transfer of separated proteins on the PAGE gel to the membrane was verified by Ponceau 
S staining. The blotted membrane was stained in 0.1% Ponceau S solution (Sigma) in a plastic 
container for a few minutes and then destained twice in ~ 100 ml water. The visible Marker 
bands or the protein bands were marked with a pencil before immunostaining.  
 
Immunostaining of the blotted specific protein  
The unspecific binding sites on the blotted nitrocellulose membrane was blocked by 
incubation with 10 ml blocking buffer (3% BSA in TBS buffer) in a plastic container for 1 h at 
room temperature or overnight at 4°C, while shaking with 60 rpm in the whole procedure. After 
washing in 10 ml TTBS-Ca2+ buffer (2 mM CaCl2 in TTBS buffer) for 5 min for three times, the 
membrane was incubated in 10 ml primary antibody solution (appropriate antibodies, 1% BSA, 
0.1% NaN3 in TTBS-Ca2+ buffer), overnight at 4°C. The membrane was then washed three 
times in 10ml TTBS-Ca2+ buffer for 5 min and incubated in 10 ml secondary antibody 
[alkalinephosphatase (AP)-labeled antibodies, 1% BSA, 0.1% NaN3 in TTBS-Ca2+ buffer] for 2 
h at room temperature. After washing twice thoroughly in 10 ml TTBS-Ca2+ buffer and once in 
10 ml TBS-Ca2+ buffer for 5 min each washing, the bands of the specific protein recognized by 
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the primary antibody were developed in 10 ml substrate solution (0.4% NBT/BCIP, 100 mM 
Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 8.8) for an appropriate time. After rinsing the 
membrane briefly with water, the membrane was dried by the paper tissue and kept in the dark. 
The immunostained membrane was documented using the GelDoc 2000 and QuantityOne4.1 
software in the white mode.  
 
(4) ELISA 
The indirect ELISA was performed to determine the presence and quantity of antigen. 
 
• Coating of antigen 
The appropriate concentration of antigen was coated onto MaxiSorb ELISA plates in 100 
µl/well and incubated overnight at 4°C with the cover of the lid and parafilm.  
 
• Antibody recognition  
After overnight incubation of antigen, plates were washed three times with 200 µl/well 
washing buffer (2 mM CaCl2, 0.05% Tween 20 in TBS buffer, pH 7.5) and tapped dry on paper 
towels. The plates were then blocked with 200 µl/well blocking buffer (3% BSA, 2 mM CaCl2, 
0.05% Tween 20 in TBS buffer, pH 7.5) for 2 h at RT. Wells were then washed three times with 
200 µl/well washing buffer, tapped dry and incubated with 100 µl/well primary antibodies 
which bind specifically to the antigen in blocking buffer for 2 h at RT. Plates were washed 
three times with 200 µl/well washing buffer, followed by the incubation for 2 h at RT with 100 
µl/well enzyme-linked secondary antibodies which are specific to the primary antibodies.  
 
• Detection  
After incubation with enzyme-linked secondary antibodies, the plates were washed three 
times with the washing buffer as previous description. The corresponding substrate was then 
added to elicit the chromogenic signal. The signal was measured with a spectrophotometer 
Spectramax 190 plate reader. Table 2.10 showed the composition of color development of the 
AP-ELISA and HRP-ELISA. The substrate of ABTS substrate solution (Bio-Rad) and stop 
solution of 2% oxalic acid were used for detection of the horseradish peroxidase 
(HRP)-labeled secondary antibody and the absorbance was measured at 415 nm. In alkaline 
phosphatase (AP)-ELISA, 1 mg/ml p-nitrophenyl phosphate disodium was used as the 
substrate for color development and the chromogenic signal was detected at 405 nm. 
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Table 2.10. Composition of the detection in HRP-ELISA and AP-ELISA. 
 HRP-ELISA AP-ELISA 
Secondary antibody HRP-labeled anti-mouse antibody, AP-labeled Goat anti-mouse IgG (Fc specific), 
 1:3000 dilute 1:3000 dilute 
Substrate ABTS substrate kit (Bio-Rad) 1 mg/ml of p-Nitrophenyl phosphate disodium in
 Stop buffer: 2% Oxalic acid 
substrate buffer (10% diethanolamine, 0.5 mM
MgCl2, pH 9.8) 
Absorption 
wavelength 415 nm 405nm 
 
2.2.4.2 Optimization of expression  
The expression of hE-LecEGF was optimized with the below parameters: 
 
a. Cell line:  
Two cell lines of Sf9 and High FiveTM were used for optimization of the hE-LecEGF expression 
in suspension cultures. Insect cell Sf9 was subcultured in Sf-900II SFM medium, High FiveTM 
was subcultured in Express Five SFM medium. 
 
b. Cell density:  
The cells were infected in the mid-logarithmic phase of growth at a density of 1x106, 1.5x106 
and 2x106 cells/ml. 
 
c. MOI:  
The cells were infected with MOI of 1, 2, 5 and 10, respectively. 
 
d. Time course:  
The time course of 24 h, 48 h, 72 h and 96 h post-infection was performed to determine the 
expression kinetics of the recombinant protein. 
 
2.2.4.3 Detection of the recombinant protein  
ELISA and Western-blotting with the monoclonal anti-flag antibody M2 were performed to 
detect the expression of the recombinant protein hE-LecEGF fused with the N-terminal flag 
tag. 
 
(1) ELISA 
ELISA was performed as described in section 2.2.4.1. 150 µl of culture supernatant was 
coated onto MaxiSorb ELISA plates at 4°C overnight, covered with the lid and parafilm. After 
Materials and Methods
 
                                                                                    
 64 
 
 
blocking with 3% BSA, the monoclonal anti-flag antibody M2 (SIGMA) was used to recognize 
the hE-LecEGF. Horseradish peroxidase (HRP)-labeled anti-mouse antibody solution (Goat 
anti-mouse-IgG-HRP) was used as the secondary antibody for detection. ABTS solution 
(Bio-Rad) was added as the substrate for the color development. 2% oxalic acid was used for 
stopping the development. The absorbance was read at 415 nm in a Spectramax190 plate 
reader. 
 
(2) Western-blotting analysis 
50 µl of culture supernatant was first separated by SDS-PAGE electrophoresis under reducing 
conditions. After electro-transferring to the nitrocellulose membrane, the monoclonal anti-flag 
antibody M2 (SIGMA) with a final concentration of 2 µg/ml was used to recognize the 
hE-LecEGF. The anti-Mouse IgG (whole molecule)−Alkaline Phosphatase antibody (Sigma) 
was used for detection of hE-LecEGF. 0.4% NBT/BCIP was used as substrate for the color 
development. 
 
2.2.4.4 Production of hE-LecEGF in insect cells 
The production of hE-LecEGF in insect cells was performed according to the optimized 
expression condition in Sf9 cells and High fiveTM cells with a appropriate cell density, MOI and 
post-infection time, respectively. The production was performed at 27°C in several flasks with 
100 ml appropriate medium in a 300 ml flask. The supernatant of the culture medium was 
collected by centrifugation at 500 g for 10 min at 4°C, filtered with 0.22 µM membrane and 
stored at -20°C for further purification. 
 
2.2.5 Purification and characterization of hE-LecEGF 
2.2.5.1 Monoclonal anti-E-selectin antibody 7A9 production, purification and coupling 
to sepharose 4B matrix 
(1) Cell culture of hybridoma cell HB-10135 
• Recovering cells from liquid nitrogen  
Hybridoma cell line HB-10135, purchased from American Type Culture Collection (ATCC), 
expresses the monoclonal functional blocking anti-E-selectin antibody 7A9 (mAb 7A9). The 
cells were thawed and recovered in fresh RPMI-15 Medium with concentration of 2-4x105 
cells/ml in a T25 flask and incubated at 37°C (5% CO2, 100% humidity) using the method 
described in section 2.2.3.1. The shape of the cells was controlled under the microscope and 
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the high dense cultures were split. 
 
• Cell splitting and adaptation to Low FCS Medium 
Cell splitting 
After recovering from liquid nitrogen, hybridoma cells were subcultured in a 37°C, 5% CO2 
incubator according to a protocol of Harlow Ed[311]. When cell density reaches 1x106 cells/ml, 
the cells were split by diluting the cells in the ratio of 1:10 or 1:20 with fresh medium. 
 
Adaptation to low FCS medium 
Hybridoma cells were adapted to grow in RPMI-6 medium with 6% FCS and in RPMI-2 
medium with 2% FCS from RPMI-15 medium with 15% FCS by initially diluting cell 
suspension 1:1 with the new medium and continuously diluting cells with increasing 
concentrations of the new medium. Finally, cells were subcultured in RPMI-2 Medium with 2% 
FCS.   
 
• Cell freezing  
Hybridoma cells were frozen in RPMI-15 medium containing 10% DMSO as described in 
section 2.2.3.1. 
 
(2) Production of the monoclonal antibody 7A9 
The production of the mAb 7A9 was following the procedure of Harlow E. et al.[311] in both 
T-flasks and roller bottles. 
 
• Production in T-Flasks 
The production of the mAb 7A9 was carried out in RPMI-2 Medium in T175 flasks (50 ml/flask) 
with inoculation of 5x104 -5x105 cells/ml of adapted hybridoma cells. The yellowish culture 
medium containing living cells was collected by centrifugation at 400 g for 5 min. After filtration 
with StericupTM (0.22 µM, Millipore), the cleared supernatant was re-inoculated and 
subcultured with cells to increase the yield of antibodies, or stored at 4°C with addition of 
0.02% NaN3 until the affinity purification. The cell pellet was resuspended in fresh RPMI-2 
media and was propagated for the production following the same procedure.  
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• Production in Roller bottles 
The production of the mAb 7A9 was also performed in a roller bottle (1700cm2, Coring) with a 
rolling speed of 0.5-1 rpm. The adapted hybridoma cells growing in RPMI-2 medium were 
seeded with a concentration of ∼ 5x105 cells/ml in 350 ml RPMI-2 Medium in a roller bottle. 
After a few days culture, the cells were diluted to 450 ml with fresh RPMI-2 medium. The 
yellowish medium was then collected using the same procedure as described in section 
2.2.5.1.  
 
(3) Affinity purification of the monoclonal antibody 7A9 
mAb 7A9, an IgG1 antibody, was affinity-purified on the HiTrap Protein G-Sepharose columns 
(Amersham Pharmacia) by the below procedures.  
 
The Protein G-Sepharose column was run at 4°C by FPLC on a BioLogic workstation with the 
EZLogic software using degassed buffers at 4°C. After equilibrating the column with 10 ml 
PBS buffer (pH 7.5), 250 ml clear supernatant (see section 2.2.5.1) diluted with 250 ml PBS 
buffer was loaded onto one or two HiTrap Protein G HP columns (1ml bed-volume) at a flow 
rate of 0.5 ml/min. The column was then washed with 10 column-volumes of PBS buffer at a 
flow rate of 0.5 ml/min, and the bound antibodies were eluted with 10 column-volumes of 
glycine (100 mM, pH 3.0) at a flow rate of 0.5-1 ml/min. The eluting antibodies were detected 
by absorbance monitor at 280 nm and 1 ml fractions were collected in 1.5 ml tubes containing 
50 µl Tris-HCl (1 M, pH 8.8) for neutralization. The column was neutralized by washing with 5 
ml washing buffer and 5 ml water at a flow rate of 1 ml/min and stored in 20% ethanol. The 
collected fractions were analyzed by SDS-PAGE and pooled for quantification. After addition 
of 0.02% NaN3, the antibody solution was stored at 4°C or - 20°C. 
 
(4) Characterization of the monoclonal antibody 7A9 
• Purity analysis 
The purity of the purified mAb 7A9 was checked by 12% SDS-PAGE under reducing condition 
with silver staining as described in section 2.2.4.1. 
 
• Verification of the mAb 7A9 
mAb 7A9 is a murine antibody 
Western-blotting analysis with Anti-Mouse IgG (Fc specific)–Alkaline Phosphatase antibody 
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produced in goat (Sigma, A1418) was performed to confirm that mAb 7A9 is a murine 
antibody.  
 
1 µg mAb 7A9 was run on 12% SDS-PAGE under reducing condition. After transfer to the 
nitrocellulose membrane, the Anti-Mouse IgG (Fc specific)–Alkaline Phosphatase antibody 
(Sigma, A1418) with dilution of 1:5000 in TTBS buffer was used to recognize the mouse 
original antibody. 0.4% NBT/BCIP was used as the substrate for signal detection. 
 
mAb 7A9 is a functional blocking anti-E-selectin antibody 
Two western-blotting analysis were performed to verify that mAb 7A9 is a functional blocking 
anti-E-selectin antibody using the procedure described in section 2.2.4.1. One is carried out 
with 15 µg of native hE-LecEGF as the antigen, which was separated by 8% native PAGE. The 
other one is performed with 15 µg of reduced and denatured hE-LecEGF as the antigen, 
separated by 12 % SDS-PAGE. In two experiments, 10 µg/ml of mAb 7A9 was used as the 
primary antibody and the Anti-Mouse IgG (Fc specific)–Alkaline Phosphatase antibody 
(Sigma, A1418, in 1:5000 dilution) was chosen as the secondary antibody. The color 
development was done with 0.4% NBT/BCIP. 
 
• Yield  
The amount of the purified mAb 7A9 was determined by Bradford micro-assay as described in 
section 2.2.4.1. 
 
(5) Coupling of the monoclonal antibody 7A9 to CNBr-activated Sepharose 4B 
In order to functionally purify the hE-LecEGF, the purified functional blocking anti-E-selectin 
mAb 7A9 was coupled to cyanogen bromide activated Sepharose 4B (Sigma, C9142). The 
below procedure is for the preparation of 2 ml matrix. 
 
• Preparation of protein 
The purified mAb 7A9 was in the buffer containing glycine and Tris (see section 2.2.5.1). In 
order to remove these primary amines, which can disturb the coupling, the buffer was 
changed to the coupling buffer (0.1 M NaHCO3, 0.5 M NaCl, pH 8.5) by using the Amicon 
Ultra-4 centrifugal filter devices (Millipore, 10 kDa) at 3500 g for 20 min at 4°C. The amount of 
mAb 7A9 in coupling buffer was then determined by Bradford micro-assay method described 
in section 2.2.4.1. 
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• Preparation of resin 
0.8 g cyanogen-bromide activated Sepharose 4B matrix was washed and swollen in 1 mM 
HCl (cold) for at least 30 minutes. A total of 160 ml HCl was added in several aliquots.  
 
• Coupling  
The cyanogen-bromide activated Sepharose 4B matrix was rinsed with 5 ml coupling buffer 
(0.1M NaHCO3, 0.5M NaCl, pH8.5) and immediately transferred to the mAb 7A9 solution (14 
mg in coupling buffer). The matrix was then incubated with antibody at 4°C overnight on an 
end-over-end mixer. Bradford micro-assay was used to evaluate the coupling efficiency. After 
coupling, the matrix was then blocked in blocking buffer (0.2 M glycine, 0.1 M NaHCO3, 0.5 M 
NaCl, pH 8.0) for 2 hours at room temperature. After blocking, the matrix was extensively 
washed with a cycle of high pH (basic coupling buffer) and low pH (0.1 M Na-Acetate, 0.5 M 
NaCl, pH 4) buffers for five times. The mAb 7A9 coupled resin was then stored at 4°C in 
storing buffer (20 mM Tris-HCl, 1.0 M NaCl, 0.025% NaN3, pH 7.5).  
 
• Characterization 
A small amount of the mAb 7A9 coupled resin was treated with 5x sample buffer (200 mM 
Tris-HCl, 37.5% glycerol, 5% SDS, 250 mM DTT or 2M -mercaptoethanol, 0.015% 
bromophenol blue, pH 6.8) by vortexing. After boiling at 95°C for 5 min and briefly spin, the 
supernatant was analyzed on 12% SDS-PAGE. 
 
2.2.5.2 Purification and characterization of hE-LecEGF by anti-E-selectin affinity 
chromatography 
(1) Batch purification with the mAb 7A9 coupled matrix 
A batch purification of hE-LecEGF expressed in insect cells Hi 5 was performed with 1 ml mAb 
7A9 coupled matrix (see section 2.2.5.1) by the following procedure.  
 
The purification was carried out at 4°C in 50 ml centrifuge tubes. The mAb 7A9 coupled 
Sepharose4B matrix was first equilibrated with 30 ml binding buffer (50 mM Tris-HCl, 150 mM 
NaCl, 2 mM CaCl2, pH 7.2). The supernatant of hE-LecEGF (40 ml, see section 2.2.4.4) was 
then incubated with 1 ml mAb 7A9 coupled matrix on an end-over-end mixer at 4°C, overnight. 
After washing the matrix twice in 15 ml binding buffer, the hE-LecEGF protein was eluted with 
1 ml/aliquot elution buffer (100 mM glycine, pH 2.5) for 5 ml. The elution fractions were 
immediately neutralized with 60 µl Tris-HCl (1M, pH 8.8). The matrix was then neutralized by 
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washing twice with 15 ml binding buffer and stored in storing buffer (50 mM Tris-HCl, 1 M 
NaCl, 2 mM CaCl2, 0.025% NaN3, pH 7.2) at 4°C for the long-term storage. The collected 
fractions were stored at 4°C for further characterization.  
 
(2) SDS-PAGE and Western-blotting analysis 
The collected fractions from the batch purification with 1 ml mAb 7A9 matrix were analyzed on 
15% SDS-PAGE with silver staining as described in section 2.2.4.1. Western-blotting analysis 
of 1-2 µg reduced elution fractions was performed with the 2 µg/ml of monoclonal anti-flag M2 
antibodies (SIGMA) as the primary antibody using the procedure described in section 2.2.4.1.     
 
2.2.5.3 Purification and characterization of hE-LecEGF by anti-flag affinity 
chromatography 
(1) Anti-flag affinity chromatography by FPLC 
hE-LecEGF expressed in Hi-5 and Sf9 insect cells were purified with 2 ml anti-flag M2 
monoclonal antibodies agarose (Sigma) according to the manufacture’s instructions[268], 
respectively. The anti-flag M2 monoclonal antibodies agarose was first packed into 
BioScaleMT-2 column according to the supplier’s manual. The purification was done with 
degassed buffers at 4°C on a BioLogic workstation, using the EZLogic software.  
 
For anti-flag affinity chromatography, the anti-flag column was first equilibrated with binding 
buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM CaCl2, pH 7.5) for at least 10 bed-volumes at the 
flow rate of 1 ml/min until the baseline was reached. The supernatant of hE-LecEGF (see 
section 2.2.4.4) was then loaded onto the column at the flow rate of 1 ml/min. Contaminating 
proteins were washed out with 5-10 bed-volumes washing buffer (50 mM Tris-HCl, 150 mM 
NaCl, 2 mM CaCl2, pH 7.5) at a flow rate of 0.5-1 ml/min until the baseline was reached. Then, 
the protein hE-LecEGF fused with the N-terminal Flag tag was eluted isocratically with 3-5 
bed-volumes of elution buffer (100 mM Glycine, pH 3.5) at a flow rate of 1 ml/min. Each 1 ml 
of eluted fractions was collected in a 1.5 ml tube containing 20 µl Tris-HCl (1 M, pH 8.8) for 
neutralization. The column was then extensively washed with 5-10 bed-volumes washing 
buffer at a flow rate of 1 ml/min and stored in storing buffer (50 mM Tris-HCl, 150 mM NaCl, 2 
mM CaCl2, 50% glycerol, pH 7.5) at 4°C for the long-term storage. The collected fractions 
were analyzed by SDS-PAGE and pooled for further characterization. 
 
Materials and Methods
 
                                                                                    
 70 
 
 
(2) Optimization of anti-flag affinity chromatography by FPLC 
Since pure hE-LecEGF was not obtained by the above anti-flag affinity chromatography (see 
section 2.2.5.3), the purification strategy was optimized in below parameters. 
 
a. Binding buffer: 
PBS buffer (50 mM, 150 mM NaCl, pH 7.5) was used as the binding buffer and washing buffer 
to instead TBS buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM CaCl2, pH 7.5). 
 
b. Concentration of salts:  
The concentration of 150 mM NaCl in washing buffer was increased to 300 mM and 500 mM 
respectively to remove the non-specific binding proteins in anti-flag affinity chromatography. 
 
c. Washing volume  
10-20 bed-volumes washing buffer was used for the washing step to remove the contaminant 
proteins in chromatography.  
 
d. Addition of detergents  
The addition of 0.05% Tween 20, 0.1% TritonX-100 and 0.5% TritonX-100 respectively in 
washing buffer were used in chromatography to get the pure protein. 
 
(3) SDS-PAGE and Western-blotting analysis 
hE-LecEGF purified by the optimized anti-flag affinity chromatography was analyzed on 15% 
SDS-PAGE with commassie or silver staining as described in section 2.2.4.1. 
Western-blotting analysis was performed with 2 µg/ml of monoclonal anti-flag M2 antibodies 
(SIGMA) as described in section 2.2.5.2. 
 
(4) Monomeric identification 
The monomeric property of hE-LecEGF was analyzed on 15% SDS-PAGE under both 
reducing and non-reducing conditions with silver staining as described in section 2.2.4.1. 
 
(5) Yield  
After the purification with anti-flag chromatography, the amounts of hE-LecEGF expressed in 
Hi-5 and Sf9 cells were determined by Bradford micro assay as described in section 2.2.4.1. 
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(6) Activity determination 
Activities of the purified hE-LecEGF, expressed in Hi-5 and Sf9 cells, were identified using both 
Western-blotting and HRP-ELISA methods.  
 
• Western blotting 
Western blotting analysis of 1-2 µg of the native hE-LecEGF was done using the procedure 
described in section 2.2.4.1. The hE-LecEGF protein was separated on 12% native-PAGE 
prior to electroblotting, 10 µg/ml of mAb 7A9 (see section 2.2.5.1) was used as the primary 
antibody to recognize the hE-LecEGF protein. The anti-Mouse alkaline phosphatase 
(AP)-labeled antibody (Sigma) was employed as the secondary antibody. 0.4% NBT/BCIP 
was used as the substrate for signal detection. 
 
• ELISA 
3-5 µg of hE-LecEGF was analyzed by HRP-ELISA as described in section 2.2.4.1. The 
primary antibody was 10 µg/ml of mAb 7A9 (see section 2.2.5.1) and the secondary antibody 
was Horseradish peroxidase (HRP)-labeled anti-mouse antibody solution (GAM-IgG (H+L 
chain)-HRP, 1:3000 diluted). 
  
(7) Deglycosylation 
Deglycosylations of hE-LecEGF expressed in Hi-5 and Sf9 insect cells were performed on the 
analytical scale with Peptide-N-glycosidase F (PNGase F, Roche), Peptide-N-glycosidase A 
(Roche) and O-glycosydase (Roche), respectively. The deglycosylated hE-LecEGF was 
analyzed on SDS-PAGE under reducing condition. 
 
• Deglycosylation with PNGase F 
PNGase F, a N-deglycosidase, cleaves all types of asparagines bound N-glycans. And the 
reaction products are ammonia, aspartic acid in the peptide chain and the complete 
oligosaccharide[279]. Deglycosylations of hE-LecEGF were performed under both native and 
denaturing conditions at 37°C according to the supplier’s manual. 
 
Native condition 
The deglycosylations of 3 µg hE-LecEGF were performed with 1 U and 2 U of PNGase F in 20 
mM sodium phosphate buffer and in Tris-glycine buffer (20 mM Tris, 100 mM glycine) with pH 
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7.2 and pH 8.6 according to Table 2.11. After incubation for 48h, 72h and 96 h, the 
deglycosylated hE-LecEGF was analyzed on 15% SDS-PAGE under reducing condition.  
 
Table 2.11. Composition of the native deglycosylation condition of hE-LecEGF with PNGase F. 
 Native condition (37°C) 
20 mM sodium phosphate pH7.2 pH8.6   
Tris-glycine   pH7.2 pH8.6 
Incubation time (48, 72, 96 h) + + + + 
PNGaseF (1U, 2U) + + + + 
 
Denaturing condition 
1 U and 2 U of PNGase F was used to remove the glycans of hE-LecEGF (3 µg) in 20 mM 
sodium phosphate buffer with pH 7.2 and pH 8.6 containing SDS (0.1%, 0.2%), Triton X-100 
(1%), NP-40 (1%) or EDTA (25 mM). The reactions were heated at 99°C for 5 min or 10 min 
prior to the addition of PNGase F (See Table 2.12). After incubation of 72 hours or 96 hours, 
the deglycosylated hE-LecEGF was analyzed on 15% SDS-PAGE under reducing condition. 
 
 
Table 2.12. Composition of the denaturing deglycosylation condition of hE-LecEGF with PNGase F. 
 Denaturing condition (37°C) 
20 mM sodium phosphate pH 7.2 pH 7.2 pH 7.2 pH 8.6 pH 8.6 pH 8.6 
Incubation time (72, 96 h) + +  + +  
SDS (0.1%, 0.2%) + +  + +  
NP-40 (1%) +   +   
Triton X-100 (1%)  +   +  
EDTA (25 mM) + +  + +  
99°C (5 min, 10 min) + + + + + + 
PNGas F(1 U, 2 U) + + + + + + 
 
• Deglycosylation with peptide N-glycosidase A 
N-glycosidase A, a N-deglycosidase, cleaves all types of asparagines bound N-glycans[282], 
but not able to remove efficiently all susceptible oligosaccarides. It also degrades the N-linked 
glycans carrying a fucose linked α (1-3) to Asn-GlcNAc[284], which are presented in plant 
glycoproteins and in some of insect glycoproteins,. 
 
Deglycosylations of hE-LecEGF were performed under both native and denaturing conditions 
based on the manual instructions[321]. 
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Native condition 
Deglycosylations of hE-LecEGF (3 µg) were performed in 100 mM sodium phosphate buffer 
with pH 5.0 and pH 6.0 with 1 mU and 2 mU of N-glycosidase A for digestion of 96 hours, 
respectively (Table 2.13). The deglycosylated hE-LecEGF was analyzed on SDS-PAGE under 
reducing conditions.  
 
Denaturing condition 
Under the denaturing condition, hE-LecEGF (3 µg) was digested for 96 hours with 1 mU and 2 
mU of N-glycosidase A in 100 mM sodium phosphate buffer with pH 5.0 and pH 6.0 containing 
Triton X-100 (1%) and EDTA (10 mM). The reactions were heated at 99 °C for 5 min or 10 min 
prior to the addition of N-glycosidase A as described in Table 2.13. The deglycosylated 
hE-LecEGF was analyzed on 15% SDS-PAGE under reducing condition.  
 
Table 2.13. Composition of the native and denaturing deglycosylation conditions of hE-LecEGF with 
N-Glycosidase A. 
 Denaturing (37°C) Native (37°C) 
100 mM sodium phosphate pH 5.0 pH 6.0 pH 5.0 pH 6.0 
Incubation time (96 h) + + + + 
Triton X-100 (1%) + +   
EDTA (10 mM) + +   
99 °C (5 min, 10 min) + +   
PNGaseA (1 mU, 2 mU) + + + + 
 
 
• Deglycosylation with N-glycosidase A and PNGase F 
Deglycosylations of hE-LecEGF (5 µg) were performed at 37°C with N-glycosidase A and 
PNGase F under native condition. hE-LecEGF expressed in Hi-5 and Sf9 cells was first 
digested with N-glycosidase A (2 mU) for 96 hours. After dialysis in Dialysis Mini Tubes 
(MWCO10000, Pierce), hE-LecEGF was changed to the digestion buffer of PNGase F. 
PNGase F (2 U) was then added and incubated for additional 96 hours (see Table 2.14). 
Digestions of hE-LecEGF with PNGase F first and followed with N-glycosidase A were also 
performed using the same procedure described above. The deglycosylated hE-LecEGF was 
analyzed on 15% SDS-PAGE under reducing condition. 
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Table 2.14. Composition of the native deglycosylation condition of hE-LecEGF with N-glycosidase A and PNGase 
F. 
Native condition (37°C) 
N-glycosidase A (2 mU) PNGase F (2 U) 
100 mM sodium phosphate 20 mM sodium phosphate 
Incubation time: 96 h Incubation time: 96 h 
pH 5.0 pH 7.2, pH 8.6 
 
• Deglycosylation with O-glycosidase 
The deglycosylation of hE-LecEGF expressed in Hi-5 and Sf9 cells (10 µg) was done with 2.5 
mU of O-glycosidase (Roche) and 2 mU of Neuraminidase in 20 mM sodium phosphate buffer 
(pH 7.2) under native condition according to the supplier’s instructions. After 72 hours 
incubation, the deglycosylated hE-LecEGF was analyzed on 15% SDS-PAGE under reducing 
condition. 
 
(8) Glycans detection 
Glycans detection of the hE-LecEGF and the deglycosylated hE-LecEGF was performed with 
a GelCode Glycoprotein Staining Kit (Pierce) according to the instruction manual[266].  
 
The GelCode® Glycoprotein Staining Kit detects glycoprotein sugar moieties in 
polyacrylamide gels and on nitrocellulose membranes. The glycols in glycoproteins are 
oxidized to aldehydes when treated with Oxidizing Reagent (periodic acid). After completing 
the procedure, the glycols are stained, yielding magenta bands with a light pink or colorless 
background. 
 
hE-LecEGF and deglycosylated hE-LecEGF were separated on 15% SDS-PAGE under 
reducing condition. The gel was then fixed in 100 ml of 50% methanol for 30 min. After 
washing the gel twice in 100 ml of 3% acetic acid for 10 min by gently agitating, the gel was 
transferred to 25 ml of Oxidizing Solution and incubated for 15 min. After washing the gel three 
times with 100 ml of 3% acetic acid for 5 min, the gel was transferred to 25 ml of GelCode® 
Glycoprotein Staining Reagent for 15 min. Afterwards, the gel was transferred to 25 ml of 
Reducing Solution for 5 minutes. After washing the gel extensively with 3% acetic acid and 
then with ultra pure water, glycoproteins appear as the magenta bands. The gel was stored in 
3% acetic acid.  
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2.3 Cloning, Expression, Purification and Characterization of human 
E-LecEGF in CHO-K1 cells 
2.3.1 Buffers and Media 
Buffers 
HAB buffer: 20 mM Hepes, 150 mM NaCl, 1 mM CaCl2, pH 7.4 
HAB20 buffer: 20 mM Hepes, 150 mM NaCl, 20 mM CaCl2, pH 7.4 
 
Media 
Ham’s F12 complete medium:  
Ham’s F12 medium (500 ml, Gibco) containing 10% FBS (Invitrogen) and 50 U/ml of 
Penicillin/streptomycin (Sigma).  
 
Ham’s F12 selective medium: 
Ham’s F12 medium (500 ml, Gibco) containing 10% FBS (Invitrogen), 50 U/ml of 
Penicillin/streptomycin (Sigma) and 500 µg/ml geneticin (Invitrogen). 
 
DMEM : F12 selective medium:  
DMEM:F12 medium (500 ml, Gibco) containing 5% FBS, 50 U/ml of Penicillin/streptomycin 
(Sigma) and 500 µg/ml geneticin. 
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2.3.2 Construction of the expression plasmid pYJE  
The expression plasmid pYJE was constructed for secretion of the hE-LecEGF protein without 
a tag in CHO K1 cells. 
 
2.3.2.1 Isolation of the plasmid pcDNA3.1(+) 
The plasmid pcDNA3.1(+) was kindly offered by Ms.Courtet (Biocenter, University of Basel). 
The plasmid pcDNA3.1(+) contains a CMV promoter to regulate the expression of 
recombinant proteins in mammalian cells. Neomycin resistant gene in the plasmid was used 
to select the transfectants with geneticin in mammalian cells, Ampicillin resistant gene in the 
plasmid was used to select the transformants with ampicillin in E.coli and T7 priming site of it 
was used for verification of the inserted gene by DNA sequencing (Figure 2.6). 
 
 
 
2.3.2.2 Amplification of the SLE domains of human E-selectin by PCR 
The forward primer E1 containing a BamH I restriction endonuclease site and the backward 
primer E2 containing an EcoR I restriction site were designed (Figure 2.6) for the amplification 
of signal, lectin and EGF-like domains of human E-selectin (hE-SLE) from the genomic DNA 
isolated from CHO cells expressing human E-selecting fused with a C-terminal human IgG1 
tag (see section 2.2.2.3). 
 
Primer E1:   5′- CGGGATCCACCATGATTGCTTCACAGTTTCTC-3′ 
                    BamH I 
Primer E2:   5′- CGGAATTCTTACACAATTTGCTCACACTTGA - 3′ 
                    EcoR I 
 
 
 
Figure 2.7. The forward primer E1 and backward primer E2 designed for amplification of the SLE sequence
of human E-selectin. 
Figure 2.6. Map of the plasmid pcDNA3.1(+). 
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Using the same PCR procedure described in section 2.2.2.3, The SLE sequence of human 
E-selectin was amplified with the annealing temperature at 56 ˚C. The PCR products were 
then analyzed by agarose-gel electrophoresis and purified with GenPCR purification Kit 
(Sigma). 
 
2.3.2.3 Restriction enzyme digestion 
Restriction endonucleases BamH I and EcoR I were used to double digest both PCR product 
of the SLE fragment of human E-selectin and the vector pcDNA3.1(+). The reactions were 
performed at 37˚C for 3 h according to Table 2.15. 
 
Table 2.15. Composition of double digestion of the hE-SLE fragment and the plasmid pcDNA3.1(+) with BamH I 
and EcoR I in NEBuffer-EcoRI. Both enzymes are 100% active in this buffer. 
  E-SLecEGF fragment PcDNA3.1(+) 
DNA fragment 30 µl   15 µl  
10xNEBuffer-EcoRI 5 µl  5 µl  
BamH I (20 U/µl) 1 µl  1 µl  
EcoR I (20 U/µl) 1 µl  1 µl  
BSA (1 mg/ml) 0.5 µl  0.5 µl  
Sterilized water 12.5 µl  27.5 µl  
Total 50 µl  50 µl  
 
The digested PCR products of the hE-SLE fragment and the plasmid pcDNA3.1(+) were 
analyzed by agarose-gel electrophoresis and purified by agarose-gel extraction with the 
GenEluteTM Gel Purification kit (Sigma) according to the manufacturer’s instructions. 
 
2.3.2.4 Ligation of the hE-SLE fragment into the pcDNA3.1 (+) 
The ligation of the double-digested hE-SLE fragment into the vector of pcDNA3.1(+) with the 
same digestion was done using T4 DNA ligase as described in section 2.2.2.2. 
 
2.3.2.5 Transformation and isolation of the plasmid pYJE 
The plasmid pYJE was amplified by transformation of E.coli cloning strain DH5α and isolated 
with GenElute Plasmid Miniprep kit (Sigma) as described in section 2.2.2.2.  
 
2.3.2.6 Analysis of E.coli transformants 
(1) Colony PCR  
Colony PCR of E.coli transformants was performed as described in section 2.2.2.2, using E1 
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and E2 primers (Figure 2.7) and Taq DNA polymerase. 
 
(2) Plasmid DNA sequence verification 
The plasmid pYJE was sequenced with the primer T7 (5’- TAATACGACTCACTATAGG -3’) for the 
forward sequencing in the Biocenter sequencing group with 4 capillaries machine: ABI3100 
Avant. The samples for sequencing were prepared by the below procedure.  
 
• PCR amplification of hE-SLE sequence 
Using the PCR amplification procedure described in section 2.2.2.2, mastermix (10 µl) was 
prepared according to Table 2.16 and the amplification was done with the program shown in 
Table 2.17. After 1 min initial denaturation at 96°C, the amplification of the hE-SLE sequence 
was run for 25 cycles of 10 seconds denaturation at 96°C, 5 seconds annealing at 50 ˚C and 4 
min extension at 60°C.  
 
Table 2.16. Composition of mastermix for 10 µl PCR sequencing reactions. 
 Mastermix 
Template DNA (200-400 ng) 5 µl 
Primer (10 µM) 1 µl 
Terminator Ready Reaction Mix 3 µl 
Millipore water 1 µl 
Total 10 µl 
 
 
Table 2.17. Program of PCR amplification for sequencing with the thermal ramp is 1˚C per second. 
 Temperature Time Cycle 
Initial denaturation 96 ˚C 1 min 1 
Denaturation 96 ˚C 10 sec 25 
Annealing 50 ˚C 5 sec 25 
Extension 60 ˚C 4 min 25 
Storage 4 ˚C ∞  
 
 
• Purification of the extension products 
The amplified PCR products were transferred into a fresh 0.5 ml eppendorf tube. 10 µl of 
water, 2 µl of EDTA (125 mM, pH 8.0), 2 µl of sodium acetate (3 M, pH 4.6) and 50 µl of 100% 
ethanol were then added into the tube. After mixing and incubation on ice for 25 min, 
centrifugation was performed at 10000 rpm, 4 ˚C for 20 min. The supernatant was removed 
with 200 µl pipette tips as much as possible. After washing with 70% ethanol and 
centrifugation at 10000 rpm, 4˚C for 5min, the DNA pellet was air dried for 30 min at room 
temperature in the dark and stored at 4 ˚C in the dark until sequencing. 
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Sequences of the hE-SLE fragment were verified by alignment with the DNA sequence 
extracted from Swiss-prot using the Blast program bl2seq of NCBI server. 
 
2.3.3 Construction of the plasmid pYJ-EG  
2.3.3.1 Construction of the plasmid pYJ-IgG 
(1) PCR-amplification of the human IgG1 tag  
A part of CH1 domain, complete CH2 and CH3 domains of human IgG1 Fc fragment (hIgG1 tag) 
were amplified from the genomic DNA isolated from CHO-E-sel/IgG cells with IgG1 and IgG2 
primers (Figure2.8). The forward primer IgG1 contains an EcoR I restriction endonuclease site 
and the backward primer IgG2 contains an Xho I site and a stop codon. 
 
Primer IgG1:   5′- CGGAATTCTGTGAAGTGGACAAGAAAGTT-3′ 
                      EcoR I 
Primer IgG2:   5′- CCGCTCGAGTTATTTACCCGGAGACAGGGA-3′ 
                       Xho I 
 
 
 
The PCR amplification was done using the same procedure described in section 2.2.2.2 with 
the annealing temperature at 56 ˚C. The PCR products were analyzed by agarose-gel 
electrophoresis and purified with GenPCR purification Kit (Sigma). 
 
(2) Restriction enzyme digestion 
Restriction digestions of the PCR amplified hIgG1 fragment and the plasmid pcDNA3.1(+) 
were performed with Xho I and EcoR I at 37˚C for 3 h with Table 2.18. 
 
Table 2.18. Composition of double digestion of the hIgG1 tag fragment and the plasmid pcDNA3.1(+) with Xho I 
and EcoR I in NEBuffer-EcoRI. Both enzymes are 100% active in this buffer. 
  E-SLecEGF fragment pcDNA3.1(+) 
DNA fragment 30 µl   15 µl  
10xNEBuffer-EcoRI 5 µl  5 µl  
Xho I (20 U/µl) 1 µl  1 µl  
EcoR I (20 U/µl) 1 µl  1 µl  
BSA (1 mg/ml) 0.5 µl  0.5 µl  
Sterilized water 12.5 µl  27.5 µl  
Total 50 µl  50 µl  
 
 
 
Figure 2.8. The forward primer IgG1 and the backward primer IgG2 designed for amplification of the hIgG1 tag. 
Materials and Methods
 
                                                                                    
 80 
 
 
The digested hIgG1 tag fragments and the plasmid pcDNA3.1(+) were analyzed by 
agarose-gel electrophoresis and purified by agarose-gel extraction with the GenEluteTM Gel 
Purification kit (Sigma). 
 
(3) Ligation of human IgG1 tag fragment into the pcDNA3.1(+) 
The ligation of double-digested human IgG1 fragment into the same digested vector 
pcDNA3.1 (+) was performed using T4 DNA ligase as described in section 2.2.2.2. 
 
(4) Transformation and isolation of the pYJ-IgG 
The transformation of the plasmid pYJ-IgG into E.coli DH 5α competent cells and isolation of 
this plasmid from transformants were conducted as described in section 2.2.2.2. A number of 
transformed clones were then analyzed as described below. 
 
(5) Analysis of E.coli transformants 
• PCR analysis 
Using IgG1 and IgG2 primers (Figure 2.8) and Taq DNA polymerase, colony PCR of E.coli 
transformants was performed as described in section 2.2.2.2. 
 
• Plasmid DNA sequence verification  
The plasmid pYJ-IgG was sequenced with the primer T7 (5’- TAATACGACTCACTATAGG -3’) 
for the forward sequencing by the Biocenter sequencing group as described in section 2.3.2.6. 
The sequences of the human IgG1 tag were verified by the alignment with the DNA sequence 
extracted from Swiss-prot using the Blast program bl2seq of NCBI server. 
 
2.3.3.2 Cloning of hE-LecEGF into the plasmid pYJ-IgG 
(1) PCR amplification of the hE-SLE fragment  
The forward primer E1 containing a BamH I restriction site (Figure 2.7) and the backward 
primer E3 containing an EcoR I site and an enterokinase cleavage site (DDDDK) (Figure 2.9) 
were designed for amplification of the hE-SLE fragment from the genomic DNA of 
CHO-E-sel/IgG cells. 
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Primer E3:  5′- CGGAATTCCTTGTCGTCATCGTCCACAATTTGCTCACACTTGA - 3′ 
                 EcoR I  (D  D   D   D  K) 
Enterokinase recognition sequence 
 
 
 
The PCR amplification was performed with the annealing temperature at 56 ˚C using the 
procedure described in section 2.2.2.2. The amplified PCR products were analyzed by 
agarose-gel electrophoresis and purified with GenPCR purification Kit (Sigma). 
 
(2) Restriction enzyme digestion 
BamH I and EcoR I restriction endonucleases were used to double-digest the PCR amplified 
hE-SLE fragment and the vector pYJ-IgG at 37˚C for 3 h according to Table 2.19.  
 
Table 2.19. Composition of double digestions of the PCR amplified hE-SLE fragment and the plasmid pYJ-IgG 
with BamH I and EcoR I in NEBuffer-EcoRI. Both enzymes are 100% active in this buffer. 
  hE-SLE fragment pYJG 
DNA fragment 30 µl   15 µl  
10xNEBuffer-EcoRI 5 µl  5 µl  
BamH I (20 U/µl) 1 µl  1 µl  
EcoR I (20 U/µl) 1 µl  1 µl  
BSA (1 mg/ml) 0.5 µl  0.5 µl  
Sterilized water 12.5 µl  27.5 µl  
Total 50 µl  50 µl  
 
 
The digested PCR amplified hE-SLE fragment and the plasmid pYJ-IgG were analyzed by 
agarose-gel electrophoresis and purified by agarose-gel extraction with the GenEluteTM Gel 
Purification kit (Sigma). 
 
(3) Ligation of hE-SLE fragment into plasmid pYJ-IgG 
Using the ligation procedure described in section 2.2.2.2, the doubly digested hE-SLE 
fragments were inserted into the same digested vector pYJ-IgG using T4 DNA ligase. 
 
(4) Transformation and isolation of plasmid pYJEG 
The plasmid pYJEG was amplified by transformation of E.coli cloning strain DH5α and 
purified with GenElute Plasmid Miniprep kit (Sigma) as described in section 2.2.2.2.  
 
Figure 2.9. The backward primer E3 designed for amplification of the hE-SLE fragment. 
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(5) Analysis of E.coli transformants 
• PCR analysis 
Colony PCR of E.coli transformants was performed as described in section 2.2.2.2, using E1 
(Figure 2.7) and E3 (Figure 2.9) primers and Taq DNA polymerase. 
 
• Plasmid DNA sequence verification  
The plasmid pYJEG was sequenced and verified by using the primer T7 (5’- 
TAATACGACTCACTATAGG -3’) for the hE-SLE fragment and the Primer IgG1 (Figure 2.8) 
for the human IgG1 tag as described in section 2.3.2.6.  
 
2.3.4 Transfection  
2.3.4.1 Cell culture of CHO K1 cells 
(1) Recovering cells from liquid nitrogen 
CHO K1 cells were recovered from liquid nitrogen in complete Ham’s F12 medium (Ham’s 
F12 medium containing 10% FBS) in a T25 flask using the general method described in 
section 2.2.3.1.  
 
(2) Cell splitting 
When the cell monolayer reaches 100% confluent, cells were split. Trypsin-EDTA method 
(see section 2.2.2.3) was used to detach the cells. The collected cells were then diluted in 1:5 
to1:10 with fresh Ham’s F12 complete medium (Ham’s F12 medium containing 10% FBS). 
The cells were subcultured in T75 flasks in a 37°C and 5% CO2 humid incubator for the further 
transfection and protein production. 
 
(3) Cell Freezing 
CHO K1 cells were frozen in Ham’s F12 medium containing 10% DMSO and 10% FBS using 
the method described in section 2.2.3.1. 
 
2.3.4.2 Determination of geneticin sensitivity 
In order to select the stable expression clones and subclones of the recombinant protein, the 
sensitivity of CHO K1 cells to geneticin was determined by the below procedure. 
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CHO K1 cells were seeded into a 6 well plate with approximately 25% confluent in Ham’s F12 
complete medium (Ham’s F12 medium containing 10% FBS) and incubated at 37°C overnight. 
The next day, the culture medium was substituted with the medium containing varying 
concentrations of geneticin (0, 100, 200, 400, 600 and 800 µg/ml geneticin). The selective 
media were replenished every 3-4 days and the percentage of surviving cells was observed 
under a microscope. The number of viable cells was counted to determine the appropriate 
concentration of geneticin that killed cells within 2-3 weeks after addition of geneticin. 
 
2.3.4.3 Linearization of the expression plasmids pYJE and pYJEG 
The restriction endonuclease Sca I was used to linearize the plasmid pYJE and pYJEG. The 
reaction was performed at 37˚C for 3 h according to Table 2.20. 
 
Table 2.20. Composition of digestion of the plasmids pYJE and pYJEG with Sca I in NEBuffer-3. Sca I is 100% 
active in this buffer. 
  pYJE pYJEG 
DNA fragment 16 µl   16 µl  
10xNEBuffer-3  5 µl  5 µl  
Sca I (20 U/µl) 2 µl  2 µl  
Sterilized water 27 µl  27 µl  
Total 50 µl  50 µl  
 
The Sca I restriction endonuclease was inactivated by heating at 80˚C for 20min. The 
linearized plasmids were analyzed by agarose-gel electrophoresis and purified with GenPCR 
purification Kit (Sigma). 
 
2.3.4.4 Transfection of the plasmids pYJE and pYJEG into CHO K1 cells 
The transfection of the linearized plasmids pYJE and pYJEG were performed with 
MetafecteneTM (Biontex)[322] by the below procedure. 
 
CHO K1 cells were seeded into 6-well cell culture plates at 2x105 cells per well in 2 ml Ham’s 
F12 Medium containing 10% FBS. The cells were incubated at 37˚C overnight until reached 
30%-50% confluency (growing area should covered 90-100%). The confluency of cells was 
checked under an inverted phase microscope. The solutions of DNA and metafectene 
transfection reagent were prepared in Polypropylene tubes as below: a) 2 µg of DNA (The 
expression plasmids of pYJE or pYJEG) in 100 µl OPTI-MEM I medium. b) 6 µl of 
metafectene in 100 µl OPTI-MEM I medium. Two solutions were then combined, mixed gently 
by carefully pipetting several times, and incubated at room temperature for 15-20 min in order 
to form the DNA-lipid complex. The DNA-lipid complex was then added to the cells and mixed 
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gently. In order to avoid the toxicity of the transfection mixture, the transfection mixture was 
removed after incubation of 3-6 hours at 37˚C and replaced with fresh medium Ham’s F12 
medium containing 10% FBS.  
 
The negative control of the transfection was the cells transfected with the transfection mixture 
without plasmids. 
 
2.3.5 Selection of stable expression cell lines of CHO-YJE and CHO-YJEG 
500 µg/ml of geneticin was used for screening the stable expression cell lines. The 
concentration of geneticin was determined as described in section 2.3.4.2.  
 
2.3.5.1 Selection of high, stable expression clones  
(1) Selection of stable clones 
For screening the stable clones, the transfectants were subcultured in 96-well cell culture 
plates in Ham’s F12 selective medium (containing 10% FBS and 500 µg/ml geneticin) at 37˚C 
after transfection of 48 hours. The Ham’s F12 selective medium was replenished to the cells 
every three to four days until geneticin-resistant clones were identified. 
 
(2) Detection of high expression clones  
In order to select the high expression stable clones, the expression of hE-LecEGF from each 
stable clones were detected by AP-ELISA method (see section 2.2.4.1). 100 µl of culture 
supernatant from each clones was analyzed in AP-ELISA assays with 10 µg/ml of mAb 7A9 
as the primary antibody, a AP-labeled goat-anti-mouse antibody solution (Sigma, 1:3000 
dilution) as the secondary antibody and 1 mg/ml of p-nitrophenylphosphate as the substrate. 
The color was developed for 15-20 min at RT prior to reading the absorbance at 405 nm in a 
Spectramax190 plate reader. 
 
For the same clone, AP-ELISA assay was performed twice in order to avoid the false one. The 
high, stable expression clones of CHO-YJE and CHO-YJEG were then frozen in liquid nitrogen 
as described in section 2.3.4.1. 
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2.3.5.2 Selection of high, stable expression subclones  
(1) Adaptation to DMEM:F12 Medium 
In order to reduce the cost and facilitate the purification, the high, stable expression clones of 
CHO-YJE and CHO-YJEG were adapted to grow in DMEM:F12 selective medium containing 
5% FBS instead of Ham’s F12 selective medium containing 10% FCS prior to screening the 
subclones. The adaptation was performed as described in section 2.2.5.1. 
 
(2) Selection of subclones  
A limiting dilution method described by Born R.[323] was carried out to get the subclones of 
CHO-YJE and CHO-YJEG. The cells were diluted to 0.3 cell/well, 1 cell/well, 10 cells/well and 
100 cells/ well in DMEM:F12 selective medium containing 5% FBS in 96-well cell culture 
plates and incubated at 37˚C in a 5% CO2 incubator. The subclone from a single cell was 
inspected under the microscope. 
 
(3) Detection of high expression subclones  
The AP-ELISA was performed twice for detection of the high expression subclones of 
CHO-YJES and CHO-YJEGS as described in section 2.3.5.1. The high, stable expression 
subclones of CHO-YJES and CHO-YJEGS were then frozen in liquid nitrogen as described in 
section 2.3.4.1. 
 
2.3.5.3 Characterization of subclones of CHO-YJES and CHO-YJEGS 
(1) Characterization on DNA level 
For the CHO-YJES subclones, the encoding gene for the signal, lectin and EGF-like domains 
of human E selectin (hE-SLE) was amplified from subclones of CHO-YJES by colony PCR 
with E1 and E2 primers (Figure 2.7) as described in section 2.3.2.6. For the CHO-YJEGS 
subclones, the PCR amplification of the hE-SLE fragment with E1 and E3 primers (Figure 2.7, 
Figure 2.9) and the human IgG1 tag with IgG1 and IgG2 primers (Figure 2.8) were performed 
as described in section 2.3.3.2. 
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(2) Characterization on protein level 
• Characterization of CHO-YJE subclones 
Supernatant preparation 
The selected subclone CHO-YJES1 was cultured in T175 flasks in DMEM:F12 selective 
medium containing 5% FBS and 500 µg/ml geneticin for production of the hE-LecEGF protein. 
100 ml supernatant was collected by centrifugation at 5000 rpm 10 min at 4˚C. After filtration 
with 0.22 µM membrane, the collected supernatant was 1:1 diluted with the binding buffer for 
further purification. 
 
Purification by the mAb7A9-coupled column 
A mAb 7A9 coupled column (2 ml) (see section 2.2.5.1) was used to purify hE-LecEGF from 
the supernatant of the subclone CHO-YJS culture medium (see section 2.3.5.3). 
 
The purification was performed at 4°C on a BioLogic workstation, using the EZLogic software. 
The mAb 7A9 coupled column was first equilibrated with binding buffer (50 mM Tris-HCl, 150 
mM NaCl, 2 mM CaCl2, pH 7.2) for at least 10 bed volumes at the flow rate of 0.5 ml/min until 
the baseline was reached. The supernatant of hE-LecEGF was then loaded onto the column 
at the flow rate of 0.5 ml/min. After washing with 5-10 bed-volumes binding buffer at a flow 
rate of 0.5 ml/min, the hE-LecEGF protein was eluted isocratically with 5 bed-volumes elution 
buffer (100 mM glycine, 2 mM CaCl2, pH 2.5) at a flow rate of 0.5-1 ml/min. 1 ml of aliquots of 
the eluted fractions were collected in a 1.5 ml tube containing 60 µl of Tris-HCl (1M, pH 8.8) 
for neutralization. The column was then neutralized by washing with 5-10 bed volumes 
binding buffer at a flow rate of 1 ml/min and stored in storing buffer (50 mM Tris-HCl, 1M NaCl, 
2 mM CaCl2, 0.025% NaN3, pH 7.2) at 4°C for the long-term storage. The collected fractions 
were analyzed by 15% SDS-PAGE and pooled for further characterization. 
 
Western blotting analysis with the anti-E-selectin N18 antibody 
1-2 µg reduced and non-reduced hE-LecEGF protein, expressed from the CHO-YJS subclone, 
was analyzed by western-blotting method described in section 2.2.4.1. The anti-E-selectin 
N18 antibody (Santa Cruz Biotechnology) at a concentration of 2 µg/ml was employed as the 
primary antibody and the anti-mouse IgG (Fc specific)–alkaline phosphatase antibody (Sigma) 
was used as the secondary antibody. The signal detection was performed with BCIP/NBT as 
the substrate. 
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• Characterization of the CHO-YJEG subclones 
Supernatant preparation 
In order to identify the expression of hE-LecEGF/IgG (hE-LecEGF fused with C-terminal 
hIgG1 tag) from the subclone CHO-YJEGS1, 100 ml supernatant of the culture medium was 
prepared above. 
 
Purification by Protein A column  
The hE-LecEGF/IgG protein was purified with a 1 ml HiTrap rProtein A FF agarose matrix (GE 
Healthcare) according to the manufacturer’s instructions. Using the purification procedure 
described in section 2.3.5.3, the purification was done using the binding buffer (20 mM sodium 
phosphate, 150 mM NaCl, 1 mM CaCl2, pH 7.0) for equilibrating and washing the column at 
the flow rate of 1 ml/min, and the elution buffer (100 mM sodium citrate, pH 3.0) at a flow rate 
of 1 ml/min for elution of the hE-LecEGF/IgG protein. The eluted protein was collected in 
fractions. 1 ml of aliquots of the eluted fractions was collected in a 1.5 ml tube containing 40 µl 
of Tris-HCl (1 M, pH 8.8) for neutralization. The column was then extensively washed with 
5-10 bed volumes binding buffer at a flow rate of 1 ml/min and stored in storing buffer (20% 
ethanol) at 4°C for the long-term storage. The collected fractions were analyzed by 12% 
SDS-PAGE and pooled for further characterization. 
 
Western-blotting analysis with the anti-human IgG1 antibody 
1-2 µg reduced and non-reduced hE-LecEGF/IgG, purified from protein A column, was first 
separated by 12% SDS-PAGE. The proteins were then transferred to the nitrocellulose 
membrane. After blocking the nonspecific binding sites on the membrane with 3% BSA in TBS 
buffer, the hE-LecEGF/IgG protein was probed with the anti-human IgG1 monoclonal antibody 
conjugated with alkaline phosphatase (1 µg/ml). The detection was carried out by color 
development with BCIP/NBT. 
 
2.3.6 Production of hE-LecEGF  
The production of hE-LecEGF was performed by subculturing the CHO-YJES1 cells in both 
T-flasks and roller bottles at 37°C in the 5% CO2 humid incubator.  
 
2.3.6.1 Production in T-Flasks 
The production of hE-LecEGF in T-Flasks was optimized from a protocol described by Dragic 
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Z.[324]. 1x106 CHO-YJES cells were seeded in 50 ml DMEM:F12 selective medium in T175 
Flasks and grown to reach the full confluency in T-flasks. The production phase then started 
by collecting the yellowish medium and replenishing the fresh medium. The whole production 
phase lasted three to five weeks.   
 
The supernatant containing the hE-LecEGF protein was collected after centrifugation at 5000 
rpm for 10 min at 4°C. After filtration with StericupTM (0.22 µM), the supernatant was stored at 
4°C or -20°C for further affinity purification. 
 
2.3.6.2 Production in roller bottles 
The production of hE-LecEGF in roller bottles was optimized from Dragic Z. [324]. 7x106 
CHO-YJES cells were seeded in 350 ml DMEM:F12 selective medium in a roller bottle 
(1700cm2, Coring) with rolling speed at 0.5 rpm for cells adhesion to the surface of the bottle 
and 1 rpm for cells growing. After cells reached the full confluency in the roller bottle, the 
production phase then started by harvesting the yellowish medium and addition of 450 ml 
fresh medium per bottle. The whole production phase lasted three to four weeks. The 
supernatant was then collected as described in section 2.3.6.1. 
 
2.3.6.3 Sodium butyrate effect on protein expression 
The effect of sodium butyrate on the protein expression was checked by the below procedure. 
In the production phase of the T-flask production, 1 mM, 2 mM and 4 mM of sodium butyrate 
were added, respectively. The culture supernatant was collected every 3 days and the 
production of hE-LecEGF was evaluated by AP-ELISA as described in section 2.3.5.1. The 
cell viability and cell counting was determined by Trypan blue method described in section 
2.2.3.1. 
 
2.3.7 Purification and characterization of hE-LecEGF expressed in CHO-K1 cells 
2.3.7.1 Purification and SDS-PAGE analysis 
The purification of hE-lecEGF expressed by CHO-YJES1 subclone was performed with a 2 ml 
or 5 ml mAb 7A9 coupled column as described in section 2.3.5.3. The collected fractions were 
analyzed by 15% SDS-PAGE (see section 2.2.4.1) and pooled for further characterization. 
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2.3.7.2 Deglycosylation of hE-LecEGF expressed in CHO-K1 cells 
(1) Deglycosylation under native condition 
Deglycosylation of hE-LecEGF (5 µg) was performed at 37°C with 1 U and 2 U of 
Peptide-N-glycosydase F (PNGase F, Roche) in 20 mM sodium phosphate buffer (pH 7.2) and 
in Tris buffer (50 mM Tris, 2 mM CaCl2, pH 8.0) according to Table 2.21. After digestion for 24, 
48 and 72 hours, the deglycosylated hE-LecEGF was analyzed on 15% SDS-PAGE under 
reducing condition. 
 
Table 2.21. Composition of deglycosylation of hE-LecEGF under native conditions. 
37°C  Incubation buffer 
 Sodium phosphate (pH 7.2) Tris buffer (PH 8.0) 
Incubation time (48, 72h) + + 
PNGas F (1 U, 2 U) + + 
 
(2) Purification of the deglycosylated hE-LecEGF 
Ion exchange chromatography with Sepharose Q column was performed to purify the 
deglycosylated hE-LecEGF by syringe. 0.5 ml Sepharose Q Fast Flow agarose matrix 
(Amersham Biosciences) packed in the 1 ml Column Mobicol (MoBiTec) was first equilibrated 
with 5 ml Buffer I (50 mM Tris, 2 mM CaCl2, pH 8.0). The protein sample in the Buffer I was 
then loaded onto the column drop by drop. After washing with 2.5-5 ml Buffer I, the column 
was washed by 2-3 ml Buffer II (50 mM Tris, 100 mM NaCl, pH 8.0) and 2-3 ml Buffer III (50 
mM Tris, 500 mM NaCl, pH 8.0). 1 ml aliquots of the fractions were collected in 1.5 ml tubes. 
The column was then equilibrated in storing buffer (50 mM Tris, 500 mM NaCl, 20% ethanol, 
pH 8.0) and stored at 4°C. The collected fractions were analyzed on 15% SDS-PAGE and 
pooled for further characterization. 
 
(3) Glycans detection  
The GelCode Glycoprotein Staining Kit (Pierce) was used to detect the glycans of the 
hE-LecEGF and the deglycosylated hE-LecEGF as described in section 2.2.5.3. 
 
2.3.7.3 Protein identification by western-blotting analysis 
The hE-LecEGF protein (reduced and non-reduced, 1 µg) and the deglycosylated hE-LecEGF 
protein (reduced and non-reduced, 1 µg) were analyzed by western blotting method with the 
monoclonal anti-E-selectin N18 antibody as described in section 2.3.5.3. 
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2.3.7.4 Yield  
The amounts of hE-LecEGF produced in T-flasks and roller bottles were determined by 
Bradford standard assay or Bradford micro-assay as described in section 2.2.4.1. 
 
2.3.7.5 Mass spectrometry analysis 
Mass spectrometry analysis was performed in Mass Spectrometry group in Biocenter, 
University of Basel. 
 
(1) Peptide identification by MS 
• Sample preparation  
Pure hE-LecEGF (2 µg) was separated by SDS-PAGE under reducing condition and stained 
with Simply Blue SafeStain (invitrogen) followed by destaining with water according to the 
manufacturer’s instructions. The protein band in the gel was excised with a razor blade and 
reduced with 10 mM DTT for 2 h at 37oC and alkylated with iodoacetamide at 50 mM final 
concentration for 15 min at room temperature in the dark. The gel piece was then digested 
with 125 ng trypsin (Sequencing Grade, Promega) for 18 h at 37oC. The peptides in the 
supernatant were collected and the gel piece was extracted with 0.1% formic acid/50% 
acetonitrile. The extract was pooled with the tryptic peptides. The digest was dried in a speed 
vac and redissolved in 0.1% formic acid/2% acetonitrile. 10 µl were used for mass 
spectrometric analysis. 
 
• LC-MS-MS identification 
The trypsin digested proteins were analyzed by capillary liquid chromatography tandem MS 
(LC/MS/MS) using a 300SB C-18 column (0.3x50mm) (Agilent Technologies, Basel, 
Switzerland) connected on line to an LCQ Advantage Max instrument (Thermo Finnigan, San 
Jose, CA, USA). A linear gradient from 2% to 60% solvent B (0.1% formic acid and 80% 
acetonitrile in water) in solvent A (0.1% formic acid and 2% acetonitrile in water) in 85 min was 
delivered with a Rheos 2000 pump (Flux Instruments, Basel, Switzerland) at a flow rate of 100 
µl/min. A pre-column split was used to reduce the flow rate to approximately 500 nl/min. 10 µl 
sample were injected with an auto sampler. And the eluting peptides were ionized at 1.6 kV. 
The mass spectrometer was operated in a data-dependent fashion so that the peptide ions 
were automatically selected for fragmentation by collision-induced dissociation (MS/MS). The 
MS/MS spectra were then searched against the data bank using TurboSequest software. 
 
Materials and Methods
 
                                                                                    
 91 
 
 
(2) Molecular weight determination by MS 
• Sample preparation 
The hE-LecEGF protein purified from the mAb 7A9 coupled column was in the buffer 
containing 100 mM glycine, 60 mM Tris and 2 mM CaCl2 (see section 2.3.5.3). In order to 
remove these salts, which are not suitable for MS analysis, the reverse phase high 
performance liquid chromatography (RP-HPLC) was performed on a Peptide / Protein C18 
column. With the gradient program described in Table 2.22, hE-LecEGF (10 µg) was loaded 
onto the column in two times with the flow rate of 1 ml/min using buffer A (0.1% TFA in HPLC 
grade water) and buffer B (0.1% TFA in HPLC grade acetonitrile). The collected protein 
fractions were shock-frozen in liquid nitrogen, lyophilized overnight and analyzed by MS. 
 
Table 2.22. Gradient program used for RP-HPLC purification of hE-LecEGF. 
Time (min) A% B% Flow rate(ml/min) 
0 75 25 1 
10 62 38 1 
15 62 38 1 
20 75 25 1 
25 75 25 1 
 
• MS measurement 
The proteins were analyzed using the procedure described in LC-MS-MS identification (see 
above). 10 µl of sample were injected with an auto sampler. The mass spectrometer was 
operated in MS mode only and was scanned between 400 and 1600 m/z range. 
 
2.3.7.6 Activity determination  
Western-blotting, ELISA, Polymer assay and NMR methods were used to characterize the 
activities of pure hE-LecEGF and deglycosylated hE-LecEGF. 
 
(1) Western-blotting with the mAb 7A9 
The pure hE-LecEGF and the deglycosylated hE-LecEGF (1-2 µg) were identified by western 
blotting with the mAb 7A9 under native condition as described in section 2.2.5.3. 
 
(2) ELISA 
The pure hE-LecEGF and the deglycosylated hE-LecEGF (3-5 µg) were analyzed by 
HRP-ELISA with the mAb 7A9 as described in section 2.3.5.1. 
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(3) Polymer assay 
The binding of sialyl Lewis-a (sLea) polymer to the purified hE-LecEGF protein was tested in a 
sLea-polymer assay[324, 325]. 
 
• Preparation of sLea-polymer-biotin-streptavidin-POD complex 
The biotinylated sLea-polyacrylamide polymer (Glycotech) was dissolved in HAB buffer (20 
mM Hepes, 150 mM NaCl, 1 mM CaCl2, pH 7.4) at 1 mg/ml and stored at -20°C for the 
long-term storage. In order to form SLea-polymer-biotin-streptavidin-POD complex, the matrix 
was prepared in a 1.5 ml tube with streptavidin-POD-conjugate (500 U/ml, Roche) according 
to Table 2.23. After incubation at 37°C for 2h, The sLea-polymer-biotin-streptavidin-POD 
complex (100 µg/ml) was formed. It was further stored at 4°C in the dark and it was stable 
over several weeks. 
 
Table 2.23. Composition of sLea polymer complex. 
 Matrix 
sLea-polymer  20 µl  
Streptavidin-POD conjugate  80 µl  
Fetal calb serum  20 µl  
HAB  80 µl  
Total 200µl  
 
• sLea Polymer assay 
100 µl of hE-LecEGF (3 µg/ml) in HAB buffer (20 mM Hepes, 150 mM NaCl, 1 mM CaCl2, pH 
7.4) were coated onto MaxiSorb 96 well ELISA plates (Nunc) at 4°C, overnight. The plates 
were then washed gently with HAB buffer for three times and the plates were tapped dry on 
the paper towels. The non-specific sites were blocked with 200 µl /well blocking buffer (3% 
BSA in HAB buffer) for 3 h at room temperature. After washing three times with 200 µl /well 
HAB buffer and tapping dry on paper towels, 100 µl /well sLea – polymer complex (0.1 µg/ml in 
HAB-buffer) were distributed in triplicate and incubated on the shaker with 56 rpm at room 
temperature for 3h. The plates were then washed three times with 200 µl /well HAB buffer and 
tapped dry on paper towels before addition of 100 µl /well ABTS solution (Bio-Rad). After the 
incubation with ABTS solution for 10 min in the dark, the color development was stopped with 
100 µl/well oxalic acid (2%) and the absorbance was read at 415 nm in a Spectramax190 
plate reader. The evaporation in the assay was prevented by incubation in a humidified 
chamber during assay. In the assay, the negative control used is HAB buffer and the positive 
control is the E-selectin/IgG protein. 
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• Optimization of sLea Polymer assay 
The signal of the hE-LecEGF protein in sLea Polymer assay[324, 325] was difficult to be detected 
with above conditions. Hence, the sLea Polymer assay was optimized by the below 
parameters: 
 
a. Concentration of hE-LecEGF 
3 µg/ml, 5µg/ml, 10 µg/ml and 20 µg/ml of hE-LecEGF were used to increase the assay 
signal. 
 
b. Concentration of the sLea polymer complex 
0.1 µg/ml, 0.3 µg/ml, 0.5 µg/ml and 1 µg/ml of the sLea-polymer complex were employed 
respectively in the assay. 
 
c. Binding buffer 
HAB buffer and HAB20 buffer (HAB buffer containing 20 mM CaCl2) were used.  
 
d. Developing time 
The developing time was prolonged to 10 min, 15 min and 20 min in order to increase the 
detection signal. 
 
(4) NMR analysis 
Two independent NMR experiments were preformed to assess the binding of CGP69669 (an 
antagonist of E-selectin) to hE-LecEGF. The T1rho experiment[326] and the STD NMR 
experiment[327] are subject to independent sources of experimental errors. Thus, a positive 
identification of ligand binding from both experiments would serve as cross-validation of the 
results. NMR experiments performed by Dr. Brain Cutting (Institute of molecular pharmacy, 
university of Basel) were conducted on a Bruker Avance DMX-500 (500 MHz) spectrometer.  
 
• Sample preparation 
Using the Amicon ultra-4 (5KDa) centrifugal filter devices and Centricon™ filtration units, the 
pure hE-LecEGF protein was concentrated and changed to the NMR assay buffer (20 mM 
d11-Tris, 20mM CaCl2 in 99.8% D2O, pH7.4) according to the manufacturer’s instruction. 52 
µM of hE-LecEGF in 280 µl NMR assay buffer was used for the below NMR experiments. 
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• STD NMR experiment 
STD measures the transfer of magnetization to a bound ligand following irradiation of the 
protein. Ligands that bind protein will give rise to a signal in the STD spectrum, while 
non-binding ligands, as well as the proteins, will not. STD NMR experiment of hE-LecEGF (52 
µM) with the ligand CGP69669 (1.5 mM) was measured at 200 µl using a restricted volume 
Shigemi NMR tube[328]. The NMR experiment was performed as described by Mayer M.[327], 
with the exception that the protein was saturated with a train of 40 E-Burp-1 pulses[329] of 40 
Hz root-mean-square intensity for 50 ms at 0 ppm[330]. 
 
• T1rho experiment 
To assess the binding, the transverse relaxation rates were measured. The measurement 
used an in-house sequence to quantitate T1rho, which is a measure of the transverse 
relaxation and is less sensitive to magnetic field inhomogeneity. The measurement of T1rho 
was advantageous with respect to spin-echo schemes, since changing from the free ligand to 
the ligand complexed with the protein might have different levels of magnetic field 
homogeneity. 
 
T1rho experiment of hE-LecEGF with the ligand CGP69669 was also measured at 200 µl 
using Shigemi NMR tube. The intensity of 1.5 mM ligands with or without protein (52 µM) was 
measured at the time of 0.01, 0.05, 0.1, 0.15 and 0.2 seconds. The signal loss with the 
increasing relaxation times was quantified and analyzed with the Prism curve-fitting software 
package from GraphPad Software, Inc. 
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2.4 Capture-binding assay development 
A capture-binding assay was created based on the references[25,36,325] to evaluate the binding 
affinity of the hE-selectin ligands to hE-LecEGF. This assay can evaluate the binding activity 
of the purified hE-LecEGF as well. 
 
2.4.1 Selection of Anti-E selectin antibody  
The appropriate anti-E-selectin antibody was searched for immobilization of the hE-LecEGF 
protein on ELISA plates from the literature[25]. 
 
2.4.2 Capture-binding assay 
The capture-binding assay was developed from the references[36,325]. 
 
100 µl/well of anti-E-selectin/anti-P-selectin antibody BBA1 in the coating buffer (50 mM 
Na2CO3, pH 9.6) was coated onto MaxiSorb 96 well ELISA plates (Nunc) at 4°C, overnight. 
After washing three times with 200 µl/well HAB20 buffer (20 mM Hepes, pH 7.4, 150 mM NaCl, 
20 mM CaCl2), the plates were tapped dry on the paper towels. The non-specific sites were 
blocked with 200 µl/well blocking buffer (3% BSA in HAB20 buffer) for 3 h at room temperature. 
After washing three times with 200 µl/well HAB20 buffer and tapping dry on paper towels, 100 
µl/well hE-LecEGF in HAB20 buffer were added and incubated at 4°C and overnight. After 
three times washing with 200 µl/well HAB20 buffer, 100 µl/well sLea-polymer complex at a 
appropriate concentration were distributed in triplicate and incubated on the shaker with 56 
rpm or 250 rpm at room temperature for 3 h. The plates were then washed three times with 
200 µl/well HAB20 buffer and tapped dry on paper towels. After addition of 100 µl/well ABTS 
solution (Bio-Rad), the plates were incubated for 10 min in the dark. The color development 
was stopped with 100 µl /well oxalic acid (2%) and the absorbance was read at 415 nm in a 
Spectramax190 plate reader. The evaporation in the assay was prevented by incubation in a 
humidified chamber during assay. The negative control used in the assay is the 
anti-E-selectin/anti-P-selectin antibody BBA1 and the positive control is E-selectin/IgG 
protein.  
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2.4.3 Optimization of capture-binding assay 
The capture-binding assay was further optimized in different concentrations of hE-LecEGF (1 
µg/ml, 3 µg/ml and 5 µg/ml) and different concentrations of the sLea polymer complex (0.1 
µg/ml, 0.3 µg/ml and 0.5 µg/ml). 
 
2.4.4 EC50 determination of sLea-polymer  
The EC50 of the sLea-polymer complex to the protein hE-LecEGF was determined by the 
capture-binding assay with serial concentrations of sLea-polymer complex (0.3 ng/ml-300 
ng/ml) as described in section 2.4.2. The value of EC50 of sLea-polymer complex to 
hE-LecEGF was calculated using the Prism4 software. 
 
2.4.5 Competitive capture-binding assay 
Using the procedure described in section 2.4.2, the competitive capture-binding assay was 
performed by adding 50 µl of E-selectin ligands in serial concentrations and 50 µl of 0.1 µg/ml 
sLea-polymer complex simultaneously instead of addition of 100 µl/well sLea-polymer complex 
(0.1 µg/ml) in the capture binding assay. The developing time in the competitive capture- 
binding assay is around 5 min. Using the Prism4 software, the binding curve of E-selectin 
antagonist was drawn and the IC50 of antagonist to hE-LecEGF was calculated. 
 
2.4.6 Surface plasmon resonance assay  
Surface plasmon resonance (Biacore) assays performed by Celine Weckerle (Institute of 
molecular pharmacy, university of Basel) were measured on a Biacore 3000 instrument (GE 
Healthcare, Freiburg, Germany) at 25 °C. The running buffer was HBS-P buffer (10 mM 
HEPES, 150 mM NaCl, pH 7.4, 0.002% v/v surfactant P20). For all experiments, a polyclonal 
goat anti-human Fc specific antibody (Sigma) was first immobilized onto the research grade 
CM5 sensor chip via amine coupling using the manufacturer’s protocol (Biacore). In a typical 
experiment, a 20 µg/ml solution of the polyclonal antibody diluted in acetate buffer (10 mM 
sodium acetate, pH 5) was injected at 10 µl/min for 10 min over all flow cells. Following the 
polyclonal antibody coupling, the flow path was changed to exclude the reference flow cell 
containing only immobilized polyclonal antibody. A 50 µg/ml solution of E-Selectin/IgG diluted 
in acetate buffer (10 mM sodium acetate, pH 5.5) was injected at 5 µl/min for 20 min over a 
single flow cell, designated the active flow cell. The reference and active flow cells were 
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equilibrated at 5 µl/min for 12 h in HBS-P running buffer that was supplemented with 20 mM 
calcium. Before injecting the analyte, the system was equilibrated for 2 h in HBS-P running 
buffer that was supplemented with 20 mM calcium and 2.5% DMSO (v/v). Different 
concentrations of analyte were prepared in HBS-P buffer that was supplemented with 20 mM 
calcium and 2.5% DMSO (v/v). The analyte dilutions were injected with a 60 s dissociation 
time over the reference and the active flow cells. To compare the binding affinity of the 
different selectin ligands, the sensorgrams from SPR experiments were processed with 
Scrubber-2.0a (BioLogic Software Pty Ltd., Campbell, Australia). The response observed in 
the reference flow cell was subtracted from the active flow cell. The apparent equilibrium 
dissociation constant KD was determined by using a simple steady state affinity 1:1 binding 
model. Because of the influence of DMSO to the binding signal, a calibration was 
necessary[331]. For that purpose, different solutions of DMSO were injected before the each 
cycle of measurement. The signal corrections based on the calibration solutions were directly 
performed during binding evaluation in the software Scrubber 2.0a.  
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2.5 Crystallization of hE-LecEGF 
Crystallization of hE-LecEGF was performed by a sitting-drop method on the EMBO course[332] 
in OPPF, University of Oxford. 
 
2.5.1 Sample preparation 
Pure hE-LecEGF was concentrated to a final concentration of ~ 9 mg/ml in a ~ 60 µl Tris 
buffer (60 mM Tris, 2 mM CaCl2) by ultracentrifugation.  
 
2.5.2 Crystallization 
The crystallization screening of hE-LecEGF was performed with Hampton crystallization 
screening kit I and II at 4°C and 20°C using the nanoliter-scale sitting-drop vapour-diffusion 
method. Three plates were done by Cartesian instrument in the single-dispense mode. The 
droplet for crystallization was composed of 100 nl of protein plus 100 nl of reservoir solution. 
The crystallization was performed with standard crystallization screening kits (Hampton) on 
the 96 well crystallization plates (Greiner). The barcoded crystallization plates were entered 
into an automated storage system with a fully integrated imaging system. The plates were 
imaged in accordance with a pre-programmed schedule and the resulting digital data for each 
droplet are harvested into a laboratory information management system, scored by crystal 
recognition software and displayed for analysis via a web-based interface. 
Materials and Methods
 
                                                                                    
 99 
 
 
3. Results and Discussion 
3.1 Sequence analysis 
3.1.1 DNA sequence 
The amino acid sequence of human E-selectin was extracted from UniProtKB/Swiss-Prot with 
the entry number P16581 and used for sequence analysis. The nucleic acid sequence of 
human E-selectin was extracted from GenBank with the entry number M30640 and used for 
primers design and DNA sequencing analysis. The amino acid and nucleic acid sequences of 
human E-selectin are shown in Figure 3.1. The domains of human E-selectin are also shown 
in Figure 3.1, including the N-terminal signal sequence (21 amino acids), the lectin domain 
(118 amino acids), the EGF-like domain (36 amino acids), 6 consensus repeat domains, the 
transmembrane region (22 amino acids) and the C-terminal cytoplasmic domain (32 amino 
acids).  
 
 
N:  atgattgcttcacagtttctctcagctctcactttggtgcttctcattaaagagagtgga 
A:  M··I··A··S··Q··F··L··S··A··L··T··L··V··L··L··I··K··E··S··G··   20 
 
N:  gcctggtcttacaacacctccacggaagctatgacttatgatgaggccagtgcttattgt 
A:  A··W··S··Y··N··T··S··T··E··A··M··T··Y··D··E··A··S··A··Y··C··   40 
 
N:  cagcaaaggtacacacacctggttgcaattcaaaacaaagaagagattgagtacctaaac 
A:  Q··Q··R··Y··T··H··L··V··A··I··Q··N··K··E··E··I··E··Y··L··N··   60 
 
N:  tccatattgagctattcaccaagttattactggattggaatcagaaaagtcaacaatgtg 
A:  S··I··L··S··Y··S··P··S··Y··Y··W··I··G··I··R··K··V··N··N··V··   80 
 
N:  tgggtctgggtaggaacccagaaacctctgacagaagaagccaagaactgggctccaggt 
A:  W··V··W··V··G··T··Q··K··P··L··T··E··E··A··K··N··W··A··P··G··  100 
 
N:  gaacccaacaataggcaaaaagatgaggactgcgtggagatctacatcaagagagaaaaa 
A:  E··P··N··N··R··Q··K··D··E··D··C··V··E··I··Y··I··K··R··E··K··  120 
 
N:  gatgtgggcatgtggaatgatgagaggtgcagcaagaagaagcttgccctatgctacaca 
A:  D··V··G··M··W··N··D··E··R··C··S··K··K··K··L··A··L··C··Y··T··  140 
 
N:  gctgcctgtaccaatacatcctgcagtggccacggtgaatgtgtagagaccatcaataat 
A:  A··A··C··T··N··T··S··C··S··G··H··G··E··C··V··E··T··I··N··N··  160 
 
N:  tacacttgcaagtgtgaccctggcttcagtggactcaagtgtgagcaaattgtgaactgt 
A:  Y··T··C··K··C··D··P··G··F··S··G··L··K··C··E··Q··I··V··N··C··  180 
 
N:  acagccctggaatcccctgagcatggaagcctggtttgcagtcacccactgggaaacttc 
A:  T··A··L··E··S··P··E··H··G··S··L··V··C··S··H··P··L··G··N··F··  200 
 
N:  agctacaattcttcctgctctatcagctgtgataggggttacctgccaagcagcatggag 
A:  S··Y··N··S··S··C··S··I··S··C··D··R··G··Y··L··P··S··S··M··E··  220 
 
N:  accatgcagtgtatgtcctctggagaatggagtgctcctattccagcctgcaatgtggtt 
A:  T··M··Q··C··M··S··S··G··E··W··S··A··P··I··P··A··C··N··V··V··  240 
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N:  gagtgtgatgctgtgacaaatccagccaatgggttcgtggaatgtttccaaaaccctgga 
A:  E··C··D··A··V··T··N··P··A··N··G··F··V··E··C··F··Q··N··P··G··  260 
 
N:  agcttcccatggaacacaacctgtacatttgactgtgaagaaggatttgaactaatggga 
A:  S··F··P··W··N··T··T··C··T··F··D··C··E··E··G··F··E··L··M··G··  280 
 
N:  gcccagagccttcagtgtacctcatctgggaattgggacaacgagaagccaacgtgtaaa 
A:  A··Q··S··L··Q··C··T··S··S··G··N··W··D··N··E··K··P··T··C··K··  300 
 
N:  gctgtgacatgcagggccgtccgccagcctcagaatggctctgtgaggtgcagccattcc 
A:  A··V··T··C··R··A··V··R··Q··P··Q··N··G··S··V··R··C··S··H··S··  320 
 
N:  cctgctggagagttcaccttcaaatcatcctgcaacttcacctgtgaggaaggcttcatg 
A:  P··A··G··E··F··T··F··K··S··S··C··N··F··T··C··E··E··G··F··M··  340 
 
N: ttgcagggaccagcccaggttgaatgcaccactcaagggcagtggacacagcaaatccca 
A:  L··Q··G··P··A··Q··V··E··C··T··T··Q··G··Q··W··T··Q··Q··I··P··  360 
 
N:  gtttgtgaagctttccagtgcacagccttgtccaaccccgagcgaggctacatgaattgt 
A:  V··C··E··A··F··Q··C··T··A··L··S··N··P··E··R··G··Y··M··N··C··  380 
 
N:  cttcctagtgcttctggcagtttccgttatgggtccagctgtgagttctcctgtgagcag 
A:  L··P··S··A··S··G··S··F··R··Y··G··S··S··C··E··F··S··C··E··Q··  400 
 
N:  ggttttgtgttgaagggatccaaaaggctccaatgtggccccacaggggagtgggacaac 
A:  G··F··V··L··K··G··S··K··R··L··Q··C··G··P··T··G··E··W··D··N··  420 
 
N:  gagaagcccacatgtgaagctgtgagatgcgatgctgtccaccagcccccgaagggtttg 
A:  E··K··P··T··C··E··A··V··R··C··D··A··V··H··Q··P··P··K··G··L··  440 
 
N: gtgaggtgtgctcattcccctattggagaattcacctacaagtcctcttgtgccttcagc 
A:  V··R··C··A··H··S··P··I··G··E··F··T··Y··K··S··S··C··A··F··S··  460 
 
N:  tgtgaggagggatttgaattacatggatcaactcaacttgagtgcacatctcagggacaa 
A:  C··E··E··G··F··E··L··H··G··S··T··Q··L··E··C··T··S··Q··G··Q··  480 
 
N:  tggacagaagaggttccttcctgccaagtggtaaaatgttcaagcctggcagttccggga 
A:  W··T··E··E··V··P··S··C··Q··V··V··K··C··S··S··L··A··V··P··G··  500 
 
N:  aagatcaacatgagctgcagtggggagcccgtgtttggcactgtgtgcaagttcgcctgt 
A:  K··I··N··M··S··C··S··G··E··P··V··F··G··T··V··C··K··F··A··C··  520 
 
N:  cctgaaggatggacgctcaatggctctgcagctcggacatgtggagccacaggacactgg 
A:  P··E··G··W··T··L··N··G··S··A··A··R··T··C··G··A··T··G··H··W··  540 
 
N:  tctggcctgctacctacctgtgaagctcccactgagtccaacattcccttggtagctgga 
A:  S··G··L··L··P··T··C··E··A··P··T··E··S··N··I··P··L··V··A··G··  560 
 
N:  ctttctgctgctggactctccctcctgacattagcaccatttctcctctggcttcggaaa 
A:  L··S··A··A··G··L··S··L··L··T··L··A··P··F··L··L··W··L··R··K··  580 
 
N:  tgcttacggaaagcaaagaaatttgttcctgccagcagctgccaaagccttgaatcagat 
A:  C··L··R··K··A··K··K··F··V··P··A··S··S··C··Q··S··L··E··S··D··  600 
 
N:  ggaagctaccaaaagccttcttacatcctt 
A:  G··S··Y··Q··K··P··S··Y··I··L··  610 
 
 
 
 
 
Figure 3.1. The nucleic acid sequence (N) and amino acid sequence (A) of human E-selectin. The
N-terminal signal sequence is shown in grey, the lectin domain in red, the EGF-like domain in blue, 6
consensus repeat domains in green, the transmembrane region in purple and the C-terminal
cytoplasmic domain in black.  
Results and Discussion
 
                                                                                    
 101 
 
 
3.1.2 Prediction of post-translational modification  
3.1.2.1 Prediction of N-glycosylation sites 
The potential N-glycosylation site in hE-LecEGF was predicted by NetNglyc1.0 server as 
described in section 2.1.2.1. Asn4, Asn124 and Asn139 were predicted as the potential 
N-glycosylation sites by examining the sequence context of Asn-Xaa-Ser/Thr sequons, 
including Asn-Pro-Ser/Thr. 
 
3.1.2.2 Prediction of O-glycosylation sites 
The prediction of the O-glycosylation site in hE-LecEGF by the program of NetOglyc3.1 and 
OGPET showed that there is no potential O-glycosylation site in hE-LecEGF. 
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3.2 Cloning, Expression, Purification and Characterization of Human 
E-LecEGF in Insect Cells 
The baculovirus-infected insect cell expression system was initially chosen for the expression 
of the lectin and EGF-like domains of human E-selectin (hE-LecEGF). This expression 
system has the advantages of high expression of the target gene, ease of scale-up and the 
ablity to produce proteins with post-translational modifications[261]. 
 
3.2.1 Cloning of hE-LecEGF 
3.2.1.1 Construction of the secretion plasmid pFastBacYJS 
In order to express hE-LecEGF in a secreted form in insect cells, the secretion plasmid 
pFastBacYJS was first generated. The gp67 signal sequence, the most effective 
baculovirus-encoded signal sequence for protein secretion in insect cells[261], was  
introduced to the pFastBacTM1 vector to construct the plasmid pFastBacYJS. pFastBacTM1 
contains the strong promoter of polyhedrin promoter for the expression of the recombinant 
protein in insect cells (see Figure 2.3). Thus, the construct pFastBacYJS secretes the proteins 
of interest under the control of polyhedrin promoter in insect cells system.  
 
(1) Cloning of the gp67 signal sequence 
The gp67 signal sequence (114 bp) was amplified by PCR from the plasmid pAcGP67-A 
(9761 bp) baculovirus transfer vector with 5’ primer SN1 containing a BamH I restriction 
endonuclease site and 3’ primer SN2 containing an Xba I restriction site as described in 
section 2.2.2.2. The PCR product was then analyzed on 2% agarose gel (Figure 3.2). In order 
to construct the plasmid pFastBacYJS, a double-digested PCR fragment of the gp67 signal 
sequence with BamH I and Xba I restriction endonucleases was ligated by T4 DNA ligase into 
the insect cell expression vector pFastBacTM1, which was also double-digested with these two 
restriction endonucleases. After transformation into E.coli DH5α and clone screening, the 
constructs pFastBacYJS (4824 bp) (Figure 3.3) were purified using the GenElute Plasmid 
Miniprep kit (Sigma) and were further characterized. 
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(2) Characterization of the plasmid pFastBacYJS 
Colony PCR, restriction enzyme digestion and DNA sequencing were performed to confirm 
that the pFastBacYJS constructs contain the correct gp67 signal sequence. 
 
• Colony PCR 
Colony PCR was performed to screen the recombinant clones by amplifying the gp67 signal 
sequence with SN1and SN2 primers and Taq DNA polymerase as described in section 2.2.2.2. 
The amplified fragments (133 bp) from clones C1-C8 indicated the presence of the gp67 
signal sequence in the clones C2-C8 (Figure 3.4).  
 
 
 
Figure 3.2. PCR amplified fragment of the gp67 signal sequence on
2% agarose gel stained with ethidium bromide. Lane 1: Negative
control; Lane 2: The gp67 signal sequence amplified with SN1 and
SN2 primers and pfu DNA polymerase. 
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Figure 3.3. Map of the plasmid pFastBacYJS. 
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• Restriction enzyme digestion 
Double digestions of the pFastBacYJS constructs were performed with the restriction 
endonucleases BamH I and Xba I. The constructs pFastBacYJS (pFastBacYJS 2, 3, 4 and 8) 
were cut into the gp67 signal sequence fragments (124 bp) and pFastBac TM1 vectors (4700 
bp), respectively (Figure 3.5). 
 
 
 
 
Figure 3.4. Colony PCR amplified fragments of the gp67
signal sequence on 2% agarose gel with SN1 and SN2
primers and Taq DNA polymerase. NC: Negative control; PC:
Positive control with the plasmid pAcGPgp67-A; C1-C8:
PCR fragments amplified from clones C1-C8. 
 
Figure 3.5.  Double digestions of constructs pFastBacYJS2, 3, 4
and 8 with BamH I and Xba I on 2% agarose gel stained with
ethidium bromide. P: Plasmid pFastBacYJS; C2, C3, C4, and C8:
Plasmids pFastBacYJS 2, 3, 4 and 8. 
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• DNA sequencing of the plasmid pFastBacYJS 
Two clones of the plasmid pFastBacYJS were sequenced with the FastBacf primer for plus 
strand determination as described in section 2.2.2.2. Alignment by the Blast program bl2seq 
showed that the 153 bases sequencing result overlapped with the gp67 signal sequence and 
the identity was 100% (Figure 3.6). This result indicated that both of these two constructs 
pFastBacYJS contained the correct gp67 signal sequence. 
 
 
 
 
Figure 3.6. Bl2seq alignment of the plus strand sequence of the pFastBacYJS sequencing result (Query) and the 
gp67 signal sequence (in gray) in plasmid pFastBacTM1 (Sbjct). The identity was 100% (153/153residues) in the 
alignment. 
 
 
3.2.1.2 Construction of the hE-LecEGF expression plasmid pFastBacYJSE 
In order to express hE-LecEGF in insect cells, the expression plasmid pFastBacYJSE was 
constructed by inserting the PCR fragment of hE-LecEGF into the vector pFastBacYJS. An 
N-terminal Flag-tag was fused to the hE-LecEGF by primer design to facilitate the purification 
with affinity chromatography (Figure 3.7). The Flag-tag can be completely removed by the 
enterokinase to avoid interference of the tag in structure studies.  
 
 
 
 
 
 
 
 Figure 3.7. Schematic representation of hE-LecEGF expressed in insect cells. 
Flag-tag NH2 - hE-LecEGF gp67 signal 
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(1) Genomic DNA isolation from CHO-E-sel/IgG cells  
CHO-E-sel/IgG cells, generated by Novartis, are CHO cells expressing the extracellular 
domains (the lectin, the EGF-like and consensus repeats domains) of human E-selectin with a 
C-terminal human IgG1 tag[333]. The genomic DNA of CHO-E-sel/IgG cells was isolated using 
a WIZARD Genomic Purification Kit (Promega) as described in section 2.2.2.3, analyzed on 
0.8% agarose gel (Figure 3.8) and used as the template for PCR amplification of the 
hE-LecEGF sequence.  
 
 
                  
 
 
 
(2) Cloning of hE-LecEGF into the pFastBacYJS vector 
5’ primer E-FLE1 and 3’ primer E-ELE2 were designed to amplify the hE-LecEGF sequence 
from the genomic DNA of CHO-E-sel/IgG cells (see section 2.2.2.3). The amplified fragments 
include the lectin and the EGF-like domain and three additional amino acids of the consensus 
repeat domain of hE-selectin, like the construct used previously for the crystallization of 
hE-LecEGF[30,31]. The 5’ primer E-FLE1 contains an Xba I restriction endonuclease site and a 
flag tag (DYKDDDDK) designed for affinity purification and identification of the recombinant 
protein. Protease enterokinase can recognize the sequence DDDDK in the flag tag and 
cleave after the K residue to completely remove the tag. The 3’ primer E-ELE2 introduces a 
stop codon after the hE-LecEGF sequence and an Xho I restriction endonuclease site for 
cloning. The lectin and the EGF-like domains of human E-selectin (471 bp) were amplified by 
PCR as described in section 2.2.2.3. The analysis of PCR product is shown in Figure 3.9.   
 
 
 
 
 
 M    1     2    E1     E2 
Figure 3.8. Isolated genomic DNA of CHO-E-sel-IgG cells (Lane 1, 2) on 0.8%
agarose gel stained with ethidium bromide. Lane M: DNA marker X. 
 
9162 bp 
3054 bp 
 
2036 bp 
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Using the same restriction/ligation cloning method for the construction of the plasmid 
pFastBacYJS (see section 2.2.2.2), the hE-LecEGF expression plasmid pFastBacYJSE 
(5241 bp, Figure 3.10) was constructed by insertion of the PCR products of hE-LecEGF into 
the vector pFastBacYJS (Figure 3.3). The constructed plasmid pFastBacYJSE contains the 
gp67 signal sequence and the hE-LecEGF sequence fused with an N-terminal Flag tag. As 
shown in Figure 3.10, the expression of hE-LecEGF was regulated by the polyhedrin 
promoter (PPH). 
 
 
 
                    
 
 
 
(3) Characterization of the expression plasmid pFastBacYJSE 
pFastBacYJSE constructs were confirmed by colony PCR, restriction enzyme digestion and 
DNA sequencing. 
Figure 3.9. PCR products 1 and 2 of hE-LecEGF (Lane E1 and E2)
amplified with E-LEF1 and E-LEF2 primers and pfu DNA polymerase
on 1.5% agarose gel.  
E1    E2 
— 517bp 
Figure 3.10. Map of the plasmid pFastBacYJSE. 
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• Colony PCR 
Colony PCR of the clones C6-C8 was performed to verify the presence of the hE-LecEGF 
sequence with E-FLE1 and E-FLE2 primers and Taq DNA polymerase. The amplified 
fragment (517 bp) from each clone (Figure 3.11) indicated the presence of the hE-LecEGF 
sequence. The positive control of colony PCR was the genomic DNA of CHO-E-sel/IgG and 
the negative control was the plasmid pFastBacYJS. 
 
 
  
 
• Restriction digestion analysis 
Double digestions of pFastBacYJSE6 and pFastBacYJSE8 were performed with the 
restriction endonucleases Xba I and Xho I. Two fragments of the pFastBacYJS vector (4737 
bp) and hE-LecEGF (504 bp) were generated after digestion as shown in Figure 3.12, 
indicating the presence of the hE-LecEGF sequence in the constructs. 
 
 
 
   1       
Figure 3.11. Colony PCR amplified fragments of hE-LecEGF
on 1.5% agarose gel with E-FLE1 and E-FLE2 primers and
Taq DNA polymerase. NC: Negative control (plasmid
pFastBasYJS); PC: Positive control, the genomic DNA of
CHO-E-sel-IgG cells; C6-C8: plasmids of pFastBacYJSE5-8.
Figure 3.12. Double digestions of plasmid pFastBacYJSE6
(Lane 1) and pFastBacYJSE8 (Lane 2) with Xba I and Xho I
on 1.5% agarose gel.  
1        2 
C8  C7  C6      NC  PC 
— 517 bp 
⎯ hE-LecEGF, 504 bp 
 ⎯ pFastBacYJS, 4737 bp 
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• DNA sequencing of the pFastBacYJSE plasmids 
DNA sequencing of two constructs of pFastBacYJSE was performed with the primer FastBacf 
for plus strand determination as described in section 2.2.2.3. Alignment by the Blast program 
bl2seq showed that the sequence displayed 100% identity with the gp67 signal sequence 
(114 bp) and the hE-LecEGF fused with an N-terminal flag tag (498 bp) (Figure 3.13). It 
indicates that both of these two constructs pFastBacYJSE are correct. 
 
 
 
Figure 3.13. Bl2seq alignment of the plus strand sequence of the pFastBacYJSE (Query) and the gp67 signal 
sequence fused with the hE-LecEGF containing an N-terminal flag tag (Sbjct). The identity was 100%. The gp67 
sequence is shown in deep grey and hE-LecEGF in light gray. 
    1         
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3.2.2 Generation of the recombinant Bacmid 
Recombinant bacmids were generated by transformation of the expression plasmid 
pFastBacYJSE (1ng) into MAX Efficiency® DH10BacTM competent cells (see section 2.2.2.4). 
The DH10BacTM E.coli strain contains a helper plasmid for supplying the transposition protein 
and a baculovirus shuttle vector (bacmid). The recombinant bacmid was generated by 
transposition of the mini-Tn7 element on the pFastBacTM1 constructs to the mini-attTn7 site 
on the bacmid with transposition protein. Five recombinant bacmids’ DNA were generated 
and isolated. The isolated recombinant bacmid DNA is greater than 135kb in size. Since 
restriction enzyme analysis is difficult to perform with DNA of this size, PCR analysis was 
used to verify the presence of the hE-LecEGF gene in the recombinant bacmid. The 
transposed pFastBacYJSE sequence in the recombinant bacmid can be amplified by M13 
Forward (-40) and M13 Reverse primers as shown in Figure 3.14.  
 
 
 
  
 
 
 
 
The presence of PCR fragments of 514 bp amplified with E-FLE1 (Forward) and E-FLE2 
primers and the presence of PCR fragments of ~3000 bp on 1% agarose gel with M13 
Forward (-40) and M13 Reverse primers indicated that the purified recombinant bacmids DNA 
contain the hE-LecEGF sequence (Figure 3.15).   
   
 
 
 
 
Figure 3.14. Schematic representation of the transposed sequence in bacmid DNA amplified by M13
Forward and M13 Reverse primers. 
Mini-Tn7 
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3.2.3 Production of the recombinant baculovirus  
3.2.3.1 Transfection of insect cells and isolation of P1 viral stock 
Transfection of insect cells Sf9 (9 x 105 cells, viability > 97%) with four purified recombinant 
Bacmids DNA (1 µg) was performed in an unsupplemented Grace’s Medium in a 6-well tissue 
culture plate, respectively, in order to get the high expression biculovirus (see section 2.2.3.3). 
6 µl of Cellfectin® Reagent, a liposome formulation, was used for mediating the transfection. 
After 5 hours of transfection, the cells were cultured in the complete growth media Sf-900 II 
SFM at 27 °C for further 72 hours or until signs of viral infection were observed by using an 
inverted phase microscope at 400x magnification. 
 
P1 viral stock was isolated and collected when the cells showed signs of late and very late 
infection as described in section 2.2.3.4 (see Figure 3.16). Compared to the non-transfected 
cells, signs of the late infection are that the cell growth stops, cells increase 25-50% in cell 
diameter, the viral budding and vesicular appear, and cells detach from the plate. Signs of 
very late infection are that the cells appear lysed and show signs of clearing in the monolayer. 
The collected P1 viral stock containing 2% fetal bovine serum was then used for further viral 
plaque assay and plaque purification.  
 
 
 
 
 
1   2  3   4   M   5   6  7   8  9  10    
. 
 
 
Figure 3.15. Identification of the purified recombinant 
bacmids1, 2, 3 and 4 by PCR amplification with Taq
DNA polymerase on 1% agarose gel. Lane 1-4: 
Fragments amplified from bacmids 1-4 with M13 
forward and M13 reverse primers; Lane M: DNA 
marker X; Lane 5-8: Fragments amplified from 
bacmids 1-4 with E-FLE1 and E-FLE2 primers; Lane 
9: Positive control with the genomic DNA of 
CHO-E-sel/IgG cells; Lane 10: Negative control. 
3054 bp 
1018 bp 
2036 bp 
1636 bp 
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3.2.3.2 Viral Plaque Assay 
In order to determine the titer of the baculoviral stock and isolate the single viral clone, viral 
plaque assay was performed (see section 2.2.3.5). The titer of P1 viral stock was determined 
as 2x106 pfu/ml and the single viral clones were isolated for further PCR identification and 
virus amplification. PCR amplification of the hE-LecEGF sequence from the isolated single 
viral clones P11 and P12 was performed as described in section 2.2.3.8. The amplified 
fragments of hE-LecEGF analyzed on 1.5% agarose gel indicated that the isolated single viral 
clones P11 and P12 contained the recombinant sequence of hE-LecEGF (Figure 3.17). 
 
 
 
 
 
Figure 3.16. Non-transfected Sf9 cells (a) and Sf9 cells transfected with the recombinant baculovirus
of hE-LecEGF (b) were observed after transfection of 72 hours under the inverted phase microscope
at 400x magnification. 
4      3      2       1 
Figure 3.17. PCR amplified fragments of hE-LecEGF
from the isolated single viral clones P11 (Lane 1) and
P12 (Lane 2) on 1.5% agarose gel stained with ethidium
bromide. Lane 3: Positive control with the plasmid
pFastBacYJSE; Lane 4: Negative control.  
⎯ 517 bp 
a.                                            b. 
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3.2.3.3 Preparation of P2 and P3 viral stocks  
The collected P1 viral stock is a small-scale and low-titer stock, therefore, the high-titer viral 
stocks P2 and P3 were amplified for further expression using P1 or P2 viral stock with an MOI 
of 0.05 (see section 2.2.3.6 and 2.2.3.7). The titers of P2 and P3 were determined to be ~ 
2x107 pfu/ml and ~ 1x108 pfu/ml, respectively, by viral plaque assay. 
 
3.2.4 Expression of the recombinant protein hE-LecEGF  
The expression condition of the recombinant protein hE-LecEGF was optimized by using 
different cell lines, cell density, MOI and time course (see section 2.2.4.2). 
 
Sf9 and High FiveTM cells were selected for secretion of hE-LecEGF with an MOI of 1, 2, 5 
and10, and a time course of 24, 48, 72 and 96 hours post-infection. The expression of 
hE-LecEGF was detected by sandwich ELISA with the monoclonal functional blocking 
antibody 7A9 and Western-blotting with the anti-flag antibody M2 as described in section 
2.2.4.3. In Figure 3.18, hE-LecEGF was strongly expressed in Hi5 cells after transfection of 48 
hours and then degraded. Under the same expression condition, High FiveTM cells showed 
better expression of hE-LecEGF than Sf9 cells. This result is in agreement with that High 
FiveTM cells are suitable for secretion of recombinant proteins[262]. 
  
 
 
The best expression conditions of hE-LecEGF in Sf9 and Hi5 insect cells are shown in table 
3.1.  
Table 3.1. Optimized expression conditions of human E-LecEGF in Sf9 and Hi5 insect cells. 
 Sf9 High FiveTM 
Medium Sf-900II SFM Express Five SFM 
Cell density (cells/ml) 2x106 1x106 
MOI (1,2,5,10) 10 5 
Post-infection time (hours) 72 48 
 
Figure 3.18. Western blotting analysis of the time course
(post-infection of 24, 48, 72 and 96 hours) of expression of
hE-LecEGF in Sf9 and Hi5 insect cells, detected with the
monoclonal anti-flag M2 antibody. Lane M: Low molecular
weight marker. 
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3.2.5 Purification and characterization of hE-LecEGF expressed in insect cells 
3.2.5.1 Monoclonal anti-E-selectin antibody 7A9 production, purification and coupling 
to sepharose 4B matrix 
 
The monoclonal anti-E-selectin antibody 7A9 (mAb 7A9) is a functional blocking 
anti-E-selectin antibody[295,296]. In order to functionally purify the hE-LecEGF protein, mAb 7A9 
was produced, purified, characterized and coupled to the sepharose as described below. 
 
(1) Production of mAb 7A9 
Hybridoma cell line 7A9 (ATCC Deposit No. HB-10135) expresses the monoclonal functional 
blocking anti-E-selectin antibody 7A9 (mAb 7A9). The cell line was recovered from liquid 
nitrogen and cultured in the RPMI-15 medium containing 15% FBS (recommended medium 
by the manufacturer). 
 
In order to reduce the contamination of IgG from fetal bovine serum (FBS) and facilitate 
purification, the cells were adapted to grow in the medium RPMI-2 with 2% FBS (see section 
of 2.2.5.1). In addition, the special FBS serum containing ultra low IgG (5 µg/ml) was 
supplemented in the culture medium. 
 
Monoclonal antibody 7A9 was produced in the RPMI-2 medium containing 2% FBS in both 
T175 Flasks and a roller bottle (1700 cm2 expanded surface, Corning). In order to increase 
the yield of antibody, the culture supernatant was inoculated twice with cells as described in 
section 2.2.5.1.  
 
(2) Purification of mAb 7A9 
The produced mAb 7A9 in culture supernatant is an IgG1 subclass antibody[295,296]. Since the 
murine IgG1 antibody showed stronger binding affinity to Protein G matrix than Protein A, 
mAb 7A9 was purified by a Protein G column (Amersham Pharmacia) attached to an FPLC 
system as described in section 2.2.5.1. The purified mAb 7A9 was further characterized by 
SDS-PAGE, Bradford Assay, Western-blotting and ELISA methods. 
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(3) Characterization of mAb 7A9 
• SDS-PAGE analysis 
The purified mAb 7A9 was analyzed by 12% SDS-PAGE and silver staining (Figure 3.19). 
Under reducing conditions, two bands were shown on the gel, the upper band is the 55 kDa of 
the heavy chain of mAb 7A9 and the lower band is 25 kDa of the light chain. No contaminants 
were visible on the gel, indicating that highly pure mAb 7A9 was obtained. 
 
    
 
• Verification of mAb 7A9   
Three western-blotting analyses were performed to confirm the functionality of mAb 7A9 as 
described in section 2.2.5.1.  
mAb 7A9 is a murine antibody 
Reduced mAb 7A9 (1 µg) was blotted to the nitrocellulose membrane after separation by 12% 
SDS-PAGE. The recognition of mAb 7A9 by the anti-mouse IgG (whole molecule)–alkaline 
phosphatase antibody indicated that mAb 7A9 is a murine antibody (see Figure 3.20). 
  
    
M    1   2       
Figure 3.19. 12% SDS-PAGE analysis of the purified mAb 7A9 fraction 1
(Lane 1) and fraction 2 (Lane 2) under reducing condition and silver staining.
Lane M: Low molecular weight marker. 
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 M    1      
Figure 3.20. Western-blotting analysis of reduced mAb 7A9 with AP-Mouse IgG
(whole molecule). Lane M: Low molecular weight marker. 
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mAb 7A9 is a functional blocking anti-E-selectin antibody 
Western-blotting analysis of native and denatured hE-LecEGF (15 µg) with mAb 7A9 (10 
µg/ml) were performed. The blotted hE-LecEGF on nitrocellulose membrane was verified by 
staining with Ponceau S solution prior to antibody detection. The recognition of native 
hE-LecEGF (Figure 3.21) and non-recognition of the denatured and reduced hE-LecEGF 
(Figure 3.22) by mAb 7A9 indicated that mAb 7A9 only recognizes the functional hE-LecEGF. 
This is in agreement with the previous report[296]. Unlike the others antibodies, a higher 
concentration of mAb 7A9 (10 µg/ml) was needed for identification of hE-LecEGF as reported 
by Ishii [334]. This could be due to the low avidity of mAb 7A9. 
 
   
  
 
 
 
 
• Yield determination 
The amount of purified mAb 7A9, estimated by Bradford micro-assay, was 17.3 mg from 1L 
culture supernatant in the roller bottle and 5 mg in the tissue flask with the same cell density of 
5x105 cells/ml. It showed that production in a roller bottle was three times higher than in tissue 
Figure 3.21.  a. 8% Native-PAGE of the hE-LecEGF; b. Western-blotting result of the native hE-LecEGF,
identified by mAb 7A9.  
a.           b. 
Figure 3.22. Western-blotting analysis of reduced and denatured
hE-LecEGF identified by mAb 7A9. Lane M: Low molecular weight
marker. 
 1    M 
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flasks (Figure 3.23). Compared with the culture in T-flasks, the slow rolling of the roller bottle 
offers more CO2 and nutrients in the culture, contributing to the higher production. The yield of 
10.9 mg/L in the first-time purification of the supernatant, and of 5.4 mg/L in the second-time 
purification of the same supernatant showed that multiple purifications of the same 
supernatant were crucial for high yields of antibody (see Figure 3.24). This is in agreement 
with the previous report[323]. Although the binding capacity of the Protein G column is ∼ 25 
mg/ml of human IgG[335], only 10.9 mg/ml of mAb 7A9 was obtained from the first-time 
purification, it could be due to the lower binding capacity of the column to mouse IgG1 than 
human IgG1, or other IgGs from serum compete the binding sites on the column. 
 
      
 
 
 
(4) Coupling of mAb 7A9 to CNBr-activated Sepharose 4B matrix 
Pure mAb 7A9 was coupled to cyanogen bromide activated sepharose 4B matrix for the 
functional purification of hE-LecEGF, according to the manufacturer’s instructions.  
 
Prior to the coupling, the purified mAb 7A9 was concentrated and buffer-exchanged to the 
coupling buffer (0.1M NaHCO3, 0.5 M NaCl, pH 8.5) by Amicon Ultra-4 (10 kDa) centrifugal 
filter devices in order to remove the contaminants in the buffer, such as Tris and glycine (see 
section 2.2.5.1). 68% mAb 7A9 was recovered in the coupling buffer as shown in Table 3.2. 
 
Table 3.2. Recovery of mAb 7A9 during the concentrating and buffer exchange. 
mAb 7A9 Total protein (mg) Recovery 
Pure  protein 15  
Concentration 12.8 85% 
Buffer changing 10.2 68% 
 
Purification T-Flask (mg/L) Roller bottle (mg/L)
1 4.1 10.9 
2 0.9 5.4 
3  1 
Total 5 17.3 
 
Figure 3.23. Yields of mAb 7A9 purified by the Protein G column, quantified by Bradford micro-assay.
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The coupling of mAb 7A9 to the matrix was performed as described in section 2.2.5.1. The 
coupling efficiency, determined by Bradford micro-assay, is ∼ 97%. The mAb 7A9 coupled 
matrix was further analyzed on 12% SDS-PAGE under reducing conditions as described in 
section 2.2.5.1. On the gel, the antibody bands detected from the coupled matrix showed that 
sepharose 4B matrix was coupled with the mAb 7A9 (Figure 3.24).  
 
 
    
In total, three mAb 7A9 coupled columns were prepared. 1 ml sepharose 4B matrix coupled 
with 7 mg mAb 7A9 was used for purification of hE-LecEGF expressed in insect cells; 2 ml 
and 5 ml matrix coupled with 14 mg and 20 mg mAb 7A9 respectively were used for 
hE-LecEGF expressed in CHO K1 cells.  
 
3.2.5.2 Purification and characterization of hE-LecEGF by anti-E-selectin affinity 
chromatography 
(1) Batch purification with mAb 7A9 coupled matrix 
Functional purification of hE-LecEGF expressed in High FiveTM and Sf9 insect cells was 
performed by batch purification with a 1 ml mAb 7A9 coupled sepharose matrix (see section 
2.2.5.1) using the buffer described in Table 3.3. CaCl2 (2 mM) was added in all purification 
buffers since the binding activity of hE-LecEGF is calcium-dependent.  
 
Table 3.3. Buffers for the purification of hE-LecEGF with the mAb 7A9 coupled matrix. 
 Composition 
Binding buffer 50 mM Tris-HCl, 150 mM NaCl, 2 mM CaCl2, pH 7.5 
Washing buffer 
 
50 mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-100, 
2 mM CaCl2, pH 7.5 
Elution buffer 100 mM Glycine, 2 mM CaCl2, pH 3.5 
 
Figure 3.24. 12% SDS-PAGE analysis of mAb 7A9 coupled
(Lane 1) and non-coupled CNBr activated sepharose 4B
matrix (Lane 2) under reducing condition with commassie
staining. Lane M: Low molecular weight marker. 
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(2) SDS-PAGE and Western-blotting analysis 
hE-LecEGF purified by the mAb 7A9 coupled matrix was analyzed on 15% SDS-PAGE with 
silver staining. Under reducing conditions, two bands at molecular weight 24-29 kDa and one 
band at 66 kDa were shown on the gel (Figure 3.25). Western-blotting analysis was then 
performed to identify the bands on gel. 
 
 
  
Western-blotting analysis of the purified hE-LecEGF with monoclonal anti-flag M2 antibodies 
(SIGMA) is shown in Figure 3.26. The anti-flag M2 antibody was used for detection of the 
denaturing and reducing hE-LecEGF protein, since mAb 7A9 only recognizes the native 
hE-LecEGF. On the membrane, the main two bands recognized by the anti-flag antibody are 
at the molecular weight of 24-29 kDa (Figure 3.26), indicating the two bands with the same 
molecular weights on SDS-PAGE (Figure 3.25) represent the hE-LecEGF protein. The band 
at 66 kDa on the gel (Figure 3.25) could be contaminant BSA from serum. The two bands on 
the membrane could be the glycosylation isotype of hE-LecEGF, since it contains three 
potential N-glycosylation sites (Asn4, Asn124 and Asn139) as predicted in section 3.1.2.1. 
This result showed that the hE-LecEGF protein can be purified with the mAb 7A9 coupled 
matrix.  
 
 
M  
Figure 3.26. Western blotting analysis (with the monoclonal anti-flag M2
antibody) of hE-LecEGF purified by the mAb7A9 coupled matrix. Lane
M: Low molecular weight marker. 
Figure 3.25. 15% SDS-PAGE analysis (reducing condition and silver
staining) of the purified hE-LecEGF fraction 1 (Lane 1) and fraction 2
(Lane 2) by batch purification with the mAb 7A9 coupled sepharose 4B
matrix. Lane M: Low Molecular weight marker. 
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3.2.5.3 Purification and characterization of hE-LecEGF by anti-flag affinity 
chromatography 
 
(1) SDS-PAGE and Western-blotting analysis 
hE-LecEGF expressed in insect cells was fused with an N-terminal flag tag (see section 
3.2.1.2). Therefore, the purification of hE-LecEGF can be performed by affinity 
chromatography with the anti-flag antibody coupled matrix. A 2 ml anti-flag M2 monoclonal 
antibodies agarose (SIGMA) column was used for the purification of hE-LecEGF expressed in 
High FiveTM and Sf9 cells by FPLC according to the manufacturer’s instructions (see section 
2.2.5.3). After washing with 10 bed-volumes of the washing buffer (50 mM Tris-HCl, 150 mM 
NaCl, 2 mM CaCl2, pH 7.5), the eluted hE-LecEGF with the elution buffer (100 mM glycine, pH 
3.5) was analyzed on 15% SDS-PAGE under reducing conditions and commassie staining 
(see Figure 3.27). The elution fractions (Lane 1 and 2) showed strong signals at the molecular 
weight of 24-29 kDa and several several bands of above 45 kDa on the gel (Figure 3.27). 
 
 
       
 
 
Western-blotting analysis of the eluted hE-LecEGF was performed for the identification of 
hE-LecEGF (see section 2.2.5.3). On the membrane, the specific bands recognized by 
monoclonal anti-flag M2 antibodies (Sigma) are at the molecular weight of 24-29 kDa (Figure 
3.28), indicating that the bands at the same molecular weights on the SDS-PAGE represent 
the recombinant protein of hE-LecEGF fused with the N-terminal Flag tag and there exists 
contaminants in the eluted fractions (Figure 3.27). Therefore, the anti-flag chromatography 
needs to be further optimized or other chromatographies should be performed in order to 
obtain the pure protein. 
 
Figure 3.27. 15% SDS-PAGE analysis of hE-LecEGF
purified by anti-flag affinity chromatography under
reducing conditions and commassie staining. Lane M:
Low molecular weight marker; Lane 1 and 2: The eluted
fractions 1 and 2; Lane 3: The supernatant; Lane 4: The
flow through. 
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In Figure 3.26, the main two bands of hE-LecEGF purified by the mAb 7A9 coupled matrix 
were recognized by anti-flag antibodies, whereas four bands of hE-LecEGF purified by the 
anti-flag column were recognized by the same antibody (Figure 3.28). It indicated that 
hE-LecEGF purified by the anti-flag column might contain the non-correctly folded proteins, 
which were recognized by anti-flag antibodies, but not the functional blocking anti-E-selectin 
antibody mAb 7A9. 
 
The molecular weight of hE-LecEGF fused with the N-terminal flag tag was predicted as 
19.0792 kDa by the program ProtParam (see section 2.1.3). The purified hE-LecEGF showed 
four bands at the molecular weight of 24-29 kDa (Figure 3.28), indicating that hE-LecEGF 
expressed in insect cells was post-translationally modified. 
 
In order to obtain pure protein in one-step purification by anti-flag affinity chromatography, the 
purification conditions of hE-LecEGF were further optimized as described in section 2.2.5.3. 
The purified hE-LecEGF was analyzed on 15% SDS-PAGE under reducing conditions and 
silver staining. Under the optimized condition (Table 3.4), pure protein hE-LecEGF was 
achieved by addition of 0.5% Triton X-100 to the washing buffer (see Figure 3.29). The 
non-ionic detergent Triton X-100 was used to reduce the non-specific binding of 
contaminating proteins which hydrophobically or ionically interact with the column.   
 
Table 3.4. The optimized purification condition of hE-LecEGF by anti-flag affinity chromatography. 
 Composition Flow rate 
Binding buffer 50 mM Tris-HCl, 150 mM NaCl, 2 mM CaCl2, pH 7.5 1.0 ml/min 
Washing buffer 
 
50 mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-100, 
2 mM CaCl2, pH 7.5 1.0 ml/min 
Elution buffer 100 mM Glycine, 2 mM CaCl2, pH 3.5 0.5-1 ml/min 
 
 
Figure 3.28. Western blotting analysis of hE-LecEGF purified by anti-flag
chromatography with monoclonal anti-flag M2 antibodies. Lane M: Low
molecular weight marker. 
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(2) Monomeric identification  
hE-LecEGF purified by the optimized anti-Flag affinity chromatography was analyzed on 15% 
SDS-PAGE under both reducing and non-reducing conditions and silver staining (Figure 3.30). 
According to the western-blotting result (Figure 3.28), the purified hE-LecEGF is pure. 
Oligomerization of hE-LecEGF under non-reducing conditions was not observed, indicating 
that the hE-LecEGF protein is a monomer. This result is in agreement with the previous 
report[336]. 
 
 
 
 
(3) Yield determination 
The amount of the purified hE-LecEGF was quantified by Bradford micro-assay (see section 
2.2.5.3). 5.82 mg/L of pure hE-LecEGF was obtained in High FiveTM (Hi5) cells expression 
and 4.99 mg/L in Sf9 cells (Figure 3.31). Hi5 cells showed better production of hE-LecEGF 
than Sf9, confirming that High Five™ cells are suitable for secretion of proteins than other 
insect cells[262]. 
6    5    4     3     2     1    M 
Figure 3.29. hE-LecEGF purified by the optimized
anti-flag affinity chromatography on 15% SDS-PAGE
and silver staining. Lane M: Low molecular weight
marker; Lane 1-6: Eluted hE-LecEGF fractions 1-6.
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Figure 3.30. 15% SDS-PAGE analysis of the purified hE-LecEGF
under non-reducing (Lane 1) and reducing (Lane 2) conditions and
commassie staining. Lane M: Low molecular weight marker. 
66 kDa 
 
45 kDa 
36 kDa 
29 kDa 
24 kDa 
 
 
20 kDa 
Results and Discussion
 
                                                                                    
 123 
 
 
 
 
 
 
 
 
 
  
 
 
(4) Activity determination  
Western-blotting and HRP-ELISA were performed to identify the activities of the purified 
hE-LecEGF (see section 2.2.5.3). The native hE-LecEGF expressed in Hi-5 cells was 
recognized by the functional blocking anti-E-selectin mAb 7A9 in western-blotting (Figure 3.32) 
and in HRP-ELISA (Figure 3.33). Under the native condition, hE-LecEGF was separated not 
only by the size of protein, but also by the shape and charge, hence, it showed several bands 
on the membrane (Figure 3.32). The recognition of hE-LecEGF by the mAb 7A9 in both 
western-blotting and ELISA indicated that the purified hE-LecEGF is active. 
 
 
                       
 
 
 
Figure 3.31.  Yields of the purified hE-LecEGF from the expression in High Five™ and Sf9 cells. 
Figure 3.32. Western-blotting analysis of the native
hE-LecEGF expressed in Hi-5 cells with the
functional blocking mAb 7A9. 
Insect cells Medium Yield (mg/L)
High Five™ Express Five SFM  5.82 
Sf9 Sf-900II SFM  4.99 
 
  TM 
Figure 3.33. HRP ELISA analysis of the hE-LecEGF
expressed in Hi-5 with the functional blocking mAb
7A9. 
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(5) Deglycosylation of hE-LecEGF  
hE-LecEGF contains three potential N-glycosylation sites at Asn4, Asn124 and Asn139 as 
predicted by the NetNglyc1.0 server (see section 3.1.2.1). The purified hE-LecEGF showed 
four bands on SDS-PAGE at the molecular weight of 24-29 kDa rather than the predicted 
19.07 kDa (Figure 3.29), indicating the post-translational glycosylation of the protein. In order 
to obtain the homogeneous hE-LecEGF, deglycosylation was performed. 
 
• Deglycosylation with PNGase F and N-Glycosidase A 
Peptide-N-glycosydase F (PNGase F, Roche) and N-glycosydase A (Roche) were used to 
remove the glycans of hE-LecEGF expressed in High fiveTM and Sf9 cells by either separately 
or combined. PNGase F is a widely used deglycosidase[281]. It recognizes the high-mannose, 
hybrid or complex type of glycans[281]. N-Glycosidase A recognizes all types of asparagine 
bound N-glycans[281] and the core alpha (1,3)-fucose modification in High Five™ cells, which 
was resistant to PNGase F. 
 
Deglycosylations were performed at 37°C under native and denaturing conditions, 
respectively (see section 2.2.5.3). The deglycosylated hE-LecEGF was analyzed on 15% 
SDS-PAGE under reducing conditions and commassie staining. Under native and denaturing 
conditions, compared with the untreated hE-LecEGF protein, no apparent shift of hE-LecEGF 
was observed on gel after 96 hours’ digestion with PNGase F (Figure 3.34) and 
N-Glycosidase A (Figure 3.35). The same pattern was also observed under native conditions 
by combination digestion of hE-LecEGF with these two deglycosidases (Figure 3.36). 
 
Under native and denaturing conditions, the uniform deglycosylated hE-LecEGF was not 
obtained by deglycosylation with PNGase F and N-Glycosidase A. This result is similar to the 
previous report[324]. The hE-LecEGF protein expressed in insect cells showed resistance to 
these deglycosidases. The features of these deglycosidases may partly explain this result. 
PNGase F is sensitive to the protein conformation, especially when the asparagine residue 
sequon is on the amino or carboxyl end of a peptide[278,279,285]. N-Glycosidase A is not able to 
efficiently remove all susceptible oligosaccharides on proteins, e.g. ovalbumin and 
orosomucoid. This could be due to the large size of the enzyme (66.8 kDa), which may impair 
its access to cleavage sites, or to the fact that the N-glycosyl residue is located on the 
carboxyl or amino terminal end of a peptide[285]. The limitation of these enzymes might 
influence the removal of glycans from hE-LecEGF.   
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Figure 3.34. 15% SDS-PAGE analysis
(reducing condition and commassie
staining) of deglycosylation of the
hE-LecEGF expressed in Sf9 and Hi5,
treated with PNGase F for 96 h under
native and denaturing conditions. Lane M:
Low molecular weight marker; Lane 1-3:
Deglycosylated hE-LecEGF expressed in
Sf9, Lane 1: Native conditions. Lane 2,3:
Denaturing conditions, Lane 4: Untreated
hE-LecEGF expressed in Sf9; Lane 5-7:
Deglycosylated hE-LecEGF expressed in
Hi5, Lane 5: Native conditions. Lane 6,7:
Denaturing conditions, Lane 8: Untreated
hE-LecEGF expressed in Hi5. 
 
     Hi 5     M        Sf9 
1   2  3   4      5   6   7   8 
Figure 3.35. 15% SDS-PAGE analysis (reducing
condition and commassie staining) of
deglycosylation of the hE-LecEGF expressed in Sf9
and Hi5, treated with N-glycosidase A for 96 h under
native and denaturing condition. Lane M: Low
molecular weight marker; Lane 1: Untreated
hE-LecEGF expressed in Hi5; Lane 2-4:
Deglycosylated hE-LecEGF expressed in Hi5, Lane
2: Native conditions, Lane3,4: Denaturing
conditions, Lane 5: Untreated hE-LecEGF
expressed in Sf9; Lane 6-8: Deglycosylated
hE-LecEGF expressed in Sf9, Lane 6: Native
conditions, Lane 7,8: Denaturing conditions. 
M     1      2      3 
Figure 3.36. 15% SDS-PAGE analysis (reducing conditions and
commassie staining) of deglycosylation of the hE-LecEGF expressed in
Sf9 and Hi5, treated with N-glycosidase A and PNGase F under native
conditions. Lane M: Low molecular weight marker; Lane 1: Untreated
hE-LecEGF expressed in Hi5; Lane 2: Deglycosylated hE-LecEGF
expressed in Sf9 under native conditions; Lane 3: Deglycosylated
hE-LecEGF expressed in Hi5 under native conditions. 
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• Deglycosylation with O-glycosidase 
hE-LecEGF expressed in Hi5 and Sf9 cells was also treated with O-glycosidase under native 
conditions (see section 2.2.5.3). The deglycosylated hE-LecEGF was analyzed on 15% 
SDS-PAGE under reducing conditions with Commassie staining. No obvious shift was found 
between the hE-LecEGF and the deglycosylated hE-LecEGF (Figure 3.37), indicating that no 
O-linked glycan was removed, coinciding with the prediction that there is no O-glycosylation 
site in the hE-LecEGF (see section 2.1.2.2).  
  
 
  
 
(6) Glycans detection  
Detection of glycans of hE-LecEGF and hE-LecEGF treated with deglycosidases was 
performed with a GelCode Glycoprotein Staining Kit (Pierce) as described in section 2.2.5.3. 
The magenta bands of the deglycosylated hE-LecEGF on gel indicated that glycans of 
hE-LecEGF expressed in either Hi5 or Sf9 cells were not removed by PNGase F and 
N-glycosidase A under native or denaturing conditions (data not shown, due to the problem of 
documentation). This result might be due to the restriction of the deglycosidases as discussed 
above. 
 
M    1    2    3 
Figure 3.37. 15% SDS-PAGE analysis (reducing conditions and
commassie staining) of the deglycosylated hE-LecEGF expressed in Hi5
(Lane 1) and Sf9 cells (Lane 2), treated with O-glycosidase under native
condition.Lane M: Low molecular weight marker; Lane 3: Untreated
hE-LecEGF expressed in Hi5. 
66 kDa 
45 kDa 
36 kDa 
29 kDa 
24 kDa 
20 kDa 
 
14.2 kDa 
Results and Discussion
 
                                                                                    
 127 
 
 
3.3 Cloning, Expression, Purification and Characterization of human 
E-LecEGF in CHO-K1 cells 
3.3.1 Cloning of hE-LecEGF in CHO K1 cells 
hE-LecEGF was then expressed in CHO K1 cells, since the uniform hE-LecEGF was not 
obtained in the insect cells expression system (see section 3.2). Two hE-LecEGF expression 
clones were generated. One clone expresses hE-LecEGF without tag and can be functionally 
purified by the mAb 7A9 coupled column (Figure 3.38a). The other contains the partial CH1 
domain and complete CH2 and CH3 domains of human IgG1 (hIgG1 tag) like the previously 
reported E-selectin/IgG chimeras (the extracellular domains of human E-selectin fused with a 
C-terminal hIgG1 tag)[333], which can be purified by a Protein A column (Figure 3.38b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NH2 - Signal  hE-LecEGF 
a. 
b. 
CH2    CH2 
CH3    CH3 
CH1                    CH1 
Signal 
Signal 
hE-LecEGF               hE-LecEGF
 
Figure 3.38. Schematic representation of hE-LecEGF constructs expressed in CHO K1cell, the
signal will be deleted when protein is secreted to the medium. a: the hE-LecEGF expressed
without tag; b: the hE-LecEGF/IgG expressed with a hIgG1 tag. 
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3.3.1.1 Construction of the expression plasmid pYJE 
The expression plasmid pYJE was constructed for expression of hE-LecEGF without tag.  
 
(1) Cloning of hE-LecEGF into the vector pcDNA3.1 (+) 
In order to secret the hE-LecEGF protein into the medium, the signal, lectin and EGF-like 
domains of human E-selectin (SLE sequence, 534bp) were amplified by PCR from the 
genomic DNA of CHO-E-sel/IgG cells with the forward primer E1 containing a BamH I 
restriction endonuclease site and the backward primer E2 containing a stop codon 
downstream of the SLE sequence and an EcoR I site as described in section 2.3.2.2. The 
PCR product was analyzed on 2% agarose gel (Figure 3.39, Lane E1). Using the 
restriction/ligation cloning method, the PCR fragment of the SLE sequence was inserted into 
the vector pcDNA3.1 (+) (5428bp) to construct the expression plasmid pYJE (5899bp, Figure 
3.40). The expression of hE-LecEGF was under the control of the CMV promoter (PCMV) as 
shown in Figure 3.40. 
 
  
 
 
 
 
 
 
 
 
Figure 3.39. PCR products of hE-LecEGF and hIgG1 tag with pfu
DNA polymerase on 2% agarose gel stained with ethidium
bromide. Lane M: DNA marker X; Lane E1: Amplified hE-LecEGF
fragment with E1and E2 primers; Lane E2: Amplified hE-LecEGF
fragment with E1and E3 primers; Lane IgG: Amplified human IgG1
tag with IgG1 and IgG2 primers. 
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Figure 3.40. Map of the plasmid pYJE. 
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(2) Characterization of the plasmid pYJE 
The pYJE constructs were confirmed by colony PCR and DNA sequencing methods (see 
section 2.3.2.6). 
 
• Colony PCR 
The SLE sequence of human E-selectin was amplified by colony PCR from recombinant 
clones (C1-C3) with E1 and E2 primers and Taq DNA polymerase. The amplified PCR 
products (534 bp) indicated the presence of the SLE sequence in the recombinant clones 
(see Figure 3.41). 
 
 
 
 
 
 
• DNA sequencing of the plasmid pYJE 
Two constructs of pYJE were sequenced with T7 primer for plus strand determination as 
described in section 2.3.2.6. 100% identity of the SLE sequence (534 bp) in the alignment 
result indicated that both two plasmids pYJE were correct (Figure 3.42). 
 
 
Figure 3.41. The SLE fragments amplified by Colony PCR on 1.5%
agarose gel with E1 and E2 primers and Taq DNA polymerase. Lane
M: DNA marker X; Lane 1: Positive control, amplified from the genomic
DNA of CHO-E-sel-IgG cells; Lane 2-4: Recombinant clones C1-3. 
 
1    2    3    4   M 
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Figure 3.42. Bl2seq alignment of the plus strand sequence of the pYJS (Query) and the SLE sequence of human 
E-selectin extracted from GenBank (sbjct). The identity was 100% in the alignment. The signal sequence is shown 
in grey italics and the hE-LecEGF in black bold. 
 
 
3.3.1.2 Construction of the expression plasmid pYJEG  
(1) Construction of the plasmid pYJ-IgG 
In order to purify hE-LecEGF with a Protein A column, the plasmid pYJ-IgG was first 
constructed to carry the hIgG1 tag.  
 
The hIgG1 tag (1020 bp) was amplified by PCR from the genomic DNA of CHO-E-sel/IgG 
cells with 5’ primer IgG1 containing an EcoR I restriction endonuclease site and 3′ primer 
Results and Discussion
 
                                                                                    
 131 
 
 
IgG2 containing a stop codon downstream of the sequence of the hIgG1 tag and an Xho I site. 
The amplified fragments of the hIgG1 tag (Figure 3.39, Lane IgG) were then cloned into the 
plasmid pcDNA3.1(+) by a restriction/ligation cloning method to get the plasmid pYJ-IgG 
(Figure 3.43).  
 
                   
 
 
 
 
 
 
The purified constructs of pYJ-IgG were further confirmed by colony PCR and sequence 
verification as described in section 2.3.3.1. The amplified fragments of the hIgG1 tag from 
pYJ-IgG1-3 clones in colony PCR (Figure 3.44) and DNA sequencing results showed that 
pYJ-IgG constructs contained the human IgG1 tag. 
 
 
 
 
 
M    1     2    3    4    5 
Figure 3.44. Colony PCR amplified fragments of the
hIgG1 tag on 1.2% agarose gel with IgG1 and IgG2
primers and Taq DNA polymerase. Lane M: DNA
marker X; Lane 1: Positive control, amplified from the
genomic DNA of CHO-E-sel-IgG cells; Lane 2-4:
Clones of pYJ-IgG1-3; Lane 5: Negative control. 
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Figure 3.43. Map of the plasmid pYJ-IgG. 
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(2) Cloning of the SLE sequence into the vector pYJ-IgG 
The expression plasmid pYJEG was constructed to carry the SLE sequence of human 
E-selectin fused with a C-terminal hIgG1 tag. An enterokinase cleavage site was introduced 
between the hE-LecEGF encoding gene and the hIgG1 tag for further complete removal of 
the tag. 
 
The forward primer E1 containing a BamH I restriction endonuclease site and the backward 
primer E3 containing a protease enterokinase site (DDDDK) and an EcoR I site were used to 
amplify the SLE sequence from the genomic DNA of CHO-E-sel/IgG cells. The PCR products 
(Figure 3.39, Lane E2) were then cloned into the vector of pYJ-IgG (see section 2.3.3.2) to get 
the expression plasmids pYJEG (Figure 3.45). The constructs of pYJEG were further 
confirmed by colony PCR and sequencing verification.  
                   
 
 
 
 
 
 
 
3.3.2 Transfection and selection of the high, stable expression clones and subclones of 
CHO-YJE and CHO-YJEG  
3.3.2.1 Determination of geneticin sensitivity 
In order to select the stable expression clones and subclones, the sensitivity of CHO K1 cells 
to the antibiotic geneticin was determined by the method described in section 2.3.4.2. A 
concentration of 500 µg/ml of geneticin was chosen for the selection. 
 
Figure 3.45. Map of the plasmid pYJEG. 
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3.3.2.2 Transfection and selection 
Prior to transfection, the expression plasmids pYJE and pYJEG were linearized by restriction 
endonuclearase Sca I, in order to decrease the likelihood of vector integration into the 
genome in such a way that disrupts the gene of interest or other elements required for the 
expression in mammalian cells. Restriction enzyme Sca I was chosen for linearization of the 
expression plasmids since this site is contained only in the ampicillin gene of the plasmids, not 
in the essential genes for expression (see section 2.3.4.3).  
 
CHO K1 cells (viability >95%) were stably transfected with the linearized expression plasmids 
of pYJE or pYJE-IgG to generate the expression clones of CHO-YJE and CHO-YJEG, 
respectively. Lipid (metafectene)-mediated transfection was performed according to the 
manufacturer’s protocol described in section 2.3.4.4. Selective medium containing 500 µg/ml 
geneticin was applied for selection of stable transfectants. High expression clones of 
CHO-YJE and CHO-YJEG were detected by AP-ELISA with mAb 7A9 post-transfection of two 
weeks (see section 2.3.5.1). AP-ELISA screenings were performed twice to avoid the false 
positive clone. Overall, for each construct, 10 high expression stable clones were obtained by 
screening 576 clones. After propagation, these generated clones were stored at –185°C in 
liquid nitrogen for long-term storage.  
 
In order to reduce costs and facilitate purification, high-expression stable clones of CHO-YJE 
and CHO-YJEG were adapted to grow in DMEM:F12 selective medium containing 5% FBS 
instead of Ham’s F12 selective medium containing 10% FBS, before screening of the 
subclones (see section 2.3.5.2). High expression subclones CHO-YJES and CHO-YJEGS 
from a single cell were selected by limiting dilution and detected twice by AP-ELISA (see 
section 2.3.5.2). Five high, stable expression subclones of CHO-YJES and CHO-YJEGS were 
achieved. The AP-ELISA results of these subclones are shown in Figure 3.45. CHO-YJES1 
and CHO-YJEGS1 showed better expression than CHO-YJES 2-5 (Figure 3.46a) and 
CHO-YJEGS 2-5 (Figure 3.46b). Therefore, CHO-YJES1 and CHO-YJEGS1 were further 
characterized. 
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3.3.2.3 Characterization of subclones CHO-YJES1 and CHO-YJEGS1 
The best expression subclones CHO-YJES1 and CHO-YJEGS1 were characterized on both 
DNA level and protein level for the expression of hE-LecEGF and hE-LecEGF/IgG. 
 
(1) Characterization on DNA level  
The SLE sequence was amplified by colony PCR from the CHO-YJES1 subclone with E1 and 
E2 primers as described in section 2.3.5.3. The amplified fragments of the SLE sequence 
indicated that the SLE sequence was integrated into the genome of CHO-YJES1 subclone 
(Figure 3.47, Lane1). 
 
Using the same method, the CHO-YJEGS1 subclone was confirmed from the presence of the 
SLE sequence and the hIgG1 tag by PCR amplification with E1 and E3 primers, and IgG1 and 
IgG2 primers (Figure 3.47, Lane 3 and 4).  
 
 
 
 
Figure 3.47. PCR products of the SLE sequence and the
hIgG1 tag by colony PCR from the CHO-YJES1 and
CHO-YJEGS1 subclones on 1.5% agarose gel. Lane M: DNA
marker X; Lane 1: The SLE sequence amplified from
CHO-YJES with E1 and E2 primers; Lane 2: Negative control
(PCR amplified the SLE sequence from CHO-K1 cells with
E1 and E2 primers); Lane 3: The hIgG1 tag amplified from
the CHO-YJEGS subclone with IgG1 and IgG2 primers; Lane
4: The SLE sequence amplified from the CHO-YJES
subclone with E1 and E3 primers. 
 
1    2     3      4      M 
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1636 bp 
Figure 3.46. The hE-LecEGF expression in CHO-YJES (a) and CHO-YJEGS (b) subclones determined by
AP-ELISA. 
a.                                                 b. 
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(2) Characterization on protein level  
• Characterization of the CHO-YJES1 subclone 
100 ml culture supernatant of subclone CHO-YJES1 was collected and purified on a 2 ml mAb 
7A9 coupled column (see section 2.2.5.1) attached to a FPLC system (see section 2.3.5.3). 
The eluted hE-LecEGF was further analyzed by the western-blotting method. Identical 
amounts of reduced and non-reduced hE-LecEGF (~1 µg) were separated by SDS-PAGE and 
blotted to the nitrocellulose membrane. 2 µg/ml of anti-E-selectin antibody N18 (Santa-Cruz 
Biotechnology) was used to detect the presence of hE-LecEGF (see section 2.3.5.3), since 
this antibody recognizes the denaturing and reducing hE-LecEGF protein. The result (Figure 
3.48) showed that the bands at a molecular weight of ~ 23 kDa under reducing and 
non-reducing conditions were visible on the membrane, indicating that the CHO-YJES1 
subclone expresses the monomeric hE-LecEGF protein.  
 
 
 
• Characterization of the CHO-YJEGS1 subclone 
Using the same characterization method of the CHO-YJES1 subclone, hE-LecEGF/IgG 
expressed from the CHO-YJEGS1 subclone was purified on a 1 ml Protein A column and 
characterized by SDS-PAGE and western-blotting analysis (see section 2.3.5.3).  
 
12% SDS-PAGE analysis of the purified hE-LecEGF/IgG from 100 ml culture supernatant of 
subclone CHO-YJEGS is shown in Figure 3.49. Under reducing conditions, two bands at 
molecular weight ~ 66 kDa and one band at ~ 55 kDa are visible. The band at ~55 kDa could 
be a heavy chain of bovine IgGs derived from serum. Two bands at ~ 66 kDa could be 
hE-LecEGF/IgG or BSA contaminant. Under non-reducing conditions, four bands were 
detected. One band was at molecular weight ~155 kDa, which could be from bovine IgGs. 
Two bands at ~130 kDa and one band at ~66 kDa could be from hE-LecEGF/IgG. This result 
24 kDa 
66 kDa 
36 kDa 
45 kDa 
29 kDa 
20 kDa Figure 3.48. Western-blotting analysis of non-reduced (Lane 1) and
reduced hE-LecEGF (Lane 2) purified from the expression of
CHO-YJES1 subclone with the anti-E-selectin antibody N18. Lane M:
Low Molecular weight marker. 
M      1      2 
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indicated that additional gel filtration was needed to get the pure hE-LecEGF/IgG protein and 
remove the contaminants derived from serum. Western-blotting was performed to identify the 
hE-LecEGF/IgG protein on the gel. 
 
 
 
In Western-blotting analysis, the recognition of reduced and non-reduced hE-LecEGF/IgG (~1 
µg) by anti-human IgG monoclonal antibodies (1 µg/ml) is shown in Figure 3.50. The 
anti-human IgG monoclonal antibody was used to identify the hE-LecEGF/IgG protein since 
the protein fused with a C-terminal hIgG1 tag. Under reducing conditions, one band with 
molecular weight of ~ 66 kDa was detected on the membrane. Under non-reducing conditions, 
two main bands of ~130 kDa were visible due to the dimer of the protein formed under 
non-reducing conditions by the C-terminal hIgG1 tag fused to the protein. The non-uniform 
bands could be due to the glycosylation isotype of the protein. This result indicated that the 
subclone of CHO-YJEGS expresses the hE-LecEGF/IgG protein fused with a hIgG1 tag. 
 
 
 
66 kDa 
45 kDa 
36 kDa 
29 kDa 
24 kDa 
Figure 3.50. Western-blotting analysis of hE-LecEGF/IgG
purified from the CHO-YJEGS1 subclone culture under
reducing (Lane 1) and non-reducing (Lane 2) conditions with
the anti-human IgG monoclonal antibody conjugated with
alkaline phosphatase. Lane M: Low molecular weight marker.
   M      1         2 
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24 kDa 
Figure 3.49. 12% SDS-PAGE analysis of hE-LecEGF-IgG purified from the
CHO-YJEGS1 culture supernatant under reducing (Lane 1) and non-reducing
(Lane 2) conditions with commassie staining. Lane M: Low Molecular weight
marker. 
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3.3.3 Expression of hE-LecEGF from the CHO-YJES1 subclone  
Compared with the hE-LecEGF/IgG protein expressed by the CHO-YJEGS subclone, 
hE-LecEGF expressed by CHO-YJES can be purified in one-step by the mAb 7A9 coupled 
column. Since it did not contain the tag (which could have the interference in structural 
studies), the best expression subclone CHO-YJES1 was used for further expression of 
hE-LecEGF (see section 3.3.2.2 and 3.3.2.3).   
 
Sodium butyrate has been reported to increase the expression of proteins regulated by some 
mammalian promoters, including cytomegalovirus (CMV) and simian virus 40 (SV40) 
promoters[337,338]. However, the usefulness of sodium butyrate for improving production is 
limited since it rapidly induces cellular apoptosis[339]. Since expression of hE-LecEGF is under 
the control of CMV promoter, the effect of sodium butyrate on the production of hE-LecEGF 
was tested as described in section 2.3.6.3. Sodium butyrate (1 mM, 2 mM and 4 mM) was 
added respectively in the production phase in T-flask production. The expression of 
hE-LecEGF was evaluated by AP-ELISA (see section 2.3.5.1) and the cell viability was 
determined by Trypan blue method (see section 2.2.3.1). The net production of hE-LecEGF 
after addition of sodium butyrate at all concentrations was lower than the culture without 
supplement of sodium butyrate. The cell viability also reduced rapidly from 95% to 0% in two 
weeks at all concentrations of sodium butyrate. This could be due to the cytotoxic effect of 
sodium butyrate[339,340]. Hence, the production of hE-LecEGF was performed without addition 
of sodium butyrate. 
 
The hE-LecEGF protein was produced in the DMEM:F12 selective medium containing 5% 
FCS in both T175cm2-flasks and roller bottles (1700cm2 expanded surface, corning) at 37°C 
and 5% CO2 in a humid incubator as described in section 2.3.6.  
 
3.3.4 Purification and characterization of hE-LecEGF expressed in CHO K1 cells 
3.3.4.1 Purification and SDS-PAGE analysis 
Column purification of hE-LecEGF expressed from the subclone CHO-YJES1 was performed 
with a 2 ml or 5 ml mAb 7A9 coupled column by FPLC as described in section 2.3.7.1. Purified 
hE-LecEGF was analyzed on 15% SDS-PAGE with silver staining (Figure 3.51). Only one 
band at molecular weight ~22 kDa was observed on the gel, indicating that pure hE-LecEGF 
can be obtained by one-step purification with the mAb 7A9 coupled column.  
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3.3.4.2 Deglycosylation of hE-LecEGF expressed in CHO-K1 cells 
hE-LecEGF contains three potential N-linked glycosylation sites (see section 3.1.2.1). The 
purified hE-LecEGF showed a higher molecular weight of ~ 22 kDa (Figure 3.51) than the 
predicted 18.1 kDa, indicating hE-LecEGF expressed in CHO K1 cells is post-translationally 
N-glycosylated. Therefore, deglycosylation of hE-LecEGF was performed in order to facilitate 
the future crystallization, since glycans on the protein could increase the solubility of protein in 
the buffer.  
 
(1) Deglycosylation  
Since the binding of hE-LecEGF to the ligands is calcium-dependent, deglycosylation of 
hE-LecEGF was performed under native conditions at 37 ºC with PNGase F (Roche) in a Tris 
buffer instead of the phosphate buffer (recommended by the manufacturer) to avoid the 
precipitation of calcium phosphate (see section 2.3.7.2). The time course of deglycosylation of 
hE-LecEGF was analyzed on post-digestion of 24, 48 and 72 hours by 15% SDS-PAGE gel 
and silver staining (Figure 3.52). Compared with the post digestion of 24 and 48 hours (Figure 
3.52a), only the deglycosylated hE-LecEGF band was observed on gel after 72 hours 
digestion (Figure 3.52b). The decrease in the molecular weight of the deglycosylated 
hE-LecEGF implies the removal of glycans of hE-LecEGF expressed in CHO K1 cells. The 
negative result of the glycan detection with a GelCode Glycoprotein Staining Kit (Pierce) also 
indicated that no glycan was detected from the deglycosylated hE-LecEGF post-digestion of 
72 hour (see section 2.3.7.2). All these results implied that glycans on hE-LecEGF (10 µg) 
were completely removed by 4U PNGase F in the Tris buffer after 72 hours digestion.  
 
 
M       1      2    3     4    
 
Figure 3.51. 15% SDS-PAGE analysis of hE-LecEGF purified
by the mAb 7A9 coupled column under reducing conditions
and silver staining. Lane M: Low molecular weight marker;
Lane 1-4: Elution fractions 1-4. 
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(2) Purification of deglycosylated hE-LecEGF and SDS-PAGE analysis 
The deglycosylated hE-LecEGF was further purified with a Sepharose Q (0.5 ml) column in 
order to remove the PNGase F (see section 2.3.7.2). The purified deglycosylated hE-LecEGF 
was analyzed on 15% SDS-PAGE under non-reducing conditions and silver staining (Figure 
3.53). Pure deglycosylated hE-LecEGF was present in the flow through. 
 
 
  
3.3.4.3 Protein identification by western-blotting analysis 
Reduced and non-reduced hE-LecEGF (1 µg) and deglycosylated hE-LecEGF (1 µg) were 
identified by western-blotting with the anti-E-selectin antibody N18 (2 µg/ml) as described in 
section 2.3.7.3 (Figure 3.54). On the nitrocellulose membrane, the reduced and non-reduced 
hE-LecEGF showed a single specific band at molecular weight ~ 22 kD. The reduced and 
non-reduced deglycosylated hE-LecEGF showed a single band at ~20 kDa. Under 
Figure 3.53. 15% SDS-PAGE analysis of the deglycosylated
hE-LecEGF purified by 0.5 ml sepharose Q column under non-reducing
condition (Lane 1); Lane 2: hE-LecEGF; Lane M: Low molecular weight
marker. 
M       1      2 
M        2    1 
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—Deglycosylated    
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Figure 3.52. 15% SDS-PAGE analysis of the time-course of post digestion of 24h (Lane 1), 48h (Lane 2) and 72h
(Lane 3) of the deglycosylated hE-LecEGF under reducing conditions and silver staining. Lane 4: The untreated
hE-LecEGF; Lane M: Low molecular weight marker. 
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non-reducing conditions, no oligomerization of either the hE-LecEGF or the deglycosylated 
hE-LecEGF was observed, indicating that hE-LecEGF is a monomer, and coinciding with the 
published result that the soluble form of E-selectin is a monomer[336]. 
 
  
 
 
3.3.4.4 Yield determination 
The amount of the purified hE-LecEGF was quantified by Bradford micro-assay as described 
in section 2.3.7.4 480 µg/L and 762 µg/L of pure hE-LecEGF were obtained from T flasks 
production and roller bottles production respectively (Figure 3.55). It showed about 1.6 times 
higher of the protein produced in roller bottles than in T flasks due to the advantages of the 
non-static culture of roller bottles. Compared to the published result that  ~ 800 µg/L of the 
crude hE-LecEGF (quantified by sandwich ELISA with mAb 1D6 and biotinylated mAb 3B7) 
was produced in fermentation before the purification[36], 762 µg/L of pure hE-LecEGF was 
obtained after the functional purification, indicating that a good hE-LecEGF stable expression 
subclone CHO-YJES1 was achieved.  
 
 
 
Figure 3.55. Yields of hE-LecEGF purified by the mAb 7A9 coupled column, quantified by Bradford micro-assay. 
  1   2      M    3     4 
Figure 3.54. Western blotting analysis of the hE-LecEGF and  the 
deglycosylated hE-LecEGF with the monoclonal anti-E-selectin 
antibody N18 under reducing and non-reducing conditions. Lane M: 
Low molecular weight marker; Lane 1: Deglycosylated hE-LecEGF 
under non-reducing conditions; Lane 2: hE-LecEGF under 
non-reducing conditions; Lane 3: Deglycosylated hE-LecEGF under 
reducing conditions; Lane 4: hE-LecEGF under reducing conditions.
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3.3.4.5 Peptide identification by mass spectrometry 
The amino acid sequence of hE-LecEGF was identified by the ESI-MS-MS method. Reduced 
hE-LecEGF (2 µg) was separated by SDS-PAGE and stained with Simply Blue SafeStain 
(Invitrogen). After treatment with DTT, iodoacetamide and trypsin, the digested hE-LecEGF 
was analyzed by LC/MS/MS as described in section 2.3.7.5. 
 
6 of 9 expected fragments were found except the fragments F1 (amino acids 1-22), F3 (amino 
acids 33-54) and F8 (amino acids 109-143) (Figure 3.56 and Table 3.5). ~ 50% of hE-LecEGF 
amino acids including the binding active sites (Glu80, Asn82, Asn105 and Asn106) were 
identified, indicating the purified protein was human E-LecEGF. The missing of the fragments 
F1 and F8 could be due to the N-glycosylation in these two fragments, since three potential 
N-glycosylation sites (Asn4, Asn124 and Asn139) predicted by NetNglyc1.0 server (see 
section 3.1.2.1) are present in these two fragments, the glycosylation on these fragments 
changed their molecular weights, leading to the failed identification of these fragments.  
 
Table 3.5. hE-LecEGF fragments identified in ESI-MS-MS. 
Fragment No. M+H Amino acids NO. 
F2 1186.66 23-32 
F4 2326.26 55-74 
 2198.16 56-74 
F5 1154.53 75-84 
F6 1482.71 85-96 
 1638.82 85-97 
F7 1378.61 98-108 
F9 923.43 144-152 
 1495.69 144-157 
 
 
 
 
Figure 3.56. The found fragments (bold amino acids) of hE-LecEGF in peptide identification by
ESI-MS-MS. N in grey is the potential glycosylation site. 
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3.3.4.6 Molecular weight determination by mass spectrometry 
The molecular weight of hE-LecEGF was determined by ESI-MS. Purified hE-LecEGF (10 µg) 
were further prepared by RP-HPLC under the gradient elution condition to remove CaCl2 in 
the protein buffer (see section 2.3.5.3). The peak with the retention time of 4.721 min in 
RP-HPLC chromatography was collected and lyophilized overnight before MS measurement.  
   
The molecular weight of hE-LecEGF was measured by ESI-MS and determined as 20.444 
kDa as described in section 2.3.7.5 (Figure 3.57). According to the predicted molecular weight 
of 18.1 kDa and the deglycosylation results in section 3.3.4.2, hE-LecEGF was 
N-glycosylated with 2.344 kDa of glycans. The three potential N-glycosylation sites predicted 
by NetNglyc1.0 server were Asn4, Asn124 and Asn139. Based on the glycosylation mode in 
CHO cells (Figure 1.10), the complete molecular weight of the glycan on one asparagine is 
2.35 kDa, the glycan of 2.344 kDa on hE-LecEGF expressed in CHO cells indicated that the 
hE-LecEGF protein was partially glycosylated on one or two or all the three potential 
glycosylation sites, since the CHO cell does not maintain the complete glycosylation under the 
production conditions[259]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.57. ESI-MS spectrum of hE-LecEGF. 
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3.3.4.7 Activity determination 
The activity of the hE-LecEGF and the deglycosylated hE-LecEGF was tested by 
western-blotting, ELISA, polymer assay and NMR methods, respectively. 
 
(1) Western blotting analysis with the mAb 7A9 
The activity of the deglycosylated hE-LecEGF (1.5 µg) was identified by western blotting with 
the mAb 7A9 under native conditions as described in section 2.3.7.6. The signal on the 
membrane (Figure 3.58) showed that the deglycosylated hE-LecEGF was recognized by the 
functional blocking anti-E-selectin antibody, indicating the deglycosylated hE-LecEGF was 
active and correctly folded. 
 
 
                                        
2) ELISA 
ELISA of the hE-LecEGF protein (5 µg) and the deglycosylated hE-LecEGF (5 µg) was also 
performed with the mAb 7A9 to identify the activities of the protein (see section 2.3.7.6). The 
results showed that the hE-LecEGF and the deglycosylated hE-LecEGF were active (Figure 
3.59). 
 
Figure 3.58. Western blotting analysis of the deglycosylated hE-LecEGF
with the mAb 7A9.  
Figure 3.59. ELISA of the hE-LecEGF and the 
deglycosylated hE-LecEGF with the mAb 7A9. 
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(3) Polymer binding assay 
Polymer binding assay[325] of hE-LecEGF with sLea-polymer-biotin-streptavidin-POD complex 
(sLea-polymer complex) was performed to identify the activity of hE-LecEGF (see section 
2.3.7.6). Pure hE-LecEGF was directly coated onto the MaxiSorb 96-well ELISA plates (Nunc). 
The sLea-polymer complex was used to detect the binding of hE-LecEGF to its ligand sialyl 
Lewis a (sLea). After colour development with peroxidase substrate ABTS, the binding of sLea 
was analyzed by the software Prism 4.  
 
Unexpected, the binding signal of the polymer assay was very low for detection even after the 
optimization with different concentrations of hE-LecEGF (5 µg/ml, 10 µg/ml and 20 µg/ml) and 
sLea polymer complex (0.1 µg/ml and 0.5 µg/ml), binding buffer (HAB20 buffer containing 20 
mM CaCl2) and prolonged developing time (10 min-20 min) (Figure 3.60).  
 
 
         
  
 
 
Compared with the positive control of hE-selectin/IgG[333] in the polymer assay, the binding 
signal of hE-LecEGF and LecEGFFlag (Z) (hE-LecEGF fused with a C-terminal flag tag)[324] 
are very low at concentrations of 5 µg/ml or 10 µg/ml (Figure 3.61). This might be due to the 
bad coating of the hE-LecEGF protein to MaxiSorb 96 well ELISA plate, as previously 
reported in the reference[36]. Bradford assay was used to check the coating of hE-LecEGF in 
ELISA plates. The weak signal from the hE-LecEGF protein immobilized in ELISA plates 
showed that hE-LecEGF can not be directly immobilized well onto the ELISA plates. 
Therefore, an immobilization strategy for the hE-LecEGF protein was developed and 
optimized for the binding assay (see section 3.4). 
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Figure 3.60. Optimization of the polymer binding assay
in different concentrations of hE-LecEGF (5, 10 and 20
µg/ml) and sLea (0.1 and 0.5 µg/ml) in HAB20 buffer
with a developing time of 15 min. 
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(4) NMR assay 
An STD NMR experiment and a T1rho experiment were performed to assess the binding of 
hE-LecEGF with its ligand CGP69669 (one antagonist of human E-selectin) as described in 
section 2.3.7.6. Pure hE-LecEGF (52 µM) in a 200 µl NMR buffer (25 mM Tris, 150 mM NaCl, 
20 mM CaCl2 in D2O) was used. CGP69669 is a sLex mimic. It shows a 10-fold increase in 
binding affinity to hE-selectin than sLex[252]. Its structure is shown in Figure 3.62, the 
cyclohexandiol and S-cyclohexylactic acid in CGP69669 replacing the GlcNAc and sialic acid 
in sLex (Figure 1.8a) respectively.  
 
 
 
Figure 3.62. Structure of CGP69669[252]. 
 
 
• STD NMR experiment 
A saturation transfer difference (STD) NMR experiment measures the intermolecular 
Overhauser transfer of magnetization and gives the information on the binding events and the 
binding epitopes of the ligands upon interaction with the protein. Due to the mechanism of the 
Overhauser process, the transfer is strongly distance-dependent and limited to internuclear 
distances of approximately 4 Angstroms or less. This enables a qualitative assessment of 
binding as evidenced by a signal from the ligand in the STD spectrum upon irradiation of the 
protein. 
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Figure 3.61. Polymer binding assay of
hE-selectin/IgG, hE-LecEGF and LecEGFFlag(Z)
with sLea (0.5 µg/ml) in HAB20 buffer. 
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The STD result is shown in Figure 3.63. The binding signal of CGP69669 to hE-LecEGF is 
similar to that of CGP69669 to hE-selectin/IgG (positive control)[324], both of them showed the 
binding signal of 2-hydroxy group of Gal in CGP69669 to proteins in position of 3.6 – 4.0 ppm, 
whereas hE-LecEGF alone (negative control) did not show any signal. This indicates that 
CGP69669 binds to the hE-LecEGF protein in the same binding mode as hE-selectin/IgG. 
Compared with hE-selectin/IgG, the weaker signal of hE-LecEGF in the STD experiment 
could be due to the molecular weight of hE-LecEGF (20.444 kDa) which is 14 times smaller 
than hE-selectin/IgG (296 kDa).    
 
       
 
 
 
• T1rho experiment 
The qualitative assay of T1rho (Transverse relaxation) NMR experiment was performed as a 
complementary diagnosis of the binding of hE-LecEGF (see section 2.3.7.6). Transverse 
relaxation determines the ligand binding because the rate of relaxation increases with 
molecular weight[341]. Hence, a ligand that binds to a large receptor displays a faster decay of 
magnetization (a greater rate of relaxation) than the free ligand. The obtained T1rho spectrum 
of CGP69669 displayed the increased relaxation of ligand CGP69669 in the presence of 
hE-LecEGF (Figure 3.64), indicating the binding of CP69699 to?hE-LecEGF. 
 
Figure 3.63. STD spectrum of CGP 69669 binding with hE-LecEGF or hE-selectin/IgG, the negative
control is hE-LecEGF alone. 
STD of CGP 69669 with hE-selectin/IgG 
STD of CGP 69669 with hE-LecEGF 
Negative control 
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The qualitative assays of T1rho and STD NMR experiments both showed that CGP69669, a 
known antagonist of E-selectin, binds to the purified hE-LecEGF, indicating that the purified 
hE-LecEGF is active. 
 
Figure 3.64. T1rho spectrum of CGP 69669 and CGP69669 with hE-LecEGF.  
CGP69669 
CGP69669 + hE-LecEGF 
Results and Discussion
 
                                                                                    
 148 
 
 
3.4 Capture-binding assay development 
To date, the binding activity of hE-LecEGF has only been screened by cell-based assay[36]. 
The binding affinity of human E-selectin antagonists has only been evaluated with 
hE-selectin/IgG[325] or LecEGFFlag[324] in vitro. hE-selectin/IgG[325] and LecEGFFlag[324] 
contain the C-terminal hIgG1 tag and the C-terminal flag tag respectively. These tags may 
interfere with the binding activity of the protein.  
 
In order to determine the binding affinity of hE-selectin antagonists to a monomeric, soluble 
and tag-free protein, hE-LecEGF was used to set up a cell-free capture-binding assay for the 
first time. 
 
In previous investigations of hE-LecEGF (see section 3.3.4.7), the reason for the polymer 
assay failure has been the problem of immobilization of hE-LecEGF onto ELISA plates[36]. 
Therefore, a monoclonal anti-E-selectin antibody 1D6 [mAb 1D6, Roche (USA)] has been 
used to capture the hE-LecEGF in ELISA plates to evaluate the binding activity of hE-LecEGF 
in a cell-based assay[36]. Since mAb 1D6 is not available, a suitable anti-E-selectin antibody 
for the hE-LecEGF capturing was sourced. The ideal antibodies should recognize hE-LecEGF 
but with no or low interference in the binding activity of hE-LecEGF like the mAb 1D6.  
 
A commercial monoclonal anti-E-selectin/anti-P-selectin antibody BBA1 (mAb BBA1) showed 
similar binding features to the lectin domain of hE-selectin like the mAb 1D6[25] (Table 3.6). 
Their binding affinities are sensitive to the mutagenesis of amino acids of Y12, Y18, Q20, R22, 
N39, Y44, (K96, R97, K99), (K111, K112, K113) in the lectin domain of human E-selectin (see 
Table 3.6), indicating the epitopes recognized by mAb 1D6 and BBA1 are these amino acids. 
According to the previous crystal structural reports[324], these amino acids were not involved in 
the binding of the protein. Hence, the mAb BBA1(R&D system) was chosen for immobilization 
of hE-LecEGF in ELISA plates.
Results and Discussion
 
                                                                                    
 149 
 
 
 
Table 3.6. Summary of the binding of hE-selectin/IgG mutants with anti-E-selectin antibodies[25]. 
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3.4.1 Assay development 
A cell-free capture-binding assay was developed based on the reported polymer assay[325] 
and cell-based binding assay[36], in order to evaluate the binding affinity of hE-selectin 
antagonists (see section 2.4.2). The anti-E-selectin/anti-P-selectin mAb BBA1 was first coated 
onto the MaxiSorb 96 well ELISA plates (Nunc) at 4°C, overnight. After blocking with 3% BSA, 
hE-LecEGF was captured by the mAb BBA1 during the incubation at 4°C, overnight. The 
binding activity of hE-LecEGF was then evaluated by the binding of sLea-polymer complex. 
This assay can also be used to determine the binding activity of hE-LecEGF. 
 
A preliminary screening was performed to optimize the assay conditions with different 
concentrations of mAb BBA1 (3 µg/ml, 5 µg/ml and 10 µg/ml), hE-LecEGF (1 µg/ml, 3 µg/ml, 5 
µg/ml and 10 µg/ml) and sLea-polymer (0.1 µg/ml, 0.3 µg/ml and 0.5 µg/ml) as described in 
section 2.4.3. The strong and stable signal was obtained with 3 µg/ml of BBA, 1 µg/ml of 
hE-LecEGF and 0.1 µg/ml of sLea-polymer in HAB20 buffer with the developing time of 5 min 
(Figure 3.65). This assay condition was used for the following capture-binding assay and the 
competitive binding assay of hE-LecEGF. 
 
For qualitative determination of the binding activity of hE-LecEGF, 233 µg of hE-LecEGF was 
needed in NMR assay, whereas 0.5 µg of hE-LecEGF was enough to perform the 
capture-binding assay: much less protein was consumed by the capture-binding assay.    
 
 
 
 
 
 
Figure 3.65. Optimization of the capture-binding assay
with hE-LecEGF (1,3, 5 and 10 µg/ml) and sLea (0.1, 0.3
and 0.5 µg/ml) with 3 µg/ml of BBA1in HAB20 buffer for
developing 5 min. 
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3.4.2 EC50 determination of sLea-polymer 
The EC50 of the sLea polymer was measured by the capture-binding assay with the sLea 
polymer in the concentration range of 0.3 ng/ml - 300 ng/ml (see section 2.4.4). The binding 
curve and the value of EC50 of sLea polymer were determined with the Prism4 software by 
using a non-linear regression fit (Figure 3.66). The EC50 of the sLea polymer to hE-LecEGF 
was determined as 21.65 ng/ml. Compared with 48.28 ng/ml of EC50 of the sLea polymer to 
hE-selectin/IgG measured by the polymer assay (done by Katrin Lemme, IMP), sLea polymer 
showed stronger binding affinity to hE-LecEGF than to hE-selectin/IgG. 1.5 µg of hE-LecEGF 
was required for determination of the EC50 value of sLea polymer to hE-LecEGF. 
 
 
 
 
3.4.3 Competitive capture-binding assay 
In order to evaluate potent hE-selectin antagonists, the competitive capture-binding assay 
was developed based on the capture-binding assay by adding serial concentrations of 
hE-selectin ligand with 0.1 µg/ml of sLea simultaneously (see section 2.4.5). The IC50 of the 
antagonists was measured in this assay and calculated by the Prism4 software.  
 
3.4.3.1 IC50 of CGP69669 to hE-LecEGF and deglycosylated hE-LecEGF 
CGP69669 is an antagonists of hE-selectin[252] with an IC50 of 110 µM to hE-selectin/IgG in 
polymer assay[342,343]. 
 
EC50: 0.02165 µg/ml 
Figure 3.66. The binding curve and EC50 determination of sLea polymer to hE-LecEGF, analyzed by
the Prism4 software. 
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In order to evaluate the binding activities of hE-LecEGF and deglycosylated hE-LecEGF, the 
IC50 of CGP69669 to these proteins were determined by the competitive capture-binding 
assay, (Figure 3.67). CGP69669 showed the IC50 of 109.4 µM for the deglycosylated 
hE-LecEGF protein and 104.5 µM for the native protein, indicating that the deglycosylated 
hE-LecEGF was as active as the hE-LecEGF and the removal of glycans on hE-LecEGF did 
not affect its binding activity as reported in the previous study[30].  
 
In addition, the IC50 of 104.5 µM of CGP69669 to hE-LecEGF is similar to the published value 
of IC50 of 110 µM of CGP69669 to hE-selectin/IgG[342,343], indicating the capture binding assay 
can correctly evaluate the binding affinity of human E-selectin antagonists. 
 
 
  ?? ?           
 
 
 
 
3.4.3.2 IC50 of six potent antagonists to hE-LecEGF 
The binding affinities of six potent antagonists of human E-selectin (CGP69669, DS05-48, 
BW-408-0, DS05-65, DS05-102 and BW-186-1) were measured twice in triplicates in the 
competitive capture-binding assay. The competition binding curves (Figure 3.68, Figure 3.69 
and Figure 3.70) and IC50 values of each ligands to hE-LecEGF were determined by the Prism 
4 software. A parallel rightward shifts of dose–dependent curves of the ligands of DS05-48, 
BW-408-0, DS05-65 and CGP69669 was observed, indicating the rank order of the binding 
affinity is DS05-48 > BW-408-0 > DS05-65 > CGP69669 (Figure 3.68). 
 
IC50: 0.1045 mM IC50: 0.1094 mM 
hE-LecEGF Deglycosylated hE-LecEGF 
Figure 3.67. Competition binding curves and IC50 determination of ligand CGP69669 to hE-LecEGF (a) and
to deglycosylated hE-LecEGF (b). 
a. b.
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Figure 3.69. Competition binding curves of ligands BW186-1 and CGP69669 to hE-LecEGF. 
Figure 3.70. Competition binding curves of ligands DS05-102 and CGP69669 to hE-LecEGF. 
Figure 3.68. Competition binding curves of ligands CGP69669, DS05-65, BW-408-0 and DS05-48
to hE-LecEGF. 
CGP69669 
DS05-65 
BW-408-0 
DS05-48 
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By taking the IC50 of CGP69669 as a reference (IC50: 150 µM, measured in the present assay), 
Table 3.7 shows the rIC50 value of each ligand determined by the capture-binding assay and 
the calculated results from the published data[342]. The values of KD and rKD of three ligands 
(CGP69669, BW-408-0 and DS05-65) obtained from surface plasmon resonance assay 
(Biacore) are also shown in Table 3.7 (see section 2.4.6). The value of KD evaluates the 
equilibrium binding of the ligands to hE-LecEGF in a steady state. The rKD values of these 
ligands were calculated using the ligand of CGP69669 as a reference. 
 
Table 3.7. The rIC50, KD and rKD values of hE-selectin antagonists. 
Ligands Mw rIC50 rIC50 KD (µM)   rKD 
  
(Calculated from 
published results) 
(Measured by 
capture-binding assay)  
CGP69669 600.6282 1 1 58       1 
DS05-48 768.8416 0.1 0.085  
BW-408-0 592.6729 0.2/0.1625 0.158 7.76     0.134 
DS05-65 722.8168 0.4 0.28 5.3      0.09 
DS05-102 760.8406  0.32*  
BW-186-1 819.8216  0.55  
* Not accurate, due to the low solubility in the assay buffer. 
 
In the capture binding assay, the rIC50 values of 0.158 and 0.085 for BW-408-0 and DS 05-48 
respectively, are in close agreement with the published results of 0.1625/0.2 and 0.1 (Table 
3.7)[342]. For BW-408-0, the rIC50 of 0.158 measured by the capture-binding assay is similar to 
the rKD of 0.134 measured by Biacore (Table 3.7). Compared with the rIC50 of 0.4 for 
DS05-65 calculated from published results[342], the rIC50 of 0.28 for the same ligand measured 
by the capture-binding assay is closer to the rKD of 0.09 measured by Biacore. The difference 
between the values obtained from the capture-binding assay and Biacore could be due to the 
fact that Biacore is a dynamic assay, whereas the capture-binding assay is a static assay. 
 
All these obtained results demonstrated that the developed competitive capture-binding assay 
can correctly evaluate the binding affinity of potent hE-selectin antagonists. In summary, 
compared with the unstable polymer assay[324], the capture binding assay is accurate, 
sensitive and reproducible.  
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3.5 Crystallization of hE-LecEGF  
Crystallization conditions of hE-LecEGF were pre-screened with a sitting-drop 
vapour-diffusion method as described in section 2.5.2. Pure protein was concentrated to the 
final concentration of 9 mg/ml in a 60 µl buffer (20 mM Tris, 2 mM CaCl2, pH 7.4) by ultra 
centrifugation. The droplet for crystallization, composed of 100 nl of protein plus 100 nl of 
reservoir solution, was prepared by an automated dispensing instrument. The crystallization 
of hE-LecEGF was performed on 96 well crystallization plates (Greiner) with Hampton 
crystallization screening I and II kits at 4°C and 20°C for 3 basic screening blocks. Until now, 
only the precipitation (Figure 3.71) and a salt crystal identified by X-ray shooting (Figure 3.72) 
have been obtained. The glycans on hE-LecEGF could increase the solubility of protein in the 
crystallization buffer, causing greater difficulties in obtaining the crystal. Hence, more pure 
protein of the deglycosylated hE-LecEGF needs to be produced in order to reveal the 
appropriate crystallization conditions of the protein co-crystallized with its ligands for further 
structural studies. 
 
 
 
 
           
 
 
 
 
Figure 3.71. Precipitants formed in the crystal
drop of hE-LecEGF. 
Figure 3.72. A salt crystal formed in the crystal drop of
hE-LecEGF, identified by X-ray shooting. 
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4. Conclusion and Outlook 
Human E-selectin is a C-type lectin. It is transiently expressed on endothelial cells by 
induction of cytokines. It contains an N-terminal C-type lectin domain, an EGF-like domain, six 
CR domains, a transmembrane region and a cytoplasmic region. The key role of E-selectin is 
to mediate the initial rolling and adhering of leukocytes in the leukocyte recruitment in 
inflammation and metastasis of some cancer cells. It is fundamentally involved in many 
physiological and pathological processes. Hence, E-selectin is an attractive target for 
developing anti-inflammation drugs. The lectin and EGF-like domains of hE-selectin 
(hE-LecEGF) were identified as the minimum functional unit. Structural studies of hE-LecEGF 
or hE-selectin/IgG complexed with its natural ligand sLex by crystallization or NMR were 
reported and utilized as the structural basis for novel drug design. Many potent antagonists 
with better binding affinity than sLex were reported. However, the crystal structure of potent 
antagonist (e.g. CGP69669) with the hE-LecEGF protein remains unknown. With such a 
structure, a better understanding of the interaction between the protein and the ligand would 
facilitate the drug design. To obtain such structural information and develop more potent 
antagonists of hE-selectin are challenging tasks. A sufficient amount of the pure, active and 
characterized hE-LecEGF protein is needed to meet the demands of the protein for structure 
determination. A cell-free binding assay with the tag-free hE-LecEGF protein is also required 
for evaluation of the potent antagonists in vitro. 
 
In this thesis, hE-LecEGF was first cloned and transiently expressed in the insect cell 
expression system. The expression plasmid pFastBacYJSE was constructed for secretion of 
hE-LecEGF with an N-terminal flag tag (DYKDDDDK). The tag can be completely removed by 
the protease enterokinase. The hE-LecEGF protein was transiently expressed in both Sf9 and 
High fiveTM insect cells in a suspension culture. Pure protein was obtained using optimized 
anti-flag affinity chromatography with addition of 0.5% Triton X-100 in the washing buffer. The 
yield of purified hE-LecEGF showed that more protein was produced in High fiveTM cells (5.82 
mg/L) than in Sf9 cells (4.99 mg/L). On SDS-PAGE, the purified hE-LecEGF displayed four 
main bands of a glycosylated type at a molecular weight of 24-29 kDa, as identified by 
western-blotting analysis with the anti-flag antibody. The positive results of ELISA and 
western-blotting analysis with the functional blocking anti-E-selectin antibody 7A9 (mAb 7A9) 
indicated that the purified hE-LecEGF protein is active. However, the homogeneous 
deglycosylated hE-LecEGF protein was not obtained by deglycosylation with PNGase F and 
N-glycosidase A either separately or when combined under native and denaturing conditions. 
hE-LecEGF expressed in insect cells showed resistance to these deglycosidases. This could 
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be due to the restrictions of these deglycosidases[278,279,285]. 
 
hE-LecEGF was then cloned and stably expressed in mammalian cells CHO K1 to obtain the 
homogeneous protein. Two expression plasmids pYJE and pYJEG were constructed for 
expression of hE-LecEGF without a tag or with a C-terminal human IgG1 tag. An enterokinase 
cleavage site (DDDDK) was introduced in the plasmid pYJEG for further removal of the tag. 5 
high and stable expression subclones from a single cell, CHO-YJES1-5 and CHO-YJEGS1-5, 
were obtained by selection with geneticin and evaluation with AP-ELISA. The CHO-YJES1 
subclone was used for production of the hE-LecEGF protein in roller bottles and T-flasks due 
to the higher expression and easier purification. Pure hE-LecEGF protein was obtained by a 
one-step functional purification using the mAb 7A9 coupled column, indicating mAb 7A9 
produced by hybridoma cell, purified on a Protein A column and coupled to cyanogen bromide 
activated sepharose 4B matrix, can be used for functional purification of the hE-LecEGF 
protein. 762 µg/L purified hE-LecEGF protein were obtained from production in roller bottles 
and 480 µg/L in T-flasks. Compared with the published result[36], a good hE-LecEGF 
expressing stable subclone CHO-YJES1 was achieved. The purified hE-LecEGF protein was 
further characterized by MS, NMR and immunoassay methods. It was a glycosylated 
monomer as judged by its migration profile in reducing, non-reducing and native conditions. 
By ESI-MS-MS, the molecular weight of hE-LecEGF was determined as 20.444 kDa and ~ 
50% of its amino acid sequence (including the calcium binding sites) was identified. The 
binding activity of hE-LecEGF was confirmed by NMR (T1rho NMR and STD NMR), 
western-blotting, ELISA and the capture-binding assay. Pure and homogeneous 
deglycosylated hE-LecEGF protein was obtained by deglycosylation with PNGase F under 
native condition and additional purification on a sepharose Q matrix. The binding activity of 
the deglycosylated hE-LecEGF protein was verified by western-blotting, ELISA and the 
capture-binding assay. The results showed that the deglycosylated hE-LecEGF was as active 
as the native hE-LecEGF.  
 
A novel capture-binding assay was developed with the tag-free hE-LecEGF protein to 
evaluate the binding affinity of hE-selectin antagonists. Six known ligands were measured and 
the rIC50 of each ligand was determined. The obtained results were in close agreement with 
the published results[342]. Compared to the previous unstable polymer assay with 
hE-selectin/IgG[324], the capture-binding assay with hE-LecEGF is accurate, sensitive and 
reproducible. In addition, an anti-E-selectin/P-selectin antibody BBA1 used in the assay 
solved the immobilization problem of the hE-LecEGF protein onto ELISA plates. Therefore, 
we conclude that the capture-binding assay with the hE-LecEGF protein can correctly 
evaluate the binding affinity of E-selectin antagonists. It is a static, cell-free and reliable assay. 
Conclusion and Outlook
 
                                                                                    
 158 
 
 
In outlook, the process of preparation of pure, active and homogeneous deglycosylated 
hE-LecEGF protein from the initial cloning to the final characterization was achieved in this 
thesis. Therefore, more pure and active deglycosylated hE-LecEGF can be prepared in the 
future by large-scale production and purification by the same procedure for further structural 
study, such as co-crystallization of the leading ligands (e.g. CGP69669) with the protein, to 
elucidate the exact binding mode of the leading compound and facilitate the design of novel 
potent antagonists of human E-selectin.  
 
The novel capture-binding assay with the tag-free hE-LecEGF protein was developed in this 
thesis. It can correctly determine the binding affinity of hE-selectin antagonists and could, 
therefore, serve as an experimental tool to assist the design and synthesis of further 
antagonists. In addition, the problem of immobilization of truncated hE-LecEGF protein onto 
the ELISA plates was solved by using the BBA1 antibody to capture the hE-LecEGF protein in 
the assay. This immobilization method could be used for immobilization of the hE-LecEGF 
protein in surface plasmon resonance (Biacore) assay or other assays. 
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